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SUMMARY 
It has been well documented that the oral route is the most cost effective route for drug 
delivery and encourages patient compliance. Recent studies have shown the numerous 
advantages associated with specific drug delivery to the colon, highlighting its favourable 
conditions and long transit time as the main advantages. A number of in vitro studies also 
show that the delivery of liposomes to the colon could provide further advantages due to 
bonding to the colonic mucosa in both healthy and inflamed regions. Despite these 
apparent advantages no oral liposomal formulation has been developed for targeted 
delivery to the colon as yet. This work sets out to develop a formulation which can be 
taken orally, that will remain intact through the stomach and small intestine to release the 
liposomes, and subsequently the active ingredient, in to the colon.  
Initially, experiments were conducted in which liposomes were directly coated with the 
pH responsive polymer Eudragit S100. Although the coating was shown to slow drug 
release in simple pH buffers, it was realised it could not protect the lipid membrane from 
the model bile salt sodium taurocholate. Development of the formulation moved onto the 
production of Eudragit S100 microspheres to provide a solid barrier to protect the 
liposomes. A number of production variables including homogenisation speed and time 
were investigated to provide a homogenous microsphere population suitable for 
encapsulating liposomes. Due to the solvents required in the microsphere production it 
was essential to protect the liposomes, which was done by coating them with the enzyme 
triggered polymer chitosan. This coating would not only protect the liposomes from the 
solvents but also provide a trigger release when the liposomes reach the colonic 
microflora. The final stage involved encapsulating chitosan-coated liposomes within the 
Eudragit microspheres to produce a novel, colon targeting liposome-in-microsphere 
(LIM) formulation. Through cryo-SEM chitosan-coated liposomes could be observed 
within the microsphere core. Subsequent drug release studies showed that the LIM 
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formulation remained intact through the simulated stomach and small intestine conditions 
with drug release occurring in the colonic conditions where the model enzyme β-
glucosidase could solubilise the chitosan coating.    
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1.0 Introduction 
 
________________________________________________________________________ 
     
ABSTRACT 
The oral drug delivery route is widely seen as the most practical and cost efficient route of 
administration. Despite the well documented advantages of colonic drug delivery including 
long residence time, neutral pH and low enzyme activity, very few oral colonic drug delivery 
systems have made it to market. Recent investigations have shown that liposomes have a 
number of advantages for the prolonged release of active ingredients in the colon. Coupled 
with the advantages associated with specific targeting to the colon for drug delivery it is 
proposed that liposomal formulations capable of targeted drug release to the colon could be 
useful for both localised and systemic treatment.  
The first part of this chapter investigates the various routes of administration available, 
reviewing oral delivery in detail with an emphasis to colonic targeting. The complexities of 
the GI tract as a route for drug delivery are outlined, with pH and transit times being 
discussed in detail. It introduces the concept of various triggers for site specific drug delivery 
and summarises the advantages and disadvantages of each method. The second part discusses 
the production and applications for liposomes and introduces the possibility of coating for 
site specific colonic drug delivery. The final part of the chapter introduces the overall aims 
and objectives of this work.  
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1.1 Introduction                
The principal goal of targeted drug delivery is to deliver the drug to a specific area with 
increased efficiency and reduced adverse effects than less specific drug administration. This 
can be achieved through the prolonged and localised delivery of the drug to the diseased 
tissue thus ensuring maximal therapeutic effects are achieved whilst minimising possible side 
effects through excessive exposure. For site specific drug delivery a number of routes of 
administration can be adopted, each of which have a number of advantages and disadvantages 
(Langer 1998) which are discussed in the following section.      
1.2. Routes of drug administration             
1.2.1. Enteral drug delivery             
1.2.1.1. Oral administration   
Oral administration is widely regarded as the most practical, efficient and cost effective route 
for drug dosage and is responsible for over eighty percent of the best selling pharmaceutical 
products available (Lennernas and Abrahamsson, 2005). It not only allows for complete 
patient independence and therefore compliance but it is normally cost effective to 
manufacture and offers a lengthy shelf life which is normally determined by the active drug 
itself rather than the formulation components (Mathiowitz, 1999). There are however a 
number of complications associated with oral drug delivery including the varying conditions 
observed within the GI tract and the large populations of digestive enzymes which will 
degrade most peptide and protein drugs (Chen and Langer 1998).    
1.2.1.2. Rectal administration  
The use of rectal drug administration has a number of advantages, including being able to 
administer drugs to the colon without needing to negotiate the hostile environments of the 
stomach and small intestine. The use of rectal administration also allows for specific targeting 
to be achieved as a number of pathways are not required to reach the colon and varying 
transit times across the ileo-caecal junction would not be an issue. Furthermore, the use of 
rectal administration allows for drugs to be effectively administered whilst the patient is 
undertaking bouts of vomiting, nausea or unconscious convulsions (van Hoogdalem et al., 
Chapter 1  Introduction 
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1991). The potential disadvantages of rectal administration include patient compliance and 
the causes of bowel movements on the administration time of the dosage.          
1.2.2. Parenteral drug delivery 
Parenteral delivery is the most direct route for drug delivery and therefore has a major 
advantage over other methods. This means the drug can be administered to the specific site 
instantaneously, or can be within the circulation shortly after administration, which is 
essential when the drug is required immediately. The parenteral administration route can be 
achieved through the intravenous, intramuscular or subcutaneous approach. Despite the 
obvious advantages of this approach there are a number of disadvantages which limit the use 
of parenteral administration for all applications. The administration of the drug is required to 
be conducted by a qualified health care professional and levels of patient compliance are low 
due to the associated pain and subsequent fears. Some forms of subcutaneous and 
intramuscular delivery can be self administered but patient compliance and willingness is still 
low. If parenteral administration is required then a sustained treatment is observed as more 
favourable as it reduces the pain associated with frequent injections and the need for a 
healthcare professional to administer it. Myocet® (Enzon Pharmaceuticals) is a liposomal 
formulation containing the active ingredient doxorubicin. It is used in the treatment of 
metastatic breast cancer and is a non-pegylated version i.e. it does not have the polyethylene 
glycol (PEG) coating associated with other liposomal formulations containing doxorubicin 
(Doxil®, Caelyx®).         
1.2.3. Transdermal drug delivery   
Transdermal delivery refers to the delivery of drugs through the skin which requires 
penetration through the two sublayers of the epidermis to reach the microcirculation of the 
dermis. The advantages associated with transdermal delivery include ease of use/application 
and the possibility to provide non-invasive sustained release where other routes may not be 
applicable (oral). A current dermally administered liposomal formulation is LMX-4 (Ferndale 
Pharmaceuticals Ltd) which contains the local anaesthetic lidocaine and is therefore marketed 
as a fast and effective pain relief from medical procedures involving injection (taking blood, 
insertion of cannula etc.).            
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1.2.4. Pulmonary drug delivery  
Pulmonary drug delivery refers to drugs administered through the airways and has a number 
of advantages and applications. The use of pulmonary drug delivery would not only be 
advantageous due to the large surface area offered by the alveoli but also effective systemic 
treatment would be possible as well as localised treatment. Drawbacks associated with 
pulmonary drug delivery include the treatment can be short-term and the formulation can 
soon be cleared by the mucociliary escalator.  
Due to the numerous advantages associated with the oral drug delivery route the current 
investigation will go on to explore the possibility of developing an oral formulation and the 
subsequent issues that may arise. 
1.3. Advantages of colonic drug delivery 
After briefly reviewing a number of routes of administration it is generally accepted that the 
oral route is the most cost effective and patient compliant route. With this in mind it is 
essential to determine the best site for drug delivery within the GI tract and subsequently 
design a formulation for the application. Over recent years the colon has received a large 
amount of interest as a possible drug delivery site for the treatment of both localised diseases 
(bowel cancer, ulcerative colitis and Crohn’s disease) (McConnell et al., 2008; Ibekwe et al., 
2008a; Patel et al., 2008), but also for the administration of systematically-acting proteins and 
therapeutic peptides such as insulin (Tiwari et al., 2010). Protein and peptide drugs are 
known to be degraded by digestive enzymes present within the stomach and small intestine. 
These proteases are lower in concentration in the colon which means it is a more favourable 
site for delivery (Kumar et al., 2011). The reduced proteolytic activity in the colon compared 
to that of the small intestine mean certain drugs that are enzymatically labile in the small 
intestine would be more effectively absorbed (Mathiowitz, 1999). The specific targeted 
delivery to the colon would also allow the dosage to be reduced, therefore minimising any 
possible systemic side effects that may occur. As an example, the specific treatment of 
ulcerative colitis is through the administration of the active ingredient 5-aminosalicylic acid 
(5-ASA; Mesalazine) which is available in tablet, enema and suppository formulations. It has 
been shown that the oral formulation has a high absorption level within the upper GI tract of 
approximately 75% whilst only 19% was absorbed in the colon (Segars and Gales, 1992). 
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Due to the topical nature of the drug administration of 5-ASA it is necessary to get the 
highest efficiency of delivery to the site of infection which is the large intestine. With this in 
mind it has been shown that the use of enemas and suppositories have proven the most 
effective at treating ulcerative colitis, but the problem of patient compliance remains.  
The colon offers a number of further advantages for drug delivery including a mild pH and a 
long residence time (on average 35 hours in total), which are reviewed within this chapter. 
Few drugs (e.g. nisodipine and dilazep hydrochloride) are known to be preferentially 
absorbed in the colon; therefore specific formulations are required to target the colon (Fasinu 
et al., 2011).  
1.4. Anatomy and physiology of the gastro intestinal (GI) tract       
Although oral administration to the colon offers considerable advantages it is also the most 
complicated route of drug delivery due to the wide variation in pH, enzyme and bacterial 
levels. It is therefore essential to completely understand the environment that the formulation 
will be exposed to and any influences they may have. This not only entails understanding the 
different conditions that are found within the GI tract but also understanding the patient 
variability that can occur, especially regarding both transit times and chemical differences. It 
is also important to understand that these conditions can fluctuate through varying illnesses 
which either need to be taken into account when designing specific formulations, or ideally, 
producing a formulation with certain flexibility to take into account these changes. This has 
also led to the concept of absorption windows whereby certain drugs display region specific 
absorption and therefore drug exposure at the specific site is essential for effective drug 
dosing (Davis, 2005). To review the GI tract it can be split into the three main sections of the 
stomach, small intestine and large intestine (Figure 1.1).  
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Figure 1.1. Structure of the gastrointestinal tract showing the position of the stomach, small intestine 
(duodenum, jejunum, ileum) and the colon (http://www.umm.edu/digest/howworks.htm). 
1.4.1. Anatomy and physiology of the stomach  
After oral ingestion food travels down the oesophagus (20 – 30 seconds transit time) to the 
stomach, whereby digestion starts through the storage, mixing and production of a chyme to 
then be processed further in the small intestine. The stomach is a muscular cavity which 
produces gastric secretions upon the entering of food. The gastric juices that are secreted are 
made up of water, hydrochloric acid (HCl) (0.15 M), pepsin and mucin. The presence of the 
hydrochloric acid makes the pH of the stomach approximately 1-3, which is an optimum pH 
for the protein digesting enzymes present in the gastric juice to inhabit. The low pH coupled 
with a high intensity of stomach contractions makes for a hostile environment for orally 
administered formulations to travel. The exit of food from the stomach is controlled by the 
pyloric sphincter which relaxes to release the stomach contents into the small intestine. This 
release will only occur for smaller objects within the fed stomach (<10mm) whilst larger 
objects (>20 mm) will be retained and processed until broken into smaller particles (Davis, 
2005).        
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1.4.1.1. Structure of the stomach 
The stomach is a large muscular sac located high in the abdominal cavity just below the 
diaphragm. The stomach wall is made up of four layers; the mucosa, submucosa, muscularis 
externa and the serosa. When in the fasted state the mucosa of the stomach lies in folds but 
can then distend to approximately 5 dm3 after a large meal (Clegg and Mackean, 1999). The 
muscularis externa has three separate layers of muscle which through their contraction causes 
the contents of the stomach to be continually mixed and churned.    
1.4.1.2. pH changes in the stomach 
The pH changes throughout the GI tract have been well investigated observing a number of 
variables for subjects including feed status, age, sex and health. The standard method to 
measure GI tract pH uses a radiotelemetric capsule which is orally taken and can emit a 
signal to an antenna every second to record the pH (Ibekwe et al., 2008a; Ewe et al., 1999). 
Experiments taken place in both the fasted and fed states show that the pH of the stomach is 
in the region of 1 – 3 (Ibekwe et al., 2008a; Dressman et al., 1990; Fallingborg et al., 1989), 
which is due to the concentration of HCl. As a result of all the in vivo measurements the 
British Pharmacoepoeia recommends a pH 1-1.5 0.1M HCl to be used for simulated gastric 
media when assessing delayed release dosage forms (British Pharmacoepoeia 2010, 
Appendix XII A309).   
1.4.1.3. Transit times in the stomach 
The transit time within the stomach can vary considerably and is mainly dependent upon the 
feed status of the subject (Varum et al., 2008). The stomach transit time in the fasted state is 
normally in the range 1 – 2 hours which is due to the migrating myoelectric complex (MMC). 
The MMC involves a prolonged period (40 – 60 minutes) of low mechanical activity 
followed by intense regular contractions of 4 – 6 minutes, before emptying of the stomach 
into the small intestine (Davis, 2005). The MMC can be interrupted by the presence of food 
and therefore what is normally a regular transit time becomes irregular and can be in the 
range of a few seconds through to a number of hours. It has also been shown that the size of 
the formulation can influence transit time in the fed state with smaller dosage forms having a 
more reliable transit time but larger formulations being retained in the stomach.  
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1.4.2. Anatomy and physiology of the small intestine
1.4.2.1. Structure of the small intestine
The small intestine is on average 5 metres long, with a normal range of 3
responsible for the majority of digestion and food absorption that takes place in the human 
body. As the main role of the small intestine
the primary site for drug absorption
and ileum, with each section having different characteristics and therefore providing a 
varying environment for drug dosage formulations. 
be subjected to a completely different environment 
relatively high pH and presence of bile salts
absorption through its greatly increased surface area, which is provided by the large 
population of villi and microvilli l
digestion is completed by the digestive juices which are present within the small intestine or 
secreted due to a reflex response or hormone trigger. The two main digestive juices found in 
the small intestine are bile and pancreatic juice. 
Figure 1.2. Schematic diagram showing
structure showing the villi and microvilli 
1.4.2.2. pH changes of the small intestine
Studies have generally showed similar values for the pH within the s
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observed not only due to individual variability, but also variability has been observed over 7 
days for the same subject (Ibekwe et al., 2008).  
The small intestine has a pH ranging from 5.7 in the pylorus to 7.7 in the ileum. The pH in 
the duodenum is normally measured within the range of 6.0 to 6.6 in both the fasted and fed 
states (Ibekwe et al., 2008; McConnell et al., 2008; Fallingborg et al., 1989; Evans et al., 
1988). The pH then gradually increases down the small intestine with values in the range of 
pH 6.8 – 7.4 (Ibekwe et al., 2008; Evans et al., 1988) observed for the jejunum. The pH of 
the small intestine then peaks at the ileum whereby values recorded have been in the range of 
7.2 – 7.7 (Ibekwe et al., 2008a; Fallingborg et al., 1989; Evans et al., 1988). This patient 
variability in pH through the small intestine can therefore be problematic when designing a 
pH responsive drug dosage formulation as each patient could have a different point within the 
GI tract where drug release will be initiated.   
1.4.2.3. Transit times in the small intestine 
The transit times for the small intestine can range considerably from 1-6 hours depending 
upon the subject, with the mean being 3 hours (McConnell et al., 2008; Davis et al., 1986). 
The transit time for dosage forms of differing size is statistically similar in both the fasted and 
fed states (Rouge et al., 1996). The range in small intestine transit has not only been 
attributed to subject variability but it has been suggested that the timing of food ingestion 
may have a considerable influence on the transit time (McConnell et al., 2008). It has been 
suggested that the intestinal motility may be influenced by the MMC and the subsequent 
points along the GI tract (oesophagus, throughout the small intestine).        
1.4.2.4. Digestive juices found within the small intestine  
Bile is produced in the liver cells, stored in the gall bladder and released into the duodenum 
via the bile duct. Bile is made up of bile salts, bile pigments, cholesterol and salts. The main 
role of bile is to lower the surface tension of fat globules allowing emulsification to take 
place and therefore aid the subsequent hydrolysis of fat by lipase. The enterohepatic (bile) 
system is an efficient one with more than 95% of bile salts being reabsorbed in the terminal 
ileum, with less than 5% (0.2 – 0.6 g) being lost in faeces daily (Redinger, 2003). The 
reabsorbed bile salts are then actively transported to the gall bladder where newly synthesised 
bile salts can replenish to the required levels. Bile salts are bile acids that have been 
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compounded with a cation, usually sodium. Approximately 80% of bile salts in the human 
body are made up from the salts of taurocholic and glycocolic acids and therefore in vitro 
studies can be completed using the model bile salt sodium taurocholate. 
Pancreatic juice includes a number of enzymes including amylase, trypsin, peptidases and 
lipases which are responsible for a number of roles including the hydrolysis of starch to 
maltose and the hydrolysis of proteins to polypeptides.      
1.4.3. Anatomy and physiology of the large intestine                     
1.4.3.1. Structure of the large intestine 
The large intestine consists of the caecum and appendix, colon and rectum and is 
approximately 1.5 metres long. The large intestine has a diameter in the range of 6 – 6.3 cm 
and therefore is approximately twice that of the small intestine. The large intestine is joined 
to the small intestine at the ileo-caecal junction where the entry of digested food is controlled 
by the ileo-caecal valve. The large intestine is structurally very similar to the small intestine 
but without the villi for increased surface area. The colon’s two main roles involve 
absorption, which takes place in the proximal half, and storage, which occurs in the distal 
half. These two processes result in the colon having a lower water content and fluid mobility 
than other areas of the GI tract. These conditions mean any drug residing in the colon will 
have higher residency times due to the reduced capacity of enzymatic biodegradation, which 
will in turn allow for the maximum possible drug uptake efficiency in patients.  
Some of the advantages associated with colon specific drug delivery can be seen as 
problematic for example the reduction in water content can lead to sluggish and propulsive 
movements which may lead to size segregation. Furthermore, the variability of transit time 
for both the stomach and small intestine may influence certain drugs that have a reduced 
absorption window.        
1.4.3.2. pH changes of the large intestine  
When previously designing colonic drug delivery systems it was generally accepted that the 
pH of the GI tract continued to rise through to the colon, therefore allowing for specific pH 
controlled release to be observed. However, it has been shown that the GI tract pH increases 
distally to a peak at the ileo-caecal junction (Ibekwe et al., 2008a; McConnell et al., 2008).  
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The pH has then been shown to reduce in to the range 5.6 - 6.2, which is a significant 
decrease in comparison to the distal small intestine (Evans et al., 1988; Fallingborg et al., 
1989; Ibekwe et al., 2008a). Once the pH has decreased on arrival into the large intestine 
very few fluctuations in pH are observed, which is due to the low motility experienced 
throughout. A limited range in pH is seen through the large intestine of a healthy subject but 
some variability can be seen due to certain diseased states (McConnell et al., 2008). Reduced 
pH values of 4.7 and 5.3 have been recorded for ulcerative colitis and Crohn’s disease  
respectively. This indicates not only patient variability needs to be taken into account but also 
the effect the specific disease may have on the targeted area.       
1.4.3.3. Transit times of the large intestine  
The transit times observed within the large intestine can vary considerably, which provides a 
number of issues if designing a time-dependant drug delivery system. Before entering the 
colon it has been shown that dosage forms accumulate in the ileo-caecal junction for a 
variable period of time up to approximately 3 hours (Ibekwe et al., 2008b). Despite this, 
Ibekwe et al. (2008b) observed an average transit time of 74 minutes for the fasted state and 
81 minutes in the fed state for the ileocaecal junction, with only one subject from eight 
showing a transit time of over 100 minutes. The variable transit times are continued through 
the ascending (up to 14 hours) and transverse colon (up to 48 hours), with transit through the 
descending colon being relatively fast (Varum et al., 2010).        
1.4.3.4. Microflora of the large intestine   
The stable pH and lengthy transit times found within the large intestine provide the perfect 
conditions for bacterial growth with over 400 species residing and a range of 1011 – 1012 
CFU/g in comparison to the stomach (102 CFU/g) and small intestine (104 – 107 CFU/g). The 
main bacteria found in the large intestine are that of the oxygen intolerant anaerobic nature 
with the main isolated species being Bacteroides, Bifidobacterium and Eubacterium 
(Gorbach et al., 1967). The energy needs of the bacteria are fulfilled by fermenting various 
types of substrates (di, tri – polysaccharides, mucopolysaccharides) that have been left 
undigested by the small intestine. The colonic microflora are able to break down these 
polysaccharides by producing a large number of reductase enzymes and polysaccharidases 
(Jain et al., 2007).  
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The previous sections have outlined the varying conditions of the GI tract and the subsequent 
issues that may arise when designing a targeted drug delivery formulation. Transit times and 
varying pH values throughout the GI tract have been summarised (Tables 1.5 and 1.6).   
 
Table 1.5. Table summarising the mean varying pH values recorded throughout the GI tract 
for healthy fasted subjects in a number of studies. 
 
Reference Stomach Small intestine Large intestine 
  Duodenum Jejunum Ileum Proximal 
colon 
Mid 
colon 
Distal 
colon 
Evans et al., 
1988 
1.0 – 2.5 6.6 6.63 7.49 6.37 6.61 7.04 
Fallingborg 
et al., 1989 
1 – 3 6.4 7.0 7.3 5.6 5.7 6.6 
Dressman et 
al., 1990 
1.7 6.1      
Pye et al., 
1990 
 6.6 7.4 7.5 6.4 6.6 7.0 
Russell et al., 
1993 
1.3 6.5      
Ibekwe et al., 
2008a 
1.4 6.5 6.8 7.2 6.5   
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Table 1.6. Table summarising the varying transit times (hours) recorded throughout the GI 
tract for healthy fasted subjects in a number of studies. 
Reference Stomach Small intestine Large intestine 
  Duodenum Jejunum Ileum Proximal 
colon 
Mid 
colon 
Distal 
colon 
Davis et al., 
1986 
 
3 - 4    
Evans et al., 
1988 
 
5.7    
Fallingborg 
et al., 1989 
0.9 8 
 
17.5 
Wilding, 
2001 
0 - 2 
 0.5 - 2 0.5 – 2.5 2 - 72 
Rouge et al., 
1996 
 
3 ± 1 1 - 60 
 
In summary, the colon offers an advantageous site for drug delivery due to its near neutral 
pH, long transit time and relatively low proteolytic enzyme activity (Yang et al., 2002). Not 
only is the colon advantageous for the treatment of localised diseases but it also a suitable site 
for systemic treatments. The main challenges associated with targeting the colon for drug 
delivery is being able to preserve the formulation through the harsh acidic conditions of the 
stomach and subsequent rise in pH coupled with the influence of bile salts in the small 
intestine.    
1.6. Strategies for ensuring site-specific targeting and release to the colon 
A number of challenges have been presented when attempting to create a formulation for 
colon-specific drug delivery (Kumar et al., 2011):  
(i) The primary challenge is that of creating a formulation that can withstand the 
upper GI tract and lead to subsequent drug release in the near neutral environment 
of the colon. 
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(ii) Due to the high viscosity of the colonic fluid it is assumed that drugs need to be in 
the form of a solution within the colon to allow for successful delivery.  
(iii) The effect of the resident microflora needs to be taken into account as it may 
cause the metabolic degradation of the drug. 
(iv) Drug transport across the mucosa and into the systemic circulation can be reduced 
by the low surface area in the colon. 
With these challenges in mind a number of polymers have been investigated to produce 
formulations suitable for colonic drug delivery. These polymers can be used in a variety of 
ways from a direct spray coating formulation through to microsphere formulations composed 
of a number of polymer layers. Each coating polymer can be categorised depending upon 
their specific trigger within the GI tract i.e. what causes them to solubilise, degrade or swell 
to cause the drug release.                    
1.6.1. Time dependent triggers   
Time dependent formulations work on the concept of releasing the drug after a specified time 
e.g. taking into account transit through the stomach and small intestine to subsequently 
release in the large intestine. Time delayed systems that have been developed (e.g. Pulsincap, 
Time-Clock) rely on a multi component system which involves the use of an outer enteric 
coating which is insoluble in the stomach (Philip et al., 2010; Hebden et al., 1999; Steed et 
al., 1997). This allows for any variety in stomach transit time to be exempt from the 
calculations for the time controlled component of the formulation i.e. only the small intestine 
and ileo-caecal junction need to be accounted for. An example of a time dependant 
formulation is that of the enteric coated time-release press coated (ETP) tablets whereby a 
multilayer concept is adopted (Philip et al., 2010) (Figure 1.3). The formulation consists of a 
drug containing core tablet with a rapid release function, which is surrounded by a press 
coated swellable hydrophobic polymer Hydroxypropyl cellulose (HPC). The HPC layer 
provides a timed released function and is dependent upon the weight or composition of the 
layer. The final coating is an enteric layer which not only protects the formulation through the 
stomach but also means the varying transit time of the stomach does not need to be accounted 
for. Despite this the varying transit times through the GI tract remain an issue with the 
possibility of varying transit times through the small and large intestine causing either 
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premature drug release or even reducing drug release if colonic transit is accelerated, as has 
been observed in patients with IBD (Philip et al., 2010) 
 
 
 
 
 
 
 
Figure 1.3. Schematic diagram showing the design of the ETP tablet. The enteric coating is rapidly 
dissolved after gastric emptying, exposing the timed release HPC layer. The HPC layer slowly erodes 
throughout the small intestine to expose the rapid release core tablet for colonic drug delivery.  
   
1.6.2. pH dependent triggers 
pH dependent formulations attempt to exploit the increase in pH that is observed along the GI 
tract, from the acidic stomach through to the slightly alkaline ileo-caecal junction. Coating 
the formulation with a pH sensitive polymer would protect the contents to the point whereby 
a pH is reached that would solubilise the polymer and therefore release the active component. 
There is a range of pH responsive polymers that may be utilised in the production of a pH 
controlled drug dosage form (Table 1.7). From the pH levels through the small intestine 
(section 1.3.2.2) it is apparent that for ileo-caecal and subsequent colonic drug delivery the 
polymer would need a pH threshold level of approximately 7 as any polymer below this level 
would begin to release in the duodenum. Despite the pH of the ileum increasing to above 7 in 
most cases the nature of the polymer solubilisation would mean that drug delivery would not 
occur until the large intestine. Despite this due to the nature of the pH targeting a number of 
researchers refer to it as ileo-caecal junction delivery as opposed to colon specific delivery. 
With this in mind the most widely used polymers for colonic drug delivery are within the 
Enteric coating 
layer 
Core tablet 
containing active 
ingredient 
(rapid-release 
function) 
HPC layer 
(timed-release function) 
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Polymethacrylic-acid-methylmethacrylate-ester-copolymer, brand name Eudragits (Evonik, 
Darmstadt, Germany).  
 
Table 1.7. Widely used pH responsive polymers in oral drug delivery. 
Brand name Polymer Target site Threshold pH References 
Eudragit L100 (Evonik) Poly(methacylic acid-co-
methyl methacrylate) 1:1 
Jejunum 6.0 (Eudragit.evonik.com) 
Eudragit S100 (Evonik) Poly(methacylic acid-co-
methyl methacrylate) 1:2 
Colon 7.0 (Eudragit.evonik.com) 
Eudragit L-30D-55 
(Evonik) 
Poly(methacylic acid-co-ethyl 
acrylate) 1:1 
Duodenum 5.5 (Eudragit.evonik.com) 
Eudragit FS 30D (Evonik) Poly(methyl acrylate-co-
methyl methacrylate-co-
methacrylic acid) 7:3:1 
Colon 7 (Eudragit.evonik.com) 
Opadry, Sureteric 
(Colorcon Ltd.) 
Polyvinyl acetate phthalate 
(PVAP) 
 5.0 Liu et al., 2011;  
 CAP Cellulose acetate phthalate  6.0 Dalmoro et al. (2010); 
Liu et al. (2011)  
pH responsive Eudragit polymers are acrylate-based pharmaceutical polymers which include 
methacrylic acid copolymers (gastroresistant) and aminoalkyl methacrylate copolymers 
(gastrosoluble) (Röhm Pharma Polymers) (Figure 1.4). There are a number of methacrylic 
acid copolymers in the Eudragit range which all dissolve at different pH conditions and 
subsequently at a different section of the GI tract (Figure 1.5). For the application of colonic 
drug delivery, Eudragit L100 and S100 are mostly used, which dissolve within the pH range 
of 6 - 7 and 7 - 8 respectively. This indicates that the use of Eudragit S100 as an enteric 
coating would provide colon targeted drug delivery, with dissolution of the coating being 
initiated through the jejunum/ileum regions where the pH has been seen to increase to a 
maximum of approximately 7.2 at the ileo-caecal junction (Ibekwe et al., 2008a). 
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R1 = CH3, H 
R2 = CH3, CH3CH2 
R3 = COOH (Eudragit® L and S) 
R3 = COOCH2CH2N (CH3) Cl- (Eudragit® RL and RS) 
 
Figure 1.4. Chemical structures of Eudragit S,L, RL and RS (Chourasia and Jain, 2003). 
 
 
 
 Figure 1.5. Range of pH responsive Eudragit polymers and their anticipated point of solubilisation.  
(www.evonik.com) 
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The use of Eudragit S100 and L100 as pH responsive drug formulations is well proven, with 
a number of products currently on the market including Asacol (Medeva Pharma) and 
Salofalk (Dr Falk Pharma). Despite these drugs making it to market a number of studies have 
indicated that in some patients Asacol failed to disintegrate in the GI tract (Schroeder et al., 
1987; Sinha et al., 2003). The inability of Asacol to disintegrate during GI tract transit was 
attributed to rapid small intestine transit and therefore implying the formulation was not 
subjected to a pH above 7 for a long enough duration. This theory is reinforced by Ibekwe et 
al. (2008a) where the in vitro disintegration of Eudragit S100 coated tablets was compared to 
the relative pH and transit time throughout the GI tract of the participant. It was shown that in 
seven out of eight participants tablet disintegration occurred in the ascending colon during the 
fasted state, with one participant showing disintegration in the ileo-caecal junction. 
Contrasting this, in both the fasted and fed states it was observed that in three out of the eight 
subjects the tablet failed to disintegrate. The three tablets that failed to disintegrate could not 
be attributed to a single limiting factor (pH value, residence time), but was attributed to a 
number of factors that make up the complexities of pH responsive formulation in vivo. The 
majority of tablets in the fed state were seen to disintegrate in the ileo-caecal junction and 
therefore Ibekwe et al. (2008a) defined the use of Eudragit S100 for ileo-caecal targeting as 
opposed to the normally defined colonic targeting. The drop in pH observed upon entry to the 
small intestine would indicate Eudragit S100 would begin to solubilise prior to reaching the 
colon, but due to the quick transit time through the ileo-caecal junction and the nature of 
delayed release formulations, it is anticipated that minimal drug release will occur prior to the 
colonic region.     
A number of studies conducted by Khan et al. (1999 and 2000) showed that it was possible to 
modify the polymer characteristics, through the use of a combination of different grades of 
Eudragit (S100 and L100) as an enteric coating. Khan et al., (1999, 2000) showed that the 
addition of Eudragit L100 to Eudragit S100 in varying ratios altered the pH at which the 
tablet solubilised. This would enable formulations to be created with high accuracy, 
facilitating the possibility of tailoring them, depending upon the specific GI tract pH of the 
patient. Although this work proved useful in indicating that specific formulations can be 
produced, the inclusion of Eudragit L100 led to polymer solubilisation occurring at a pH less 
than 7, which would therefore cause drug release in the proximal small intestine, as opposed 
to the distal region at the ileo-caecal junction. Furthermore, despite the ability to produce a 
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more specific pH solubilisation point between the range of Eudragit L100 and S100 (pH 6 
and 7), it would still be susceptible to the intra and inter patient variables, as discussed 
previously. With this in mind, it is hypothesised that a system using the pH threshold of 
Eudragit S100 would enable solubilisation in all patients at the distal section of the small 
intestine, with a view for continued drug release throughout the large intestine.      
1.6.3. Microbially triggered polymers  
Microbially triggered polymers aim to utilise the vast quantity of anaerobic bacteria found 
within the colon (section 1.4.3.4.). The main polymers that have been investigated are non-
starch polysaccharides which can only be solubilised by the microflora in the colon and 
therefore will remain intact throughout the stomach and small intestine. Examples of the 
biodegradable polysaccharides used in colonic drug delivery include amylase, chitosan 
dextran, guar gum and pectin (Kumar et al., 2011). Each of these polysaccharides are 
solubilised within the large intestine due to specific enzymes as they are resistant to GI 
enzymes found within the small intestine. These polysaccharides are also soluble in acidic 
conditions and therefore an enteric coating would be required to prevent solubilisation in the 
stomach. Of the polysaccharides investigated a number of studies have managed to coat 
liposomes with chitosan through a number of techniques (Mady et al., 2009; Laye et al., 
2008; Wei and Bin, 2003; Guo et al., 2003; Henriksen et al., 1994 and 1997).  
1.7. Systems for colon specific drug delivery  
A number of approaches have been adopted in creating formulations for drug delivery to the 
colon, each of which using either one or a combination of the polymers previously 
introduced. A number of formulations have shown varied degrees of success through both in 
vitro and in vivo trials, each of which are outlined in the following section.   
1.7.1. Prodrugs  
Prodrugs are pharmacologically inactive derivatives of a parent drug molecule that require in 
vivo transformation, either spontaneously or by enzymatic degradation, to form the active 
drug (Tiwari et al., 2010). Prodrugs for colonic drug delivery are hydrolysed by the extensive 
number of enzymes produced by the colonic microflora including azoreductase, β-
galactosidase, β-xylosidase, nitro-reductase and glycosidase deaminase (Sinha and Kumria, 
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2001). These enzymes have led to a number of conjugates being investigated as possible 
prodrugs for colonic drug delivery including amino acid, glycoside, glucuronide, azo, 
dextran, and cyclodextrin. A prodrug for colonic drug delivery is normally successful if it is 
hydrophilic and bulky to minimise absorption in the upper GI tract, but upon arrival into the 
colon is converted into a more lipophilic drug molecule which is available for absorption. 
The advantages of prodrugs include their ability to deliver high percentages of the active 
ingredient directly to the colon with limited side effects and much simpler production 
techniques required in comparison to more complex multi-particulate drug carrier systems.   
The prodrug approach has a number of disadvantages including the lack of versatility as the 
formulation depends upon the functional group available on the drug moiety for chemical 
linkage. A further drawback is the fact that prodrugs are classified as new chemical entities 
and would therefore require more extensive trials than using an existing active ingredient in a 
drug delivery formulation. Furthermore to this the possible biological side effects of the 
carrier molecule are relatively unknown and would therefore require further investigation or 
prodrugs would need to be limited to the use of natural polysaccharide carriers (dextrans, 
cyclodextrins) as opposed to the synthetic carriers.          
1.7.2. Pressure-controlled colon delivery capsules (PCDCs) 
Digestive processes in the colon are controlled by forcible peristaltic movements that are 
termed mass peristalsis (Patel et al., 2008). The mass peristaltic waves only occur three to 
four times a day and are of a short duration. Despite this, the mass peristalsis temporarily 
increases the luminal pressure within the colon, which can be exploited for targeted drug 
delivery. PCDCs were initially developed by Takaya et al., (1995) by producing capsular 
shaped suppositories coated with the water-insoluble polymer ethyl cellulose. Sufficient fluid 
is present in the stomach and small intestine to prevent drug leakage. Due to the reabsorption 
of water in the colon, the viscosity of the luminal content increases, causing mass peristalstis. 
The increased pressure associated with mass peristalsis (reported up to 110 mmHg in healthy 
subjects with a duration of 14 seconds (Rao et al., 2001)), causes the PCDC to rupture and 
release the contents into the colon. The variables reported to influence the performance of 
PCDCs are the thickness of the ethylcellulose membrane, and the capsule size and density.    
Chapter 1  Introduction 
33 
 
1.7.3. Azo hydrogels 
A number of studies have described the synthesis and characterisation of azo hydrogels for 
colonic drug delivery (Brondsted and Kopecek, 1991; 1992; Kopecek et al., 1992; Akala et 
al., 1998). Colon targeting is achieved by combining pH-sensitive monomers with azo cross-
linking agents in the hydrogel structure. During transit through the GI tract the hydrogel 
continues to swell as the pH increases (to a maximum of approximately 7.4) at the ileo-caecal 
junction. Due to the swelling throughout the GI tract, upon entering the colon, the hydrogel 
cross-links are accessible to colonic enzymes and can therefore be degraded through the 
cleavage of the cross-links.           
1.7.4. Novel colon targeted delivery system (CODESTM) 
CODESTM is a colon specific drug delivery system that uses specific polysaccharides that are 
only degraded by bacteria available in the colon (Yang et al., 2003; 2002; Takemura et al., 
2000; Watanabe et al., 1998). The system usually involves the core tablet consisting of the 
active polysaccharide plus any other excipients coated by three different polymer layers 
(Figure 1.6). The three coating layers (from inside to out) include an acid soluble polymer, a 
hydroxypropyl methylcellulose (HPMC) barrier layer and finally a pH responsive enteric 
coating. Upon entry into the GI tract the core is protected by the enteric coating until the 
small intestine at which point the pH rises above 7 and therefore causes the enteric coating 
and the HPMC barrier to dissolve. The inclusion of the HPMC barrier is necessary to prevent 
any interaction between the oppositely charged enteric coating and acid soluble polymer. The 
acid soluble polymer (in many cases Eudragit E100) is soluble at pH<5 and therefore is only 
slightly permeable/swellable at a higher pH (those found in the small intestine). Upon arrival 
into the large intestine the bacteria degrade the polysaccharide and subsequently cause a 
significant decrease in pH in the surrounding area to increase dissolve the acid soluble 
polymer layer and lead to extensive drug release. In Figure 1.6 the degradation of lactulose 
generates organic acid therefore leading to a localised decrease in pH to allow for drug 
release through the dissolution of acid soluble coating layer. Other polysaccharides used 
within the CODES™ include mannitol, maltose, stachyose and fructooligosaccharide.   
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Figure 1.6. Schematic diagram showing the components of CODESTM. The diagram indicates the release 
of lactulose maintained within a traditional tablet core as the active ingredient within the system 
(Takemura et al., 2000).  
Whilst these formulations have identified and addressed the advantages of colonic drug 
delivery, little consideration is given for the actual uptake of the drug within the colon. A 
number of researchers have shown that using liposomes for site specific colonic drug delivery 
can provide a number of advantages over a standard reservoir system. This is discussed 
below after a general introduction to liposomes.      
1.7.5. Liposomes as drug delivery vesicles 
1.7.5.1. Introduction to liposomes  
Liposomes are micro-particulate spherical vesicles which spontaneously form when 
phospholipids are appropriately dispersed in an aqueous medium. The phospholipid 
molecules contain a hydrophobic, non polar tail (fatty acid chain) attached to a hydrophilic 
polar head. 
When placed in an aqueous environment the lipids align, with the hydrophilic heads facing 
the aqueous solution and the hydrophobic tails pointing inwards (Figure 1.7). The formation 
of the bilayer leads to closed phospholipid vesicles forming, which are considered stable due 
to the significant hydrophobic effect (Tanford, 1980). Each bilayer encapsulates an aqueous 
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space, with the number of spaces equalling the number of bilayers within the liposome. 
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Table 1.8 – Classification of liposomes through their diameter and number of bilayers, Storm 
and Crommelin (1998) 
 
 
 
 
 
 
 
 
 
 
 
The membrane transition temperature (Tm) of liposomes is often described as the point at 
which the bilayer membrane changes from a well ordered solid state to a fluid, more 
disordered state (Table 1.9). The Tm is not only important for the production of liposomes but 
also its ability to retain any molecules encapsulated within the aqueous spaces can be greatly 
affected.      
Bilayer properties of liposomes can be modified through both the alteration of the lipid 
component and/or the addition of further constituents, for example cholesterol (CH). Changes 
in liposomal mechanical properties can be observed when various types of lipid are used, due 
to their difference in Tm. Both naturally occurring and synthetic phospholipids are used in the 
production of liposomes with their characteristics varying considerably. Naturally occurring 
phosphatidycholine derived from egg yolk or soya bean (EPC or SPC), are used extensively 
in liposome production due to their biocompatibility, low transition temperature (facilitating 
Liposomal type Abbreviation Typical diameter 
Multilamellar large vesicle MLV >0.5µm 
Oligolamellar vesicle OLV 0.1-1µm 
Small unilamellar vesicle SUV 20-100nm 
Large unilamellar vesicle LUV >100nm 
Giant unilamellar vesicle GUV >1µm 
Multivesicular vesicle MVV >1µm 
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liposome production) and availability. Synthetic phospholipids used in the production of 
liposomes include dimyristoylphosphatidylcholine (DMPC) and dimyristoylphosphatidic acid 
(DMPA), which have an increased Tm but offer a more stable membrane. It has been shown 
that the inclusion of CH can further stabilise the bilayer and therefore decrease their 
permeability in the liquid state with amounts up to 3 molar % softening the bilayer, and any 
amounts above 3-4 molar % showing a stiffening effect and therefore a reduction in the rate 
of drug release (Lemmich et al., 1996). Not only can altering the phospholipid and the 
inclusion of CH add stability to the membrane but it can also help prevent bilayer 
solubilisation through the attack of bile salts (Rowland and Woodley, 1980).  
 
Table 1.9 – Phospholipids and their corresponding transition temperature, Tm 
 
Phospholipid 
Transition 
temperature, Tm (°C) 
Egg Phosphatidycholine (EPC) -5 to -15 
Soya Phosphatidycholine (SPC) -20 to -30 
Dimyristoylphosphatidylcholine (DMPC) 23.5 
Dipalmitoylphosphatidylcholine (DPPC) 41.3 
Distearoylphosphatidylcholine (DSPC) 55.1 
 
The properties of liposomes make them ideal for use as a drug delivery system due to their 
ability to carry a variety of substances, structural versatility and non toxicity of their 
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components. The aqueous spaces within a liposome can be used to store hydrophilic drug 
molecules whilst hydrophobic drugs can be encapsulated within the bilayer. The advantages 
of using liposomes as a drug delivery system are those relating to (Storm and Crommelin, 
1998): 
 
Structural and physiochemical characteristics – liposomes are a very diverse family of 
vehicles and can be tailored to suit the application.  
Distribution – liposomes can target, either actively or passively, specific areas in the body for 
treatment (site specific) or can be directed away from sites that are sensitive to the toxic 
nature of the drug (site –avoidance). 
Duration – liposomes act as a reservoir of drug that is slowly released over time leading to 
increased duration of action with a fewer number of administrations. 
Protection – liposomes can protect the drug from certain detrimental factors that may be 
present in the host e.g. degradative enzymes. 
Internalisation – liposomes can interact with target cells allowing the intracellular delivery of 
drugs that would normally have unfavourable physiochemical characteristics in this respect 
e.g. DNA molecules. 
Amplification – if the drug is an antigen, liposomes can act as immunological adjuvant in 
vaccine formulations.  
 
Due to the number of advantages of using liposomes for drug delivery, research and 
development has taken place to produce liposomes suitable to treat a number of conditions. A 
number of liposomal products have been developed for parenteral administration and are 
present in marketplace today, e.g. the anticancer products Doxil® (Ortho Biotech), Myocet® 
(Zeneous) and DaunoXome® (Gilead Sciences) (Zhang et al., 2008). The other main field of 
liposomal drug delivery is in the treatment of systemic fungal infections including Abelcet® 
(Enzon) and Ambisome® (Gilead Sciences). Other drugs are emerging on the market which 
use liposomes via the intravenous route including Visudyne® (QLT, Novartis) which is a 
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liposomal form of the drug verteporfin which is administered for the treatment of age related 
macular degeneration (Zhang et al., 2008). The majority of liposomal drug products within 
the marketplace are for intravenous administration. To extend their applicability to a wider 
range of disease states, it would be beneficial to create formulations for oral administration.
        
1.7.5.1. Advantages of liposomes for colonic site specific delivery 
A number of researchers have recognised the potential advantages of producing liposomal 
formulations that deliver the active ingredient to the colonic region. As mentioned previously 
specific targeting to the colon provides the ability to deliver active ingredients both topically 
and systemically, it has been shown that liposomes have the ability to adhere to both healthy 
and inflamed colonic mucosa in vitro (Tirosh et al., 2009; Jubeh et al., 2004). Tirosh et al. 
(2009) showed that negatively charged (anionic) liposomes preferentially attached 
themselves to the inflamed mucosa of the rat colon in low pH conditions characteristic of 
those found during ulcerative colitis. The lower pH values observed in inflammatory bowel 
disease relate to the production of mucosal bicarbonate and lactate, bacterial fermentation of 
carbohydrates and mucosal absorption of short chain fatty acids which could all influence the 
pH of the colon. In comparison, at a neutral pH no preferential attachment of liposomes was 
observed and therefore no improved rate of active ingredient uptake (transferrin) was 
identified. This indicates that the use of anionic liposomes would be preferential when 
treating ulcerative colitis due to their increased affinity to inflamed colonic mucosa. 
Similarly, Jubeh et al. (2004) reported a two-fold increase in anionic liposomal adhesion to 
inflamed colonic mucosa in comparison to that of neutral or cationic liposomes. Interestingly, 
a three-fold increase in adhesion for cationic liposomes was observed compared to neutral 
and anionic liposomes for healthy colonic mucosa which would indicate that they may be 
suitable for the systemic delivery of proteins through adhesion to healthy colonic mucosa.  
The interaction of liposomes with colonic mucosa has led a number of researchers to explore 
the possibility of treating both local and systemic diseases through liposomal colonic 
targeting. D’Argenio et al. (2006) considered liposomes as vehicles for delivery of carnitine 
for the reversal of colitis. Kesisoglou et al. (2005) used liposomes for encapsulating 
5-aminosalicylate and 6-mercaptupurine against inflammatory bowel disease. Although for 
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colonic action, administration of the liposomes in all of these studies was either intraluminal 
or in vitro to excised tissue; delivery via oral administration was not explored. 
One study that has explored the oral route for colonic liposomal drug delivery is that of 
Xing et al. (2003). The study describes a multicomponent drug delivery system which 
comprised drug loaded liposomes within Eudragit-coated alginate beads. The resultant 
formulation was assessed in vitro using simple buffer solutions of pH 1.2, 6.8 and 7.4. After 
two hours in pH 1.2 buffer very little release was shown indicating that the coating 
mechanism would survive the stomach in vivo. Upon exposure to the pH 6.8 phosphate buffer 
for three hours considerable drug release was shown (approximately 45%) which was 
attributed to the dissolution of the Eudragit S100 coating to expose the gel beads 
subsequently causing drug release. This would indicate that drug release would occur prior to 
the ileum and therefore significant amounts of the active ingredient would not reach the target 
of the colon. In the final three hours in pH 7.4 phosphate buffer it was shown that drug 
release up to approximately 90% could be observed. Despite the obvious protection of the 
formulation through simulated stomach conditions the formulation has a number of 
drawbacks that could be improved upon. It is indicated that drug release was controlled by 
the alginate and not the liposomes therefore making it unclear as to whether the liposomes 
could be subsequently released allowing them to adhere to the colonic mucosa, a major 
advantage of using liposomes as previously described. Furthermore, the in vitro drug release 
trials showed considerable drug release whilst in a simple pH 6.8 phosphate buffer, indicating 
that exposure to in vivo conditions containing bile salts would cause further drug release and 
therefore reduce the quantity of drug delivered to the colon.      
1.7.5.2 Production of liposomes 
As liposomes are produced by the spontaneous interaction between phospholipids and water 
(with agitation of some form – Lasic 1998), the emphasis when producing liposomes is 
mainly on the ability to form vesicles of the right size and structure with the highest 
entrapment efficiency (New, 1990). A wide variety of techniques has been adopted to 
produce liposomes which include mechanical dispersion techniques, dried-reconstituted 
vesicles, and solvent dispersion techniques (ethanol/ether injection vesicles and reverse phase 
evaporation vesicles). Most methods of producing liposomes can be said to involve three 
stages, which include the drying down of lipids from organic solvents, dispersion of the lipids 
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in aqueous media and subsequent purification of the resultant liposomes. In this work it was 
decided that a method based on that of Bangham et al. (1965) would be adopted throughout, 
as the actual production of liposomes is not under investigation, but the possibility of 
producing a formulation suitable for colonic drug delivery is. This method enabled direct 
comparison with the numerous studies that have investigated the coating of thin film 
hydration vesicles (Takeuchi et al., 2005; Guo et al., 2003; Khan et al., 2000).     
 
Thin film hydration 
The original method of producing liposomes was established by Bangham et al. (1965) and is 
a simple thin film hydration method, also known as the ‘hand shaking’ method. The method 
involves producing a lipid solution in an organic solvent such as chloroform. The lipid 
solution is then placed in a round bottomed flask, with a rotary evaporator being used to 
remove the solvent and leave a lipid film deposited on the sides of the flask. Any residual 
solvent is then removed by drying the film under a stream of nitrogen. The film is then 
hydrated with an aqueous buffer that is above the Tm of the lipid mixture. The flask is then 
agitated through hand shaking (sometimes glass beads are used) which displaces the thin film 
from the walls of the flask causing the production of liposomes. The liposomal suspension 
produced consists of a heterogeneous MLV suspension with liposomes over 1 µm in size. 
Subsequent processing (see below) can then be completed to produce a more homogenous 
formulation with a specific size range (SUVs, LUVs etc.).      
Sonicated vesicles 
To produce the homogenous SUV liposomal sample it is necessary to use a method which 
imparts energy at a high level on the lipid suspension (New, 1990). Initially Huang et al. 
(1969) produced SUVs with an approximate diameter of 25 nm by using probe sonication 
whilst Johnson et al. (1969) produced similar SUVs using a ultrasonic bath for a prolonged 
period of time (1 – 1.5 hours).  
Probe sonication can be used when suspensions require high energy in a small volume e.g. 
high concentration of lipid or the use of a viscous aqueous phase. As a consequence of this 
process heat is given off and therefore it is essential that the suspension is maintained at a 
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constant temperature by the use of a cooling bath to prevent any lipid degradation. A further 
issue that may arise through probe sonication is the possible contamination of the sample 
through the degradation of the probe therefore suspending Ti particles within the sample.  
Subsequent centrifugation or gel permeation chromatography can be used to separate any 
small MLVs remaining from the SUV population.  
The ultrasonic bath method is more suitable for dilute lipid concentrations of a higher volume 
and as there is a lower energy input, there is subsequently a lower risk of lipid degradation 
due to heat. The risk of contaminants entering the solution is reduced as the formulation can 
be maintained in a sealed container throughout the sonication process. The main drawbacks 
of the bath sonication method include the need for prolonged sonication time and the final 
liposome size may not be homogenous and thus there may be a requirement for centrifugation 
(Barenholtz et al., 1977).  
Membrane extrusion  
The use of membrane filters to reduce the size of liposomes has been investigated 
considerably with two main methods having evolved. The first method uses what is described 
as a tortuous path membrane which consists of a number of fibres criss-crossed over each 
other, which leads to specific channels which liposomes are forced through. The channel or 
pore size is controlled by the density of the fibres used in the membrane manufacture. The 
drawback of this method is that larger liposomes can become stuck within the membrane 
channels and this therefore blocks the filter. The more widely used method is that of the 
Nuclepore membrane which consists of uniform pores through a thin sheet of polymer. A 
range of pore sized membranes can be obtained, ranging from 1 µm to 50 nm. Liposomes 
which are much greater in size than the membrane will be broken down into smaller vesicles 
when extruded through the membrane. The liposomes which are only marginally larger than 
the pore size will be able to change their conformation and squeeze though the pore, which 
means despite a number of extrusions a small percentage of the liposomes will be larger than 
the pore size itself.           
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1.8. Objectives of current work    
The overall objective of this work was to develop and evaluate a (polymer-coated) liposomal 
system that will potentially allow for site specific drug delivery at the colon following oral 
administration. The liposomal component will be developed to encapsulate a model drug that 
can be either encapsulated in the aqueous space or the lipid bilayer. It is hypothesised that the 
development of a formulation containing materials with both a pH and enzyme triggered 
response would increase the accuracy of the targeting and subsequently reduce the problems 
associated with inter and intra patient variability.  
With the overall objective in mind, the specific aims were to: 
Introduce colonic drug delivery outlining the specific advantages and challenges involved. 
Investigate the characteristics of specific coating polymers used in targeted colonic drug 
delivery, comparing the difference between enzyme and pH controlled mechanisms.  
Produce a coated liposomal formulation for the purpose of site specific drug delivery to the 
colon. The direct coating of liposomes will be investigated with the possibility of producing a 
more robust system by encapsulating liposomes within a solid microsphere.  
Assess each formulation using a number of standard techniques to characterise formulations 
indicating any change in particle charge, size and morphology. 
Conduct drug release trials in vitro simulating the stomach, small intestine and colon to 
assess the formulation and its suitability for the desired application of colonic drug delivery. 
In vitro studies will include model bile salts and enzymes to produce an accurate 
representation of the GI tract.   
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ABSTRACT 
A number of different polymers are used in the production of site specific drug delivery 
vesicles. The polymers used can be categorised by the specific triggers that cause their 
solubilisation and/or degradation whether it be pH, residence time or enzymatic action. The 
two polymers used throughout this thesis have been introduced in this chapter. Eudragit 
S100, a pH responsive polymer, and chitosan, an enzyme triggered polysaccharide, have been 
selected to produce a site-specific drug delivery system to target the colon and subsequently 
release liposomes containing the active ingredient. Knowledge of the two polymers has been 
built up through a number of techniques including gel permeation chromatography (GPC), 
Fourier transform infrared spectroscopy (FTIR) and scanning electron microscopy (SEM). 
GPC provided an insight into the specific molecular weight of Eudragit S100 (122,500) and 
chitosan (237,500) which are shown to have a considerable impact on the dissolution. FTIR 
provided an insight into the ‘as received’ nature of the polymers which further enables the 
prediction of the solubilisation mechanisms/speeds due to the specific chemical structure. 
SEM offered a visual guide to the polymers with characterisation being essential to observe 
any changes that may be observed during subsequent processing. In depth discussions of the 
specific solubility mechanisms for each polymer are included to give an insight into their 
response throughout the GI tract conditions.   
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2.1.1. Introduction 
In order to investigate the possibility of coating of liposomes with polymers it is essential to 
understand the polymer and subsequently the coating mechanism that may occur. The overall 
aim of this chapter is to introduce the polymers to be used throughout this thesis and 
subsequently provide an insight into their specific properties. A number of techniques will be 
used including Fourier transform infra-red spectroscopy (FTIR) and gel permeation 
chromatography (GPC) to identify the differences in the polymers and therefore hypothesise 
how they may coat liposomal surfaces. These techniques will indicate the specific properties 
including the specific chemical bonds, molecular weight and morphology of the polymer. 
Furthermore, imaging techniques will be adopted to visualise the polymers in their as 
received state and therefore allow comparisons to be made when the liposome coating is 
undertaken.    
2.1.2. Introduction to polymer science 
Polymers can simply be described as long chain molecules of high molecular weight 
(Sperling, 1999). They are termed macromolecules which are produced by covalent bonding 
of repeat monomer units through a process called polymerisation. Bonding along the chain is 
strong but intramolecular forces only take place through weaker forces of either van der 
Waals or hydrogen bonds.  
Polymers can adopt two morphologies; amorphous or semi-crystalline. The amorphous state 
refers to a randomly entangled structure with no long range order. The glass transition 
temperature (Tg) refers to a range of temperatures whereby the amorphous polymer changes 
from a brittle solid to a viscous liquid upon heating. Crystallisation within the polymer is 
prevented due to either the irregular structure or due to rapid quenching of the sample which 
prevents the formation of ordered crystalline structures. Tg is not only dependent upon the 
chemical structure of the polymer but is also influenced by the cooling rate adopted through 
the crystallisation temperature (Tc), therefore the thermal history of a sample can have a 
considerable effect upon its properties. 
The semi-crystalline state of a polymer refers to a highly ordered microstructure that alters 
from a solid to a liquid at the melting point (Tm). Many polymers are semi-crystalline and 
have regions of both highly ordered chains and random entanglements therefore, altering in 
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state over a range of temperatures. Semi-crystalline polymers can be seen to form spherical 
structures that are termed spherulites (Figure 2.1). It has been shown that the spherulite 
consists of thin lamellae crystals that have grown radially, which are made of extensively 
folded polymer chains. The lamellae regions are separated by thin regions of amorphous 
material. The initial process of crystallisation is termed nucleation, and can either involve the 
attachment of polymer chains to a nucleating agent (heterogeneous nucleation), such as dust 
or an inorganic material, or the chains become aggregated within the melt (homogenous 
nucleation). The spherulite grows by repeated branching, which develops an intermediate 
wheat sheaf structure, with even further branching creating the spherical structure.  
 
Figure 2.1.Schematic diagram of polymer spherulite with chain folded lamellae (Callister, 2003)  
2.2. Polymers for oral colonic drug delivery 
2.2.1. Introduction to polymers for oral colonic drug delivery 
A number of polymers have been explored for the application of triggered oral colonic drug 
delivery including pectin, alginate, chitosan, Eudragit and cellulose acetate phthalate (CAP) 
(Tiwari et al., 2010; Sinha and Kumria, 2003). As previously discussed, the main triggers for 
polymer degradation and subsequent drug release utilise either the changes observed in the 
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GI tract (pH, enzyme, temperature) or relate to a specific transit time through the tract. A 
number of studies have reviewed the advantages of each method, with no single trigger 
release mechanism consistently providing a successful release in all experiments (Yang et al., 
2002; Patel et al., 2008). It has therefore been considered that a trigger system utilising two 
or more of the mechanisms would be more successful as it would reduce the influence that 
patient variability may have upon the drug delivery system (Bajpai et al., 2008). This strategy 
has been seen with the success of the CODESTM technology which uses two different 
polymers (pH and enzyme controlled) to provide drug release in the colonic region. Due to 
the significant variance that can be observed in transit times through the GI tract within both 
the fed and fasted states it has been decided to concentrate on the specific triggers of pH and 
enzyme change throughout this thesis.  
To investigate oral colonic drug delivery it has been decided two polymers will be 
investigated, one being pH dependant and one enzyme controlled. The pH triggered polymer 
selected is that of Eudragit S100 which has been used in a number of studies for colonic drug 
delivery and has also shown flexibility as it can be combined with Eudragit L100 to adjust its 
specific solubility profile (Khan et al., 1999a; 1999b). The enzyme triggered polymer to be 
used is chitosan, which is emerging as very promising for colonic drug delivery due to being 
solubilised by enzymes only found within the colon (Jain and Jain, 2007). In depth 
investigations into each of these polymers are required to further understand their properties 
and solubility mechanisms. A number of studies have been undertaken to characterise the 
polymers in their ‘as received’ state and therefore build up an understanding of how they will 
respond to the changing conditions both experimentally in vitro but also what would be 
observed in vivo.    
2.2.2. Eudragit S100 
2.2.2.1. Introduction 
The most commonly used polymers for pH responsive drug delivery are methacrylic acid and 
methyl methacrylate ester copolymers which are marketed under the brand name of Eudragits 
(Evonik, Germany). A range of pH responsive Eudragits are available (S100, L100, L30-
D55), with each one showing a different solubility trace (Figure 2.2). The Eudragit range of 
polymers have been used in a number oral delivery systems due to the number of advantages 
they possess, including: 
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• Protects active ingredients sensitive to gastric fluid
• Offers effective GI tract and colon targeting
• Provides increased drug effectiveness
• Offers either pH or time dependent release profiles through solubilisation profile
• Good storage stability 
Eudragit S100 was selected for this work
an ideal polymer for targeted drug release 
benefits of which were addressed in the previous chapter. A number of studies have used 
Eudragit S100 for colonic drug delivery (Khan 
release mechanism suitable for protection of the active ingredie
small intestine with subsequent release occurring at the ileo
Figure 2.2. Dissolution profiles of varying grades of Eudragit polymers (evonik.com). It has been shown 
that different grades of Eudragits can be combined to produce polymers with different solubility profiles 
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 due to it being soluble above pH 7.0 and therefore 
to the distal small intestine 
et al., 1999; 2000), each of which show a 
nt through the stomach and 
-caecal junction and beyond. 
(Khan et al., 1999a; 1999b).   
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and beyond, the 
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2.2.2.2. Chemical structure 
Observing the specific chemical structure of Eudragit S100 is important for a number of 
reasons. The exact chemical structure of the Eudragit determines the solubility profile, more 
specifically that of the side chains and their ratio e.g. Eudragit L100 (>pH 6) has the ratio of 
1:1 of free carboxyl groups to ester groups whilst Eudragit S100 (>pH 7) has the ratio 1:2.  
Furthermore, it may provide an insight into the possible interactions that could occur 
throughout the GI tract in relation to bile salts, enzymes etc. The specific chemical structure 
of Eudragit S100 is shown in Figure 2.3.   
 
Figure 2.3. Molecular structure of Eudragit S100. 
 
2.2.2.3. Mechanism for coating with Eudragit S100; organic vs aqueous 
It has been shown that the specific coating technique used will alter the properties of Eudragit 
S100 when investigated in vitro (Ibekwe et al., 2006a; Ibekwe et al., 2006b; Bando et al., 
2006). Traditionally film coatings are achieved by applying the polymer from a solution 
usually using Eudragit S100 dissolved in organic solvents, but there are associated 
environmental and health concerns. Film formation from organic polymer solutions results 
from the evaporation of the solvent which causes an increase in polymer concentration and 
subsequent inter-diffusion of the polymeric chains. Further solvent evaporation leads to a 
solvent free polymeric film being formed. Despite this, there will always be certain quantities 
of residual solvent within the system. 
With this in mind a formulation suitable for processing as an aqueous dispersion was 
developed which was prepared by the partial neutralisation of the methacrylic acid group of 
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the polymer. Aqueous dispersions are created through the dropwise addition of a dilute 
ammonia solution to Eudragit S100 dispersed in water whilst undergoing high speed stirring. 
Film formation from aqueous polymer solutions occur with the polymer particles coalescing 
into a film that happens in conjunction with the evaporation of water. The addition of 
ammonia can be calculated to give a specific level of neutralisation and therefore predict the 
resultant solubility profile. A number of studies use the addition of ammonia leading to 
approximately 15% neutralisation of the methacrylic acid group and therefore altering the 
solubility profile of the resultant film (Ibekwe et al., 2006a and 2006b; Bando et al., 2006). 
The neutralisation of the acid group reduces the ratio of side groups (from 2:1 towards 1:1), 
therefore producing a polymer solution between that of L100 and S100, and subsequently 
producing a film that is soluble between pH 6 and 7.  
The experimental results comparing the use of organic solutions and aqueous dispersions are 
considerably different. As expected both formulations produce a coating that provides an 
effective gastro-resistant barrier, where the pH is very low and therefore neither the organic 
or aqueous formulations show any sign of drug release. Ibekwe et al., (2006a) showed that in 
five out of eight patients the organic coated tablets reached the ascending colon, with the 
remaining three subjects showing signs of the tablet staying intact which was attributed to 
low patient GI tract pH. In comparison for aqueous coated tablets seven out of eight 
participants showed complete tablet disintegration in the proximal to mid small intestine and 
therefore indicated it would not be suitable for ileo-caecal drug delivery. Similarly, 
Bando et al., (2006) showed that two cast films, organic and aqueous, had negligible weight 
loss when exposed to 0.1 M HCl (simulated gastric conditions), but were considerably 
different during the simulated small intestine conditions. It was shown that during a 4 hour 
period in pH 6 PBS the aqueous film displayed approximately 40% weight loss in 
comparison to the negligible loss for the organic film. It was then shown that in pH 7 PBS 
that 100% weight loss occurred after 2 hours for the aqueous film whilst the organic took 
over 4 hours to completely dissolve. This indicates that the use of aqueous dispersions for 
coating, although favourable in terms of environmental and health concerns would 
considerably alter the solubility profile of the polymer and subsequently make it unsuitable 
for ileo-caecal drug delivery.  
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2.2.2.4. Solubilisation mechanism of Eudragit S100 
In order to understand the specific properties of a drug delivery formulation it is essential to 
appreciate the solubility mechanism involved in the site specific release. In the case of 
Eudragit, a pH responsive polymer, any alteration in the chemical structure will lead to an 
alteration in solubility profile. The solubility mechanism for pH responsive polymers 
revolves around the ionisation of the functional group when a shift in pH occurs. The 
ionisation leads to a large number of groups with the same charge, therefore causing 
repulsion and subsequent expansion and solubilisation. The difference in the pH at which 
solubilisation occurs is due to the ester group which is evident with the difference between 
Eudragit L100 and S100. Eudragit L100 has a 1:1 carboxyl to ester group ratio, while S100 
has a 1:2 ratio in favour of the ester group and therefore solubilisation occurs slower and at a 
higher pH.    
2.2.3. Chitosan 
2.2.3.1. Introduction 
Chitosan was selected as the enzyme triggered polymer to be used as it is a naturally 
occurring polysaccharide, cost effective, and available in abundance. Chitosan is formed 
through the alkaline deacetylation of the mucopolysaccharaide chitin. The use of chitosan is 
an attractive proposition as it is solubilised by the enzymes present in the colonic microflora 
and therefore presents a characteristic for colonic drug delivery. Chitosan refers to a large 
number of polymers which differ in their degree of deaceylation (40-98%) and molecular 
weight (50,000-2,000,000 Da) which has been shown that the molecular weight of the 
chitosan influences the solubility, and therefore the release profile considerably (Hejazi and 
Amiji, 2003; Zhang and Neau, 2002).  A chitosan grade termed by the manufacturers as low 
molecular weight (Sigma Aldrich; product code: 448869), was used throughout, however the 
specific molecular weight would be established through GPC. The manufacturer’s data sheet 
indicated that the supplied chitosan was 75-85% deacylated which further influences the 
solubility of the chitosan. It has been shown that higher levels of deaceylation lead to a 
coating with in increased solubility in comparison to chitosan with a lower deaceylation 
percentage (Filipović-Grčić et al., 2001).       
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2.2.3.2. Chemical structure of c
Chitosan is a hydrophilic, biocompatible and biodegradable polymer that is derived from 
chitin, which is a derivative of glucose predomin
shrimp. To fully understand the structure of chitosan it is necessary to view the chemical 
structure of chitin and therefore the changes that occur during the alkaline deaceylation
produce chitosan (Figure 2.4
acetylglucosamine with the repeat units being joined through a 
comparison chitosan is composed 
glucosamine (deacylated) units joined 
deaceylation, which is normally completed in 40% sodium hydroxide at 120
removes the acetyl groups (CH3
 Figure 2.4. Chemical structure of chitin and chitosan following the alkaline deaceylation of chitin.  
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2.2.3.3. Solubilisation of chitosan by the colonic microflora 
As discussed in the previous chapter the human microflora is a complex system containing an 
enormous variety of both aerobic and anaerobic bacteria creating a hugely complex 
ecosystem. Polysaccharidases like glucosidases and glycosidases are released by the colonic 
microflora, which are responsible for the degradation of polysaccharides (Jain et al, 2007). 
These polysaccharidases are responsible for the random scission of the 1,4 glycosidic bonds 
observed between the single monomer units in chitosan. As the human microflora activity has 
been shown to not be affected by diet, age and geographic location it can be assumed that 
patient variability would not influence the ability of the colonic region to digest chitosan. 
Furthermore it has been shown that the anaerobic bacteria can react to changing mixtures of 
carbohydrates entering the colon, by recognising a variety of substrates the appropriate 
digestive enzyme can then be produced to ferment the specific bonds involved.  
2.3. Materials 
2.3.1. Polymers 
Eudragit S100 was a gift from Evonik (Essen, Germany). Chitosan (low molecular weight – 
34234) was purchased from Sigma Aldrich (Dorset, England). Polymers were used in their 
‘as received’ state.   
2.4. Apparatus and methodology 
2.4.1. Gel Permeation Chromatography (GPC) 
2.4.1.1. Introduction to GPC 
GPC is a technique used to determine the molecular weight distribution of a polymer. GPC is 
a form of size exclusion chromatography which is predominately used for sizing polymers. 
The technique uses the size exclusion principle whereby a particle is defined by its 
hydrodynamic radius and therefore may or may not be able to enter small pores in a bed of 
cross-linked polymer particles (Sperling, 1999). The technique uses a column packed with gel 
(stationary phase) which has a specific pore size. A solvent is then passed through the column 
(mobile phase) at a controlled speed. The sample is then injected into the mobile phase where 
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it begins to interact with the stationary phase (Figure 2.5). Larger particles are unable to 
interact with the pores of the gel and therefore pass through the column relatively 
uninhibited, while the smaller particles diffuse in and out of the pores via Brownian motion 
and are therefore delayed. The molecular weight can then be related to the specific retention 
time of the polymer within the column.     
All GPC was completed by Rapra Smithers Technology Ltd. (Shawbury, UK). Due to the 
difference in samples, two different methods were required for the GPC of Eudragit S100 and 
chitosan which are outlined in sections 2.3.1.1 and 2.3.1.2 respectively.  
  
 
Figure 2.5. Diagrammatic representation of GPC 
(http://whale.wheelock.edu/bwcontaminants/analysis.html).    
 
2.4.1.2. GPC conditions for Eudragit S100 
Eudragit S100 had been proven insoluble in chloroform or tetrahydrofuran and therefore 
N,N’dimethylsulphoxide was adopted as the solvent. A solution was prepared by adding 15 
ml of the solvent to 30 mg of chitosan, heated to 95°C, with shaking for 4 hours. The solution 
was left overnight to stabilize and then re-heated to 95°C for 30 minutes before filtering 
through a 1.0 µm glass-fibre pad. The instrument used for experimentation was the Polymer 
Laboratories PL-GPC 120 with PL-AS-MT autosampler. The columns used were PL 
PolarGel guard plus 2 x PolarGel-M, 30 cm, 8 µm. A flow rate of 1.0 ml/min and temperature 
of 95°C were adopted throughout the experimentation.  
Chapter 2  Material Characterisation 
55 
 
2.4.1.3. GPC conditions for chitosan 
As chitosan is insoluble in solvents an aqueous based approach was adopted for GPC 
analysis. A chitosan solution was created by adding 10 ml of 10% acetic acid to 20 mg of 
chitosan and left overnight to stabilise. The solution was then warmed to 40°C and held for 
30 minutes before being vortex mixed and filtered through a 0.45 µm PVdF membrane. GPC 
was conducted using the Viscotek triple detector array TDA301 with associated pump and 
autosampler. The column used throughout was PLaquagel OH guard plus PLaquagel OH-
mixed, 30 cm, 8 µm. The eluent used was 0.5 M NaNO3; 0.01 M NaH2PO4 adjusted to pH 
2.0. A flow rate of 1.0 ml/min and temperature of 30°C were selected. The detector used 
observed refractive index with differential pressure and light scattering.  
2.4.2. Fourier Transform Infrared Spectroscopy (FTIR) 
FTIR is a branch of molecular vibrational spectroscopy whereby infra-red light is used to 
excite the covalent bonds into higher vibrations and subsequently the bonds absorb the light 
to a different extent. The specific wavelength at which the light is absorbed relates to specific 
bonds, and therefore is unique to that material and can be used to determine its structure, 
presence and quantification due to the specific absorbance level.  
Infra red spectra of as received polymer samples were recorded using a Fourier transform 
infra red (FT-IR) spectrometer (FT-IR-6300, Jasco, Great Dunmow, UK) with an attenuated 
total reflection (ATR) infrared optical unit (golden gateTM, part number 10586, Specac Ltd., 
Orpington, UK) at a resolution of 2 cm-1. Initially a background scan was completed to 
improve the signal-noise ratio. Each trace consisted of 200 scans. A small amount of dry 
polymer was then placed onto the stage. Each experiment was conducted in triplicate, with 
the mean of three independent trials being displayed. 
 
2.4.3. Scanning Electron Microscopy (SEM) 
SEM was conducted on the as received polymer samples to determine the surface 
morphology, homogeneity of the sample and indicate the general particle size. The samples 
were mounted on a SEM stub and subsequently coated with platinum using an Emscope 
SC500 sputter coater. The samples were coated for 2 minutes, depositing a layer of platinum 
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equivalent to 150 Ångström. Images were taken using a Phillips XL-30 FEG ESEM under 
vacuum conditions.   
2.5. Results and Discussion 
2.5.1. Eudragit S100 characterisation 
2.5.1.1. GPC analysis of Eudragit S100 
GPC analysis of Eudragit S100 indicates a molecular weight (Mw) in the region of 122,000 – 
123,000 (Table 2.1), which is very similar to that of 125,000 published by the manufacturer. 
The Mw is obtained by dividing the chains into a series of size ranges and subsequently 
determining the weight fraction in each range (Callister, 2003). The corresponding number 
average molecular weight which is based on the number fraction within each size range (Mn) 
was shown to be between 72,400-75,000. The wider range observed for Mn is representative 
of the theory that polymers with relatively low molecular mass are more sensitive to Mn 
while Mw is more sensitive when observing high molecular mass polymers. The 
polydispersity (PDI) of the sample is calculated by dividing the Mw by the Mn to give a value 
representative of individual molecular masses in a wide ranging sample. The PDI for 
Eudragit S100 was recorded as between 1.6-1.7, with a value being closer to 1 indicating a 
uniform polymer chain length throughout the sample. The consistency of the results is further 
emphasised by the graph showing a normal distribution for both trials (Figure 2.6) which 
overlap each other very closely.    
Table 2.1. Table showing the GPC results for two separate trials of Eudragit S100 indicating 
the range in Mw, Mn and polydispersity. 
Sample Mw Mn Polydispersity 
Eudragit S100 (A) 122,000 72,400 1.7 
Eudragit S100 (B) 123,000 75,000 1.6 
 
Chapter 2  Material Characterisation 
57 
 
 
 
 
Figure 2.6. Molecular weight distribution for as received Eudragit S100 showing two separate trials 
overlapping each other determined through GPC. 
 
2.5.1.3. FTIR analysis of Eudragit S100 
The FTIR trace provided by the manufacturer is shown in Figure 2.7. The main peaks 
identified in the analysis shows the characteristic bands of the C=O vibrations of the 
carboxylic acid groups at 1705 cm-1 and of the esterified carboxyl groups at 1730cm-1. 
Further ester vibrations were identified at 1150-1160 cm-1, 1190-1195 cm-1 and 1250-1275 
cm-1.     
The FTIR analysis of as received Eudragit S100 is shown in Figure 2.8. The main peaks have 
been identified with their corresponding bonds being outlined in the table accompanying the 
spectra. The main bonds associated with Eudragit S100 and visible on the FTIR trace are the 
C=O vibrations of the carboxylic acid groups at 1705 cm-1 and the esterified carboxyl groups 
at 1726 cm-1. Further ester vibrations can be observed at 1151, 1189 and 1249 cm-1, with CHx 
vibrations visible at 1480, 1451 and 1389 cm-1. When compared with the trace published by 
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the manufacturer the main peaks are the same, with only the level of transmittance being 
different, which is due to the quantities of Eudragit S100 used in the testing method and the 
specific testing parameters used in each trial. The FTIR trace will prove useful in future 
experiments to indicate any change in chemical structure. The technique will prove beneficial 
to ensure that the polymer does not change during both formulation and experimental 
conditions and therefore its desired properties are maintained.  
 
 
Figure 2.7. Manufacturers FTIR trace of Eudragit S100. Dry films of 15 µm thickness were produced by 
placing a few drops of the test solution on a crystal disc (KBr, NaCl) and then dried under vacuum 
conditions at approximately 70°C.   
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Figure 2.8. FTIR trace for as received Eudragit S100 showing the main bonds associated with the polymer structure. The attached table shows the exact wavelength 
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2.5.1.4. SEM analysis of Eudragit S100 
The SEM images for as received Eudragit S100 are shown in Figure 2.9. From the images it 
can be seen that the polymer is spherical in shape within in the size range 10-20 µm. The 
surface of the polymer appears to be relatively smooth with very few inclusions or 
abnormalities. The SEM images are important to future investigations as they will indicate 
whether the Eudragit S100 is present in its original form that has precipitated out of solution 
or whether a film has been formed through the interaction of the Eudragit solution and the 
liposomes. It has been shown in a number of studies that the use of chitosan produces a thin 
coating layer on liposomes (Mady et al., 2009; Laye et al., 2008; Wei and Lu, 2003), but as 
yet the direct coating of liposomes has not been completed using a Eudragit S100 solution.  
 
Figure 2.9. SEM images showing the uniform spherical nature of as received Eudragit S100. 
2.5.2. Chitosan characterisation 
2.5.2.1. GPC analysis of chitosan 
A number of studies have shown that the specific molecular weight of chitosan has a 
profound effect upon the dissolution profile (Lorenzo-Lamosa et al., 1998). Theoretically it is 
known that an increase in Mw would lead to an increase in polymer viscosity/density and 
therefore a significant slowing in drug release times would be anticipated. It is therefore 
essential that the molecular weight of the chitosan being used is known to subsequently 
predict the in vivo response. From the resultant GPC data shown in Table 2.2 and 
corresponding distribution (Figure 2.10) it can be seen that the Mw of the chitosan was 
237,000-238,000 with very little range in Mn and polydispersity being observed, which is 
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indicated by the closely overlapping distributions. Previous studies have shown the use of 
chitosan with a Mw in the region of 250,000 were suitably solubilised when exposed to 
colonic microflora. In contrast to this chitosan with an increased Mw in the region of 400,000 
showed very little solubilisation in the same conditions. Not only is the molecular weight 
important to know for in vivo predictions but it has also been shown that during in vitro 
analysis the molecular weight is an important factor when producing simulated colonic fluid 
to ensure chitosan solubilisation will occur. 
Further advantages of knowing the specific Mw of the chitosan used relates to the surface 
interactions between the polymer and liposomes. It has been observed that chitosan grades 
with lower Mw have shown a more uniform adsorption when coating liposomes 
(Henriksen et al., 1997), which in turn reduces the probability of interaction between 
different particles and subsequently reduces agglomeration. Knowledge of the exact Mw 
would therefore allow predictions to be made of the processes involved during the coating of 
liposomes with chitosan with a lower Mw chitosan having shorter chains and therefore 
produce a charge reversal of particles, whilst a larger Mw would lead to bridging effects 
dominating the process (Henriksen et al., 1994).  
      
Table 2.2. Table showing the GPC results for two separate trials of chitosan indicating the 
range of Mw, Mn and polydispersity 
Sample Mw Mn Polydispersity 
Chitosan (A) 238,000 50,300 4.7 
Chitosan (B) 237,000 50,200 4.6 
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Figure 2.10 – Molecular weight distribution for as received chitosan showing two separate trials 
overlapping each other determined through GPC. 
2.5.2.3. FTIR analysis of chitosan 
The FTIR analysis of as received chitosan is shown in Figure 2.11. The main peaks have been 
identified with their corresponding bonds being outlined in the table accompanying the 
spectra. The main bonds associated with chitosan visible on the FTIR spectra are the NH2 
bending at 1648 cm-1, 1585 cm-1, 896 cm-1 and 641 cm-1. CH2 bending is visible at 1375 cm-1 
and O-C stretching vibrations of the carboxylic acid group can be seen at 1149 cm-1, 1059 
cm-1 and 1024 cm-1.  
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Figure 2.11. FTIR trace for as received chitosan. The attached table shows the exact wavelength of the peak and the corresponding bond it represent
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2.5.2.4. SEM analysis of chitosan 
The SEM imaging of as received chitosan particles are shown in Figure 2.12. It can be seen 
that the chitosan particles vary in both size and shape, showing a number of plate-like 
particles. 
 
Figure 2.12. SEM images showing as received chitosan with irregular particle size and shape throughout 
the sample. 
2.6. Conclusions 
The current chapter provides an introduction to both the polymers being used throughout this 
thesis (Table 2.3). The chemical structures, physical properties and solubility mechanisms 
have been discussed. Through GPC the specific molecular weights of Eudragit S100 
(122,500) and chitosan (237,500) were experimentally derived. The use of FTIR built up a 
picture of each of the polymers specific characteristics including identifying the specific 
bonds within the chemical structure which lead to their solubilisation through different 
triggers. SEM showed a smooth spherical structure to Eudragit S100 whilst in comparison 
chitosan showed an irregular shape with both abnormalities and inclusions throughout the 
sample.  
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Table 2.3. Summary table displaying properties of Eudragit S100 and chitosan. 
Polymer Molecular 
weight 
Chemical Structure SEM image 
Eudragit 
S100 122,500 
 
Chitosan 237,500 
 
 
Beyond the characterisation of the polymers, the specific solubilisation mechanisms have 
been outlined with the specific triggers and subsequent bond cleavage being identified. This 
chapter acts as an introduction to the polymers involved in this thesis and subsequently 
provides a framework to analyse any future results for formulations produced using either 
Eudragit S100 or chitosan.    
 
 
 
 
  
3.0 Exploring direct coating of liposomes with Eudragit 
S100 
 
________________________________________________________________________ 
ABSTRACT  
Liposomes have been coated with the pH responsive polymer Eudragit S100, and the 
formulation’s potential for lower GI tract targeting following oral administration has been 
assessed. Cationic liposomes were coated with the anionic polymer through simple mixing. 
The evolution of a polymer coat was studied using zeta potential measurements and laser 
diffraction size analysis. Further evidence of an association between polymer and liposome 
was obtained using light and cryo electron microscopy. The results show an association 
between the liposome and polymer through a significant change in zeta potential, increased 
size and visual indication of a coating layer. Drug release studies were carried out at pH 1.4, 
pH 6.3 and pH 7.8, representing the pH conditions of the stomach, small intestine and 
ileocaecal junction, respectively. 
The polymer significantly reduced liposomal drug release at pH 1.4 and pH 6.3 but drug 
release was equivalent to the uncoated control at pH 7.8, indicating that the formulation 
displayed appropriate pH responsive release characteristics. Further drug release trials were 
conducted whereby the simulated small intestine condition included the model bile salt 
sodium taurocholate. Whilst the coating layer was not able to withstand the additional 
challenge of bile salts, this reinforces the importance of evaluating these types of 
formulations in more complex media. It is thought the interaction between liposomes and 
Eudragit S100 may follow a non-linear adsorption regime and therefore a solid coat is 
improbable.     
________________________________________________________________________
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3.1. Introduction 
A number of studies have shown that the direct coating of liposomes with chitosan is possible 
through electrostatic interactions (Henriksen et al., 1994 and 1997; Perugini et al., 2000; Guo 
et al., 2003; Mady et al., 2009). The strategy involves the simple mixing of the liposomal 
formulation with a chitosan solution usually dissolved in acetic acid. It has been decided that 
a direct coating method through stirring of a liposome solution with a polymer solution would 
be simplest and therefore the first investigation that will be carried out. As chitosan is soluble 
in the acidic environment in the stomach it was decided that attempting to directly coat 
liposomes with the pH responsive polymer Eudragit S100 would provide the simplest and 
most effective formulation at targeting the ileo-caecal junction for drug delivery.        
The main aim of the studies described in this chapter was to investigate whether liposomes 
could be directly coated with Eudragit to produce a formulation that specifically targets the 
colon. It was hypothesised that cationic liposomes could be coated through mixing with the 
anionic polymer Eudragit through electrostatic interactions which has been observed in a 
variety of other polymers. It was hypothesised the resultant formulation would be pH 
responsive and subsequently begin release in the ileo-caecal junction for drug release to occur 
in the colon. Characterisation of the coating mechanism involved was undertaken through a 
variety of methods including imaging, zeta potential and size distribution. The suitability of 
the formulation was assessed by simulating the conditions representative of the GI tract. Once 
the liposomal coating has been confirmed the formulation was then assessed in vitro in buffer 
systems representative of those experienced in vivo.  
3.2. Materials 
3.2.1. Phospholipids and cholesterol 
Liposomal membrane components included egg phosphatidylcholine (EPC) (a gift from 
Lipoid, Ludwigshafen, Germany, minimum 98% purity), cholesterol (CH) (Sigma Aldrich, 
Dorset, UK, and stearylamine (SA) (Sigma Aldrich). SA was incorporated to give the 
liposomes a positive charge, facilitating electrostatic interaction with the anionic polymer. 
EPC and CH were stored at -20°C and SA at room temperature in accordance with the 
manufacturer’s guidelines.  
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3.2.2. Model drug 
Vitamin B12 (Sigma Aldrich) was chosen as a model drug due to its high solubility in all of 
the release media used (thus ensuring sink conditions could be readily maintained during 
release studies). Vitamin B12 was stored at 4°C in accordance with the manufacturer’s 
guidelines.  
3.2.3. Buffers for simulating GI tract conditions 
For the drug release studies 0.1 M hydrochloric acid (HCl), Hanks’ balanced salt solution 
(99.015 mol% water, 0.95% Hanks’ balanced salt and 0.035% sodium bicarbonate adjusted to 
pH 6.3 using 0.1 M HCl) and phosphate buffered saline (PBS, increased to pH 7.8 using 
tribasic sodium phosphate) were used to simulate the pH conditions of the stomach (Sinha 
and Kumaria, 2003 and Ibekwe et al., 2006a), small intestine (Ibekwe et al., 2006a) and 
ileocaecal junction (Khan et al., 1999), respectively. All components for the release media 
were purchased from Sigma Aldrich (Dorset, UK). 
3.2.4. Other chemicals and reagents  
All other chemicals and solvents used were of an analytical grade and used as received. 
3.3. Apparatus and methodology 
3.3.1 Production of cationic liposomes 
Liposomes were prepared using EPC and CH in the molar ratio 1:1. Initially, a number of 
molar ratios of SA were investigated (0, 5, 10, 15, and 20%) to determine the minimum 
amount required to produce a consistently cationic liposomal formulation. The results of 
subsequent zeta potential analysis (section 3.4.1) indicated that the use of 5 mol% would be 
most suitable for the application. The conventional thin film hydration method (Bangham et 
al., 1965) was used to produce multilamellar vesicles (MLVs) for the study. The lipids were 
dissolved in 5 ml chloroform in a 50 ml round bottom flask. The chloroform was then 
removed using a rotary evaporator (Rotavapor-Buchi), leaving a thin lipid film on the side of 
the flask which was then dried under nitrogen for 2 hours to remove any trace chloroform. 
The film was then hydrated with an aqueous solution containing 10 mg/ml of vitamin B12 in 
PBS (pH 7.4). During hydration the flask was agitated by vortex mixing. Excess drug was 
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removed by centrifugation using a Sigma 3K30 centrifuge maintained at 4°C to prevent the 
sample heating up. Centrifugation was carried out at 26,000 rpm (63,000g) using a 12111 
angled rotor with the capacity of 10 x 10 ml tubes. The liposomes were centrifuged at 26,000 
rpm (relative centrifugal force (rcf) 63,000) and washed three times by removing the 
supernatant and replacing with fresh PBS (Figure 3.1). The final pellet was then re-suspended 
in 10 ml of PBS.  
 
 
  
Figure 3.1. Vitamin B12 loaded liposomes before and after centrifugation and washing. 
3.3.2. Production of Eudragit S100 coated liposomes 
To prepare the coated liposomes equal volumes of liposomal suspension and aqueous 
solution of Eudragit S100 of various concentrations (0.0125, 0.025, 0.05 and 0.1% w/v in pH 
7.4 PBS) were combined and hand-shaken for 2 minutes. 
3.3.3. Liposomal characterisation techniques 
3.3.3.1. Zeta potential  
Zeta potential measurements can be used to determine the stability of a colloidal system. The 
measurements indicate the overall surface charge of a particle and therefore provide 
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information as to whether the system may remain stable or consequently undergo aggregation 
or flocculation. Particles with a zeta potential more positive than + 30 mV, or more negative 
than -30 mV are considered stable as they will repel each other. The zeta potential of a 
colloidal system can be affected by a number of factors including pH and conductivity.  
Electrophoresis refers to the movement of a charged particle relative to the liquid it is 
suspended in under the influence of an applied electric field, and can be used to calculate the 
zeta potential of a system. It is possible to measure the electrophoretic mobility by using a 
zeta potential instrument. The relationship between zeta potential and electrophoretic 
mobility is shown through the Henry equation: 
 
 
..	


                  (1) 
Where UE = electrophoretic mobility, ε = dielectric constant, z = zeta potential, f(Ka) = 
Henry’s function and η = viscosity.  
The instrument used to calculate zeta potential measures the electrophoretic mobility by 
applying an electric field across a capillary cell. Particles then move towards the electrode 
with their velocity being measured and expressed in unit field strength as their mobility. A 
laser source is used to illuminate the particles in the sample, with scattered light being 
detected after it has passed through the sample. The movement of particles in the cell, when 
the potential is applied, will cause a fluctuation in light intensity which can then be 
interpreted by a digital signal processor and subsequently fed to a computer.  
Initially zeta potential was used to characterise the amount of SA required to produce a 
liposomal formulation which has a plateau in zeta potential and therefore suitably cationic for 
coating with the anionic polymer Eudragit S100. This also allowed for the minimum amount 
of SA to be ascertained and therefore reduce the amount of excess used within the liposomal 
system. This would be essential for the formulation due to the knowledge that SA has certain 
levels of toxicity when used in high quantities in vivo (Campbell 1983; Senior et al., 1991).    
Changes in dispersion zeta potential as a function of Eudragit S100 concentration were 
determined through electrophoretic mobility measurements (Zetamaster, Malvern 
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Instruments, UK) at pH conditions in which the polymer was insoluble. Briefly, 500 µl of the 
liposome/polymer suspensions (from section 3.3.2.) were diluted with 20 ml of distilled water 
(pH<7) before introducing to the electrophoresis cell. Ten measurements were taken at 25˚C 
on three independent samples of each preparation. The calibration of the instrument was 
periodically confirmed using a zeta master transfer standard (Malvern Instruments - 
DTS1230) that had a charge of –68 mV ± 6.8 mV at 25ºC. 
3.3.3.2. Light Microscopy 
Light microscopy was conducted using an Olympus BX50 light microscope interfaced with a 
Leica Q500IW computer, with images taken using Ph 3 (phase plate) under the phase contrast 
setting. A small drop of liposome sample was placed on a pre-cleaned microscope slide 
before covering with a cover slip. Images were taken at 1000× magnification. 
3.3.3.3. Cryo-scanning electron microscopy (cryo-SEM)  
Drops of liposomal samples were dispersed into sample wells. The sample holder was then 
quenched in liquid nitrogen under vacuum conditions. Fracturing of the samples was 
conducted within the preparation chamber through the use of a fine blade. Samples were 
fractured using a Polaron Polar Preparation 2000 attached to a Phillips XL 30 Environmental 
Scanning Electron Microscope (ESEM). The samples were then sputter coated with gold for 
2 minutes to increase conductivity and transferred into the SEM chamber. Images were taken 
at a maximum voltage of 3.0 kV to reduce temperature fluctuations associated with higher 
voltages, with the instrument maintained at -180°C by the periodic addition of liquid nitrogen 
to the cooling chamber. 
3.3.3.4. Laser diffraction particle sizing 
Vesicle size and size distribution, as a function of Eudragit S100 concentration, were 
measured using wet laser diffraction particle sizing (Mastersizer 2000 connected to a Hydro 
SM small volume sample dispersion unit, Malvern Instruments, UK). The instrument has a 
quoted measurement range of 0.02 – 2000 µm and therefore enabled the full range of 
particles to be analysed produced in this study. Measurements are taken when a helium-neon 
laser passes through a flow cell based within a column. Particles within the flow cell scatter 
the light at an angle which is inversely proportional to their size. Detectors are used to 
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measure light and subsequently calculate the particle using the Mie scattering model. The 
Mie model takes into account both diffraction and diffusion of the light around the particle in 
its medium. Measurements were carried out in pH 6.3 Hanks’ and pH 7.4 PBS where the 
polymer is insoluble and soluble respectively. Three independent formulations were produced 
and subsequently measured five times with a mean value for each trial given.  
3.3.4 Drug release studies 
3.3.4.1. UV spectral analysis and calibration curves of vitamin B12  
Initially, a UV spectra was completed to determine a suitable wavelength which Vitamin B12 
has a suitable absorbance to analyse drug release media for B12 content (Figure 3.2). All UV 
spectra were completed on a Jasco V-530 UV/Vis spectrophotometer.  A small amount of 
vitamin B12 was dissolved in water with the spectra being taken in the range 250-500 nm, at 
5 nm/second.  
 
Figure 3.2. UV spectra of Vitamin B12 dissolved in water. 
Calibration curves were then constructed for vitamin B12 dissolved in each of the buffers to 
be used during the release trials (thus allowing for concentrations to be calculated from the 
specific absorbance measured during the release trial). For each calibration curve a solution 
of 1 mg/ml of vitamin B12 was made up in the required buffer, and then a serial dilution was 
completed to a point where the absorbance level became negligible. All measurements were 
completed in triplicate on independent samples at the λmax = 361 nm.  
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Figure 3.2. Calibration curves for vitamin B12 dissolved in (A) 0.1M HCl, (B) Hanks’ solution, (C) PBS 
and (D) ethanol at 361 nm.
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3.3.4.2. Quantification of encapsulated vitamin B12 
The amount of drug present within the liposomal sample prior to coating was quantified by 
lysing the liposomes in ethanol and therefore releasing the entrapped drug. Briefly, 0.1ml of 
liposome sample was added to 0.9ml ethanol and vortex mixed to ensure all the liposomes 
had been destroyed. The solution was then analysed spectrophotometrically with the 
concentration being calculated by referring to the calibration curve in ethanol (Figure 3.2 D) 
and accounting for any dilutions.  
3.3.4.3. Drug release studies in pH conditions representative of the GI tract 
Drug release studies with uncoated and coated liposomes (liposomes + polymer will be 
referred to as coated liposomes throughout) were conducted in each of the different pH media 
described in section 3.2.3. For each release experiment, 1 ml of liposomal suspension was 
added to 40 ml of preheated (37˚C) release medium and well-agitated (100rpm) in an 
incubator maintained at 37°C. Sink conditions were maintained throughout each experiment, 
ensuring the maximum released concentration was less than 10% of the saturated solubility of 
vitamin B12 in accordance with the British Pharmacopoeia (BP). Aliquots of 1ml were 
removed at 0, 0.5, 1, 2, 4, 6, 10, 20, 30, 45, 70 and 120 hours and centrifuged to precipitate 
the liposomes. 1 ml of pre-heated fresh buffer was replaced to maintain sink conditions 
throughout. The concentration of released vitamin B12 in the supernatant was determined 
using UV spectrophotometry against a standard curve obtained at λ=361 nm. All 
measurements were taken against reference samples of the appropriate dissolution medium. 
For each formulation, the initial amount of drug (mg drug/ mg phospholipid) prior to release 
was determined by lysing the liposomes with ethanol and measuring the resulting drug 
concentration using UV spectroscopy, allowing drug release to be reported as a percentage of 
the total encapsulated.  
For all drug release studies throughout this thesis statistical methods have been adopted to 
ascertain whether there is any difference between the samples. The Mann-Whitney U test was 
adopted as it is a non-parametric statistical hypothesis test for assessing whether one of two 
independent observations is significantly different to the other. The Mann-Whitney U test 
adopts a ranking system which attributes a score to each data point between two samples. The 
sum of these scores is then used to calculate a U value for both sets of data. The lower U 
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value is then used and compared to critical values from a set of values found in specific 
tables. If the U value is lower than that of the tabulated value for that level of significance it 
can be deemed that there is a statistical difference between the two samples.  
3.3.4.4. Drug release studies with the addition of the model bile salt sodium taurocholate 
Further drug release trials with uncoated and coated liposomes were completed in the 
presence of bile salts at a concentration representative of that found in the small intestine 
(10 mM sodium taurocholate in pH 6.3 Hanks’ solution (Iwanaga et al., 1997)). These trials 
aimed to test the liposomal formulations beyond their response to pH alone. Over a period of 
4 hours (the upper estimation of small intestine transit time (Rouge et al., 1996; Wilding, 
2001; Davis et al., 1986) samples were removed and analysed spectrophotometrically at 
λ=361nm against a reference sample of the release medium.   
3.3.4.5. Investigation into bile salt interaction through size distribution and FTIR 
analysis 
The inclusion of a model bile salt to simulate the conditions experienced in the small intestine 
offers a significant challenge to liposomal formulations. The presence of a bile salt may 
influence both the drug release but also may have some bearing on the chemistry of the 
coating polymer, Eudragit S100. Infra red spectra of aqueous pastes containing polymer, bile 
salt and their mixture were recorded using a Fourier transform infra red (FT-IR) spectrometer 
(FT-IR-6300, Jasco, Great Dunmow, UK) with an attenuated total reflection (ATR) infrared 
optical unit (golden gateTM, part number 10586, Specac Ltd., Orpington, UK) at a resolution 
of 2 cm-1. Eudragit S100 powder (as received from the manufacturer) was dispersed in either 
Hanks’ solution or Hanks’ solution + sodium taurocholate and analysed using wet laser 
diffraction particle sizing over 2 hours. All material concentrations were equivalent to those 
of the drug release studies. 
The purpose of this analysis was to test for the presence of any chemical interaction between 
the paste components. Any interactions between the Eudragit and the bile salt would result in 
a shift in the peak positions (e.g. ester vibrations at 1150 cm-1 and 1250 cm-1, and C=O 
vibrations of the carboxylic acid groups at 1705 cm-1)  associated with the functional groups 
involved in the interaction.   
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3.4. Results and Discussion 
3.4.1. Investigation into stearylamine concentrations required for cationic liposomal 
formulation 
The level of SA (5 mol%) was chosen after an initial screening study showed that it increased 
the zeta potential of liposomes at pH 7.4 from -12 mV (without SA) to +63 mV (Table 3.1). 
Higher levels of SA were not found to significantly increase zeta potential, and therefore it 
was decided to use a 5 mol% throughout. It was imperative to obtain a balance between 
producing a stable cationic liposomal formulation (minimum 30 mV) but also to maintain the 
SA levels at their lowest point required due to its reported toxicity. The toxicity of SA (LD50 
2395 mg/kg in rats) is so low that for the purposes of the current formulation the levels are 
negligible. If the levels of SA were to become an issue then it may be resolved through the 
use of a synthetic cationic lipid for example DOTAP, DOPE and therefore eradicating the 
need for SA. The use of these lipids would however alter the methodology required due to the 
higher transitional temperatures seen in synthetic lipids.  
Table 3.1. Table showing the change in zeta potential when increasing the concentration of 
stearylamine in the liposomal formulation. 
 
 
 
 
 
 
 
 
 
 
SA Concentration   
(mol %) 
Zeta Potential 
(mV) 
0 -12.3 ± 10.7 
5 63 ± 3.6 
10 63 ± 6.3 
20 64 ± 4.7 
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3.4.2. Investigation into the evolution of the Eudragit S100 coating 
3.4.2.1. Zeta potential analysis to determine the presence of a Eudragit S100 coat 
Zeta potential measurements were used to monitor the evolution of the coat. This strategy has 
previously been used in the development of polymer-coated cationic and anionic liposomal 
formulations, where the point at which the zeta potential plateaus is taken to indicate 
saturation of the vesicle surface with polymer (Guo et al., 2003; Takeuchi et al., 2005). 
Guo et al. (2003) observed the evolution of a chitosan coating on liposomes of differing 
purity (Epikuron 170 and 200) through zeta potential analysis. Both samples showed a 
marked increase in zeta potential, with the lipid of lowest purity showing the greatest change 
in zeta potential due to the electrostatic interactions dominating as opposed to the high purity 
lipid where hydrophobic interactions dominate. Similarly, Takeuchi et al. (2005) observed an 
increase in zeta potential with the increasing concentration of chitosan in the presence of 
DSPC liposomes to a certain concentration where the zeta stabilised and a complete coating 
had evolved. Figure 3.3 shows the vesicle zeta potential as a function of polymer 
concentration, where the polymer concentration shown is that of the original solution that was 
mixed with the liposomes.  As no further decrease in zeta potential was seen by increasing 
the polymer concentration beyond 0.05% this was assumed to be the concentration necessary 
to cover the surface of the liposomes and was then used in all further studies.  
 
 
Figure 3.3. Change in zeta potential with the increased concentration of Eudragit S100 in water. Error 
bars represent the mean ± the standard deviation of three independent trials. 
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3.4.2.2. Laser diffraction particle sizing to investigate presence of Eudragit S100 coat 
Size distribution analysis was completed at two pH values; one at which the Eudragit S100 
was insoluble (pH 6.3) and one at which the polymer was soluble (pH 7.4). It was 
hypothesised that the coating layer should only be observed at a pH lower than 7 due to the 
solubility profile of Eudragit S100. Size distribution in pH 7.4 PBS, where the Eudragit S100 
is soluble, showed no change with the inclusion of Eudragit S100 (Figure 3.4A). The size 
distribution profile observed for uncoated liposomes is bimodal and therefore expected due to 
the heterogeneous nature of a MLV formulation. For the size distribution completed in pH 
6.3 Hanks’ solution, where the polymer is insoluble, increased vesicle size (Figure 3.4B) 
correlated with a higher concentration of polymer. This increase continued until 0.05% at 
which point there was a plateau, similar to that seen for the zeta potential results. 
Chapter 3  Eudragit S100 coated liposomes 
79 
 
(A) 
 
(B) 
 
 
Figure 3.4. Laser diffraction particle sizing distributions for Eudragit S100 coated liposomes in pH 7.4 
PBS (A) and pH 6.3 Hanks’ solution (B).
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3.4.2.3. Imaging techniques to observe Eudragit S100 coat 
Evidence of an association between the polymer and liposomes was also seen using light 
microscopy. Figure 3.5A shows the uncoated liposomes at pH 6.3. Typically for MLVs, the 
size of the vesicles was originally around 5 - 10 µm. On addition of polymer to a system at 
pH 7.8 no increase in size was observed (Figure 3.5B), consistent with the fact that the 
polymer was in solution at these conditions. At pH 6.3 the polymer was seen to precipitate 
around the vesicles forming larger agglomerates (Figure 3.5D). A control experiment (Figure 
3.6) in which liposomes were excluded showed that polymer ‘particles’ resulting from 
precipitation at pH 6.3 were considerably smaller (approximately 500 nm) than the liposomes 
used in this study. In this way, the agglomerates seen in Figure 3.5C were assumed to be 
liposomes + polymer and not precipitated polymer alone. 
 
                                 (A)                          (B) 
 
                                  (C)       (D) 
Figure 3.5. Light microscope images of (A) uncoated and (B) Eudragit S100 coated liposomes in pH 7.4 
PBS. Further light microscope images of (C) uncoated and (D) Eudragit S100 coated liposomes in pH 6.3 
Hanks’ solution. 
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Figure 3.6. Light microscope image of control experiment showing precipitated Eudragit S100 at pH 6.3 
not in the presence of liposomes.  
Cryo-SEM imaging was used to image the liposomal formulations in their ‘natural’ state as 
opposed to lyophilisation and rehydration, which has been shown to alter liposome 
characteristics (particle size, drug retention) when produced without a cryoprotectant 
(Glavas-Dodov et al., 2005). Throughout all experiments, liposomal formulations were 
investigated whilst still in a wet dispersion, having undertaken no form of drying. This further 
indicates the importance of cryo-SEM as imaging can be completed using liposomes in the 
same state that all other experiments have been completed. 
   
In Figure 3.7 typical images of uncoated liposomes from cryo-SEM are shown. The images 
clearly show the lamellae with each bilayer being visible. The central aqueous core can also 
be identified and has been labelled accordingly. The range in size of MLVs can also be 
observed, as a number of smaller vesicles, which can be seen around the larger fractured 
liposomes.  
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Figure 3.7. Cryo-SEM images of uncoated liposomes.
showing the internal structure of 
Cryo-SEM images were taken of Eudragit 
polymer was insoluble (Figure 3.8
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was not observed in the uncoa
liposomes is spherical in nature, which would indicate an agglomeration of precipitated 
Eudragit S100. The structure of the coat adopts the appearance of Eudragit S100 in its natural 
state (Figure 2.9), indicating the possibility that Eudragit S100 shows no change in form 
through the coating process. This indicates that when the polymer precipitates on the surface 
of the liposomes very little morphological change can be seen, which would indicate that a 
single coating layer may not have 
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coating. This agglomeration occurs due to the electrostatic interactions between the polymer 
and liposomes, but the actual form of Eudragit S100 indicate
bridging has occurred, which would be seen when coating liposomes with chitosan
example Henriksen et al., 1994, 1997.
(Figure 3.9) where the polymer is soluble display no visible agglomeration around the 
liposomes, but merely show similar characteristics to the uncoated 
Figure 3.7.  
 
 
Figure 3.8. Cryo-SEM images of Eudragit 
polymer is insoluble. A Eudragit S100 ‘crust’ is shown to be present around the liposome. 
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Figure 3.9. Cryo-SEM images of Eudragit S100 coated liposomes at pH 7.4 at which the polymer is 
soluble. The liposome structure can be seen without the presence of a polymer ‘crust’ similar to that seem 
for the uncoated liposomes.  
3.4.2.4. Discussion of coating mechanism for Eudragit S100 coated liposomes 
A number of studies have successfully coated both neutral and anionic liposomes with the 
cationic polymer chitosan (Henriksen et al., 1994 and 1997; Perugini et al., 2000; Guo et al., 
2003; Mady et al., 2009). In each of these studies the coating mechanism was attributed to 
electrostatic interactions, which was proven through the distinct change in surface charge 
observed on the liposomes. The main issue is whether the same coating mechanism can be 
attributed to the use of Eudragit S100 as is observed for chitosan. Perugini et al. (2000) was 
the only study which expanded on the concept of electrostatic interactions, when looking at 
the coating of neutral liposomes with chitosan.  It was hypothesised that the coating of neutral 
liposomes was through hydrogen bonding between the polysaccharide and the phospholipid 
head group. It can be assumed this would not be taking place in the current conditions due to 
the significant charge of the liposomes and the opposite charge of the Eudragit S100, 
therefore indicating that electrostatic interactions would dominate.  
Few studies have attempted to directly coat liposomes with any of the Eudragit brand 
polymers, although Hasanovic et al., (2010) appeared to have some success in improving the 
stability of DPPC liposomes through coating with Eudragit EPO. Eudragit EPO is a Poly 
(butyl-methacylate-co-(2-dimethylaminoethyl) methacrylate-co-methyl methacrylate polymer 
which is soluble in gastric fluid up to pH 5 and swellable and permeable above pH 5. The 
technique used to coat the liposomes involved the mechanical stirring of the Eudragit solution 
(varying concentrations) with liposomes for 30 minutes (1:1 ratio). Similar to the current 
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study a significant decrease in zeta potential was observed along with an increase in particle 
size. It was hypothesised that the coating mechanism is similar to that observed for chitosan-
coated liposomes with hydrogen bonding between the polymer and liposome surfaces. The 
main purpose of stabilising the liposomes was for the transdermal application of liposomes 
and therefore the specific integrity of the coat was not investigated.   
Whilst it may be assumed that the coating mechanism would be similar when using an 
oppositely charged polymer to coat liposomes, there have been a number of papers discussing 
the complexities involved with particle adsorption and the role of electrostatic interactions 
(Adamczyk, 2003). Adamczyk outlined a distinct difference between linear and non-linear 
adsorption regimes whereby a linear adsorption regime would involve the ordered coverage 
of a particle through the sequential coating layer. To support this idea Perugini et al., (2000) 
observed a number of chitosan layers surrounding the liposomes indicating the presence of 
layer by layer deposition as described by Adamczyk (2003). Non linear adsorption regimes 
occur when adsorbed particles exert specific and hydrodynamic forces on adsorbing (moving) 
particles, excluding them from the part of the volume near the interface (Adamczyk, 2003). A 
non linear adsorption regime would provide a more complicated coating mechanism which is 
governed by a number of factors including particle size and shape, surface properties 
(charge), ionic strength, transport mechanism etc. The presence of non linear adsorption 
regimes can lead to a number of blocking effects preventing a solid adsorption layer on a 
particle surface. The cryo imaging of the coated liposomes would indicate that certain areas 
of the liposomes may not have been completely coated which may in theory be due to a non 
linear adsorption regime.    
3.4.3. Drug release studies for Eudragit S100 coated liposomes 
3.4.3.1. Drug loading and subsequent encapsulated aqueous volume calculations 
Drug loading calculations were completed for each batch prior to coating and subsequent 
drug release trials. Each batch of MLVs produced was used as a source for both uncoated and 
coated drug release trials, therefore any differences between batches would be the same for 
both formulations. The range of drug loading spanned from 0.28 – 0.33 mg/ml which can be 
attributed to a number of differences occurring due to the self assembly nature of liposomes 
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which will lead to differences in size distribution and lamellarity. The encapsulated aqueous 
volume (ml) can then be calculated using the following formula: 
x1ml(mg/ml)  solution stockdrug Hydrating 
ion(mg/ml)concentrat loading Drug
volumeaqueousedEncapsulat 





  (2)
 
This value can then be expressed in relation to the amount of lipid within the system and 
expressed in terms of litres aqueous space/mol lipid (l/mol). The mean captured volume in 
relation to lipid concentration was calculated as 1.28 l/mol which is very similar to the value 
quoted by Perkins et al., 1988 of 1.2 µl/µmol for MLVs produced from dried film with a lipid 
concentration of 6 mg/ml.  
3.4.3.2. Drug release profiles in simulated GI tract conditions representative of pH 
changes 
In Figures 3.10, 3.11 and 3.12 drug release profiles for liposomes with and without polymer 
are shown in the different release media representing each stage of the GI tract. At pH 1.4 
and 6.3 (Figures 3.10 and 3.11) the amount of drug released was significantly lower at all 
time points on addition of polymer (Mann Whitney U Test (chosen level of significance 
α=0.05). For example at pH 1.4, over a 20 hour period, only 10% of the drug was released, 
which is in contrast to the 40% release over the same time period for the uncoated 
formulation. Over a time period more representative of gastric residence time (boxed graph in 
Figure 3.10) only 2.5% was released from the coated formulation compared to 10% for the 
uncoated. Similarly for a transit time representative of the small intestine (4 hours) the release 
for uncoated liposomes is approximately 12% while for the same time period only 3% release 
is observed for the coated formulation. It is perceived that the agglomeration of Eudragit 
S100 around the liposomes significantly reduces the diffusion of drug from the liposome 
bilayers in comparison of that observed for the uncoated formulations. However, it can 
clearly be seen that although drug release was significantly reduced it was not completely 
prevented. It is thought this may be due to the small channels still present between the 
Eudragit S100 particles, therefore allowing for a slower rate of drug diffusion to take place 
into the dissolution media. In comparison the coated formulations in both pH 1.2 and 6.3 
show a gradual drug release which would possibly indicate a form of ‘leaking’ through the 
polymer channels formed as the Eudragit precipitates on the surface of the liposomes. As the 
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Eudragit S100 is insoluble throughout it is assumed that the polymer remains intact, and 
therefore a relatively constant release rate should be observed. 
In contrast to this the release profile in simulated ileo-cecal junction dissolution media of 
pH 7.8 show similar release rates for both uncoated and coated formulations (Figure 3.12). 
This would be expected as previous studies looking into the solubility of Eudragit S100 in 
pH 7.0 PBS have shown thin films to form pores and partially break down within 2 minutes 
(Sabot and Krause, 2002). This would account for the very similar release profiles observed, 
and therefore little or no delay being seen in the presence of Eudragit S100. The uncoated 
formulations in the three media show a similar total release of approximately 80% after 
120 hours, which is also observed for the coated formulation in pH 7.8 PBS, indicating the 
solubility of Eudragit S100 in pH 7 and above. 
 
 
 
 
 
 
Figure 3.10. Drug release profile for uncoated (◊) and Eudragit S100 coated (■) liposomes in 0.1M pH 1.4 
HCl. Each value represents the overall mean of three independent experiments ± the standard error of 
the mean. 
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Figure 3.11. Drug release profile for uncoated (◊) and Eudragit S100 coated (■) liposomes in pH 6.3 
Hanks’ solution. Each value represents the overall mean of three independent experiments ± the standard 
error of the mean. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.12. Drug release profile for uncoated (◊) and Eudragit S100 coated (■) liposomes in pH 7.8 PBS. 
Each value represents the overall mean of three independent experiments ± the standard error of the 
mean.  
3.4.3.3. Drug release profile with the inclusion of the model bile salt sodium 
taurocholate  
The addition of bile salts to the release media significantly increased the drug release rate for 
both uncoated and coated liposomes (Figure 3.13). There was also a significant increase in 
release rate in comparison to the uncoated formulation without the presence of bile salts 
showing that the inclusion of bile salts has a marked effect on the release rates of EPC 
liposomal formulations. Interestingly there was no statistically significant difference between 
coated and uncoated formulations in the presence of bile salts indicating that both the 
structural integrity of the vesicles and the polymer barrier were affected by the bile salts. This 
observation can be seen at the first time point of 30 minutes, indicating that the presence of 
the polymer had very little effect on slowing the drug release from the liposomes. As the 
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results differ considerably to those observed without the model bile salt it is hypothesised that 
the polymer agglomeration had previously acted as a diffusional barrier, slowing drug release 
from the coated formulations in both the stomach and small intestine simulated conditions. 
However, it was unable to protect against bile salts which indicates that premature drug 
release and liposomal degradation could be expected in vivo.  
 
Drug release results in Figure 3.13 indicate that both the liposomes and the coat were 
disrupted by the bile salts.  It was hypothesised that damage to the coat could be due to either 
the bile salts interacting directly with the polymer, facilitating its dispersion, or a secondary 
effect of liposomal degradation; i.e. once the liposomes were ‘digested’ the coat dispersed 
due to the lack of a vesicle core holding it in place. The cryo-SEM images of coated 
formulations in pH 6.3 Hanks’ (Figure 3.8) indicate that there are points within the polymer 
agglomeration that would be susceptible to bile salt penetration. This would result in the lysis 
of the liposome and therefore cause the Eudragit S100 to disperse, as there is no central core 
for it to adhere to. This would then allow for similar release profiles to be observed as the 
uncoated liposomes in the presence of bile salts.  
  
 
Figure 3.13. Drug release profiles for Eudragit S100 coated (●) and uncoated (▲) liposome formulations 
at pH 6.3 in the presence of 10mM sodium taurocholate. Release data from Figure 3.10 (no bile salts) are 
shown for comparison Eudragit S100 coated (■) and uncoated (◊). Each value represents the overall mean 
of three independent experiments ± the standard error of the mean.
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The mechanism by which bile salts interact with EPC liposomal formulations has been well 
investigated (Nagata et al., 1990; Ramaldes et al., 1996; Andrieux et al., 2004), with each 
study showing that a simple EPC liposomal formulation would not withstand the rigors of 
bile salt exposure experienced in vivo. The disintegration of lipid bilayers by bile salts is 
modelled as a three stage process which can be dependent on a number of factors including 
vesicle size, surfactant concentration and rate of addition (Ramaldes et al., 1996; Annesini 
et al., 2000).  
Stage one begins with the penetration of the outer bilayer by the surfactant. This penetration 
has been described by Walde et al., (1987) and Schubert et al., (1986, 1988) as a two stage 
process that involves the aggregation of the sodium taurocholate molecules in the external 
leaflet of the bilayer, where no change in permeability is observed. The second stage occurs 
when the molecules flip to the internal leaflet as the concentration increases and the 
subsequent formation of transient membrane pores can take place. The sodium taurocholate 
molecules then redistribute within the membrane and increase in concentration to lead to the 
destabilisation of the vesicles.   
Stage two involves the further incorporation of sodium taurocholate into the bilayer 
subsequently producing mixed micelles.  
Stage three refers to a reduction in size of mixed micelles due to the increasing ratio of 
surfactant/phospholipid (Nagata et al., 1990). The process of solubilisation for MLVs is 
considered to be stepwise, with each (outer) bilayer being penetrated by the surfactant 
sequentially. It can therefore be assumed that the process is governed, in this case, by the 
permeability of the liposomal bilayer and therefore the specific CH concentration used. The 
current study uses a high CH concentration leading to a slow drug release in the presence of 
bile salts, compared to previous studies where ratios of 7/3 and 10/2 EPC to CH were used 
(Ramaldes et al., 1996; Rowland and Woodley 1980). 
The marked difference in how the Eudragit S100 coated liposomes react in the presence of 
the model bile salt sodium taurocholate is a very significant result, as it shows that the 
coating would be inadequate for use in vivo due to the concentrations and variability of bile 
salts observed throughout the small intestine. The finding also reinforces the importance of 
going beyond evaluation of liposomal formulations for site specific delivery in the GI tract on 
the basis of pH shifts alone. The addition of bile salts, while adopted by some researchers in 
examining in vitro liposomal release for oral delivery (e.g. Lee et al., 2005) has not been 
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pursued by others (e.g. Guo et al., 2003; Filipović-Grčić et al., 2001). Whilst the coating 
mechanisms in these studies may be different to those observed for Eudragit S100 coated 
liposomes, assumptions cannot be made that the coat and liposomes will remain intact in the 
presence of bile salts without the necessary investigations being undertaken. 
3.4.3.4. Influence of sodium taurocholate on the size distribution of Eudragit S100   
To explore the cause of the increased drug release in the presence of bile salts, an initial study 
was conducted, investigating if any change in particle size was observed in Hanks’ solution 
containing bile salts. This would indicate whether any polymer solubilisation/degradation 
was taking place. The resulting polymer particle size distributions are shown in Table 3.2 and 
Figure 3.14, which show identical results in both dispersion media, indicating that the bile 
salts did not facilitate polymer solubilisation or dissolution. The initial high value was 
recorded as the sample was being stirred and can therefore be attributed to dispersing the 
polymer throughout the sample chamber. This would explain the large drop in size 
distribution observed in both the media, as the polymer was added to the instrument prior to 
the first reading taking place and therefore not allowing for complete polymer dispersion to 
occur. The possibility of initial agglomerates in the chamber would then lead to skewed 
results due to the light scattering technique of the instrument thereby indicating a larger size 
distribution than is plausible. Beyond this point no significant change in particle is observed 
in both conditions, it can therefore be assumed that the bile salts have no marked effect on the 
Eudragit S100. This would be expected due to the nature of Eudragit S100 regarding its use 
as an enteric coating material for colonic release and its solubility above pH 7. This 
reinforces the use of Eudragit S100 as a pH triggered release polymer as opposed to a 
polymer triggered by bile salts as there were no obvious interactions when included.  
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Table 3.2. Size distributions for Eudragit S100 powder dispersed in pH 6.3 Hanks’ solution 
and in the presence of model bile salt sodium Taurocholate (10mM). 
 
 
 
 
Eudragit S100 in pH 6.3 Hanks’ 
Eudragit S100 + bile salt in pH 6.3 
Hanks’ 
Minutes d(0.1) d(0.5) d(0.9) d(0.1) d(0.5) d(0.9) 
0 0.094 0.352 83.66 0.102 0.399 86.053 
15 0.079 0.129 0.199 0.087 0.137 0.201 
30 0.087 0.136 0.201 0.087 0.137 0.201 
45 0.087 0.137 0.201 0.087 0.137 0.202 
60 0.087 0.137 0.202 0.087 0.137 0.202 
75 0.079 0.13 0.201 0.087 0.137 0.202 
90 0.082 0.135 0.206 0.079 0.13 0.201 
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(A) 
 
 
 
 
 
(B) 
 
Figure 3.14. Size distribution traces for Eudragit S100 powder dispersed in (A) pH 6.3 Hanks’ solution 
and (B) pH 6.3 Hanks’ solution with 10mM sodium Taurocholate. 
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3.4.3.5. FTIR investigation into possible interactions between Eudragit S100 and sodium 
taurocholate 
The results for the FT-IR analysis of Eudragit S100 dispersed in Hanks’ and Hanks’ plus bile 
salt is shown in Figure 3.15. Examination of the spectra revealed no variation in peak 
position; in fact, the spectra could be superimposed. Due to the standard resolution of 2 cm-1 
any minor shifts observed (< 2 cm-1) could be attributed to measurement error as opposed to 
significant changes in bonds. The main areas where changes in the bonds may be expected 
have been highlighted on the trace (C=O stretch, -C=C- stretch, C-C stretch and the C-O 
stretch), all of which show no significant shift in peak position. These peaks are specific to 
the Eudragit S100 trace and any direct influence on the chemical structure of the polymer 
would be indicated through a peak shift. Differences were observed for the relative 
absorbance of the peaks which can be attributed to the varying components of the mixtures 
and the actual concentrations in contact with the optical unit. Furthermore, a change in peak 
height would indicate a change in morphology, which would indicate there is no form of 
interaction between the Eudragit S100 and sodium taurocholate. The results for the size 
distributions and FT-IR therefore indicate it seems likely that disruption to the coat was due 
to the loss of liposome structure, through bilayer disintegration.  
Whilst liposomes can be designed to increase their resistance to bile salts through the 
inclusion of CH or the use of synthetic lipids (Rowland and Woodley, 1980; Kokkona et al., 
2000; Andrieux et al., 2009), it would also be necessary to improve the integrity of the coat to 
prevent bile salt ingress. Rowland and Woodley (1980) showed that when a number of 
liposomal formulations were exposed to 10mM bile salts it caused the release of over 80% of 
the entrapped marker. Only one formulation proved promising which was produced using the 
synthetic lipid DSPC, which only released 16% of the entrapped marker in the one hour 
period. It was hypothesised that the increased level of retention was due to the ‘solid’ nature 
of the liposomal bilayer due to the high transition temperature of DSPC being 58°C therefore 
resisting bile salt disruption. In comparison the formulations produced using lipids with a 
lower transition temperature (EPC, DMPC) will have a fluid like bilayer at test conditions of 
37°C and therefore allow for bile salt disruption and subsequent drug release. Similar results 
were observed by Kakkona et al. (2000) where DSPC liposomal formulations combined with 
CH showed improved drug retention properties when exposed to sodium taurocholate. The 
inclusion of CH (1:1 molar ratio) in EPC liposomes was shown to delay drug release in the 
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presence of sodium taurocholate in comparison to EPC alone, but significant release was still 
observed within the first hour (~80%). The inclusion of CH was shown to improve drug 
retention in the case of lipids with higher transition temperatures to that of EPC (DPPC, 
DSPC) throughout the 5 hours of the study, which exceeds the average small intestine transit 
time. It was therefore concluded that the lipid used, and its specific transition temperature, 
has more of an influence on the stability of liposomes in the presence of bile salts compared 
to the CH concentration. 
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3.5. Conclusions 
Eudragit S100 can be associated with cationic liposomes through a simple mixing strategy, 
creating a barrier that significantly reduces liposomal drug release at pH conditions 
representative of the stomach and small intestine. Initial results were promising, with 
characterisation techniques showing a shift in zeta potential, an increase in size and light 
microscope images showing the association between the polymer and liposomes. Despite the 
cryo-SEM images not showing a single distinctive coat around the liposomes there was 
enough of a barrier to significantly slow drug release through the stomach and small intestine 
conditions. As expected, the coated formulation drug release profile in pH 7.8 conditions was 
very similar to that of the uncoated, due to the solubility of the polymer in these conditions. 
Further rigorous testing, whereby the coated formulation was exposed to bile salts, led to a 
significant drug release in line with that of the uncoated formulation at the same conditions, 
indicating that the coat was not as stable as the initial release trials suggested. It is 
hypothesised that the bile salts could penetrate the liposomes through the channels between 
the polymer aggregates and therefore facilitate drug release through the normal digestion of 
lipids, as would be seen for the uncoated formulation. The importance of evaluating coated 
liposomes for oral drug delivery beyond pH shift studies has been demonstrated with the 
addition of bile salts.  
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4.0 Investigation into the production of Eudragit S100 
microspheres 
 
________________________________________________________________________ 
ABSTRACT  
Eudragit S100 microspheres have been produced using a double emulsion - solvent 
evaporation method, with a view to encapsulating liposomes in the internal structure. A 
number of parameters were investigated including polymer concentration, homogenisation 
speed, homogenisation time and surfactant concentration. The microspheres were 
characterised using a number of methods including laser diffraction particle sizing and SEM.  
It was found that the specific properties including size, homogeneity and yield of the 
microspheres could be controlled by altering one or more process variables.  
An increase in polymer concentration initially led to an increase in microsphere size, but 
above a certain concentration (6% w/w) a non-homogenous sample was observed with a 
number of polymer agglomerates. Increasing both the homogenisation speed and time led to a 
smaller microsphere population, with a narrower size distribution being observed. The use of 
Span 85 and Tween 85 was deemed the most successful surfactant combination yielding a 
large batch of discrete microspheres.      
________________________________________________________________________ 
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4.1.1. Introduction  
It was shown in the previous chapter that Eudragit S100 coated liposomes could not 
withstand the attack of bile salts that would be found in vivo in the small intestine. It was 
concluded that the coating around the liposomes allowed for the ingress of bile salts and 
therefore led to the solubilisation of the liposomes. It is hypothesised that producing a solid 
microparticulate system will significantly improve the stability of a liposomal system 
developed for colonic drug delivery. With this in mind the key aims of the current chapter 
were to; 
• Produce a solid Eudragit S100 microparticulate system that would protect the 
liposomes through the stomach and small intestine to begin release at the ileo-caecal 
junction.  
• Identify the most suitable processing parameters to produce a formulation with 
discrete microspheres of a high yield.  
• Evaluate the formulation for its suitability to survive varying pH conditions and 
subsequently degrade above pH 7.  
 
4.1.2. Introduction to the production of microspheres suitable for the encapsulation of 
liposomes 
Over the past thirty years a number of researchers have investigated degradable microspheres 
as a technique for controlled drug release (Freiberg and Zhu, 2004). The advantages of these 
systems include;  
• Their small size enables administration through either ingestion or injection. 
• They can be targeted for specific release profiles and even target specific organs. 
• Microspheres can be produced to enable prolonged release which not only reduces the 
number of administrations but also increases patient compliance. 
• Microsphere properties can be manipulated through adjustment of a number of 
production variables. 
• Microspheres can also be used as a solid protective barrier against specific enzymes, 
bile salts during drug delivery.  
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Primary 
emulsion 
Emulsifier 
+ 
H2O 
To be able to encapsulate a liposomal dispersion within microspheres it has been shown that 
an adapted double emulsion solvent evaporation (W/O/W) (Figure 4.1) technique can be 
utilised (Feng et al., 2004). This technique is usually used for the production of polymeric 
microspheres to encapsulate water soluble agents. For this production method the primary 
emulsion is made up by homogenising the polymer dissolved in an organic solvent with the 
encapsulant (liposomes) and an emulsifier. At this point it is important that a stable emulsion 
is formed therefore ensuring no phase separation occurs prior to the formation of the 
secondary emulsion. The use of sonication is normally undertaken to produce the primary 
emulsion but due to the presence of liposomes and the effect it would have of their structure 
it is proposed that homogenisation is used throughout.  
The secondary emulsion (W/O/W) is then produced by adding the primary emulsion to a 
large quantity of aqueous volume containing an emulsifier (e.g. PVA) which then leads to the 
formation of microspheres. Through continued stirring the microspheres harden and solvent 
evaporation occurs. The stirring is then continued for a prolonged period to ensure the 
maximum amount of residual solvent has been removed and subsequent microsphere 
harvesting can take place.  
 
  
 
 
 
 
 
 
Figure 4.1. Schematic diagram representing double emulsion method (W/O/W) for microsphere 
production. The primary emulsion (W/O) is formed by homogenising a polymer solution and a aqueous 
solution containing the drug. The W/O/W is then formed by adding the primary emulsion to a large 
quantity of aqueous volume containing the emulsifier. Microspheres are then stirred for a period of time 
to allow for hardening and subsequent solvent evaporation. 
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4.1.3. Eudragit S100 microspheres 
Whilst Eudragit S100 has been used extensively as an enteric coating for a number of other 
microsphere formulations (Maestrelli et al., 2008; Paharia et al., 2006; Oosegi et al., 2008), 
the direct production of Eudragit S100 microspheres has only come to the fore more recently. 
A number of studies have successfully produced Eudragit S100 microspheres whilst 
observing the influence of varying polymer concentrations, surfactant concentration, stirring 
speeds, and internal/external aqueous phase ratios (Jain et al., 2005; Rawat et al., 2007; 
Sipos et al., 2005). The Eudragit S100 microspheres produced in the current chapter have 
been formulated by adapting a double emulsion - solvent evaporation method previously used 
by Lee et al. (2001) and Jain et al. (2005). The initial microsphere production method is 
described in section 4.3.1., but further studies were undertaken to establish the method to 
produce the most suitable microspheres in terms of particle size, morphology and 
homogeneity for oral colonic drug delivery. The variables that were investigated were that of 
polymer concentration, homogenisation speed and homogenisation time as these are all 
known to significantly influence particle size (O’Donnell and McGinity, 1997).  
4.2. Materials 
4.2.1. Polymers 
Eudragit S100 (Evonik - Essen, Germany) was used to produce the microspheres due to its 
specific pH solubility profile making it suitable for ileo-caecal drug delivery. PVA 
(molecular weight: 125,000 Sigma Aldrich.) was also used in a variety of concentrations 
from 1 – 3% (w/w) for the secondary emulsion and subsequent microsphere hardening.  
4.2.2. Surfactants 
Polysorbate 20 (Sigma Aldrich) was used in a variety of concentrations from 1-3% (w/w).  
4.2.3. Other chemicals and reagents  
The solvents including DCM, ethanol and HCl used were all of an analytical grade and used 
as received.  
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4.3. Apparatus and methodology 
4.3.1. Production of Eudragit S100 microspheres 
Eudragit S100 microspheres were produced using a double emulsion - solvent evaporation 
method adapted from a number of studies that have previously produced Eudragit S100 
microspheres (Jain et al., 2005; Rawat et al., 2007; Sipos et al., 2005). The different 
experimental conditions used for the investigation of production variables are outlined in 
Table 4.1. The three variables of polymer concentration, homogenisation speed and 
homogenisation time were investigated therefore variables such surfactant concentrations and 
aqueous volumes were maintained. A standard method was used (outline in the following 
section), which then allowed for the single variable to be investigated whilst keeping all other 
variables the same. 
4.3.2. Standardised Eudragit S100 microsphere production method 
The internal aqueous phase consisted of 0.8 ml water vortex mixed (3,400 rpm, 20 seconds) 
with 0.2 ml 3% polysorbate solution. The primary emulsion (W1/O) was then formed by 
homogenising (3,400 rpm, IKAT25 homogeniser, Fisher Scientific) the internal aqueous 
phase with 5 ml 6% w/w Eudragit S100 dissolved in a solvent mixture of 
DCM:ethanol:propanol (5:6:4) for 2 minutes. The primary emulsion (W1/O) was then poured 
into 100 ml 1% PVA solution to create the double emulsion (W1/O/W2), whilst under 
magnetic stirring at 125 rpm (Fisher Scientific). The emulsion was then left stirring for 3 
hours to allow for the microspheres to harden through solvent evaporation. The microspheres 
were then washed using vacuum filtration with a filter membrane of 1.6 µm. The 
microspheres were then collected and allowed to dry at room temperature for 48 hours.  
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Table 4.1. Experimental conditions employed in the production of Eudragit S100 
microspheres to investigate the influence of polymer concentration, homogenisation speed 
and homogenisation time.  
Polymer concentration 
(% w/w) 
Homogenisation speed 
(rpm) 
Homogenisation time 
(minutes) 
2 
3400 1 
6 
10 
15 
6 
400 
1 3400 
7400 
6 3400 
1 
2 
4 
 
4.3.3. Scanning Electron Microscopy (SEM) 
SEM was conducted on the dried microsphere samples to determine the surface morphology, 
homogeneity of the sample and indicate the general particle size. These specific 
characteristics will be important to the final product as they will influence the specific 
solubility profile of the microspheres and therefore possibly impact the drug release profile. 
The dried samples were mounted on a SEM stub and subsequently coated with platinum 
using an Emscope SC500 sputter coater. The samples were coated for 2 minutes with a 
deposition pressure of 20 barr depositing a layer of platinum equivalent to 150 Ångström. 
Images were taken using a Phillips XL-30 FEG ESEM under vacuum conditions.   
4.3.4. Particle size distribution 
Particle size distribution was measured using the method outlined in section 3.3.3.4. The 
microsphere sample, in its dried form, was added to the dispersion unit until the obscuration 
level was in the range of 14-18% (Mastersizer 2000 handbook, Malvern Instruments). The 
sample was dispersed in pH 7.0 distilled water.  
Chapter 4  Eudragit S100 microspheres 
104 
 
4.3.5. Cryo SEM imaging of microspheres 
Microsphere samples were dispersed in 5 M sucrose solution to ensure they remained well 
dispersed throughout, therefore preventing aggregation at the base of the sample well. The 
method used for sample sectioning and imaging was the same as for the liposomal samples as 
described in section 3.3.3.3.  
4.3.6. Microsphere solubilisation in buffers representative of the GI tract 
A degradation study of blank Eudragit S100 microspheres was conducted to investigate what 
happens to the microspheres at a pH above 7 and therefore gauge their suitability for ileo-
caecal release. 50 mg of blank microspheres were placed in 40 ml of three different buffers; 
pH 1.4 0.1M HCl, pH 6.3 Hanks’ buffer and pH 7.4 PBS, maintained at 37°C and shaken at 
100 rpm in an incubator. As in chapter 3 the pH 6.3 Hanks’ buffer contained the model bile 
salt sodium taurocholate to assess the resistance to bile salt attack as would be present in the 
small intestine. 1 ml samples were taken at pre-determined intervals simulating the transit 
times of the stomach, small intestine and large intestine respectively. 1 ml of pre-heated fresh 
buffer was replaced after each sample extraction. The sample was then spun down at 26,000 
rpm (63,000 g) for 10 minutes, with the supernatant being removed. The remaining 
microspheres could then be completely dried at room temperature for 48 hours, ready for 
subsequent SEM analysis as described in section 4.3.2.       
4.4. Results and Discussions 
4.4.1. Effect of polymer concentration on Eudragit S100 microspheres 
The influence of polymer concentration on the morphology of the final microsphere sample 
can be observed in the SEM images seen in Figure 4.2. The images show the successful 
production of microspheres for 2 and 6% polymer concentrations, but for 10 and 15% the 
results are less consistent. From the images it can be clearly seen that the microspheres have a 
broad size range indicating the possible need for alteration of processing conditions. A 
sieving technique could be used to ensure a homogenous sample is obtained but this will lead 
to loss of sample and therefore a reduced drug encapsulation efficiency. The 6% polymer 
solution appears to produce the most consistent microspheres in both size and morphology, 
with 2% showing a number of microspheres with deformed morphology. In addition to this, 
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increasing the polymer concentration to 10 and 15% produced a large amount of polymer 
aggregates both throughout the sample but also deposited on the magnetic stirrer, thus 
reducing the production efficiency of this method. These observations can be attributed to the 
increased viscosity of the organic phase and therefore an increase in interfacial tension 
between the organic and aqueous phases. This theory is further reinforced by the second 
image in Figure 4.2 (D) where a microsphere has formed but is still held within a polymer 
agglomerate. As the microsphere still has a number of fibrous connections it is thought the 
shear forces involved during the homogenisation stage are not large enough to create a 
disperse, stable emulsion and subsequent polymer agglomerations are seen throughout the 
sample.     
Further evidence for the use of 6% polymer concentration is supported by the findings of 
Jain et al. (2005) where it was shown that 6% Eudragit S100 PVA-stabilised microspheres 
could be produced with a good spherical form and smooth surface. A similar solvent mix was 
used for the organic phase (DCM-ethanol-isopropyl alcohol) and in the majority of 
formulations 100 ml of 2% PVA was used as the external aqueous phase, therefore making it 
comparable to the current study. In comparison, Jain et al. (2005) adopted the same method 
to produce polyvinyl pyrrolidone (PVP) stabilised microspheres which displayed fibrous-
threadlike structures on the surface and therefore PVP was deemed an inferior stabiliser in 
comparison to PVA for the production of Eudragit S100 microspheres.  
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 (A)  
 (B)  
 (C)  
 (D)  
Figure 4.2. SEM images showing Eudragit S100 microspheres produced using (A) 2%, (B) 6%, (C) 10% 
and (D) 15% Eudragit S100 (% w/w). 
Partially formed 
microsphere 
Chapter 4  Eudragit S100 microspheres 
107 
 
Despite the 6% polymer concentration showing the promising results for the formulation of 
Eudragit S100 microspheres, it has been shown through a number of studies that altering a 
number of variables can produce a successful formulation. Rawat et al. (2007) successfully 
produced Eudragit S100 microspheres using a range of Eudragit S100 concentrations (1.9, 
2.2 and 2.7%) and subsequently compared a variety of surfactants (Tween 20, 40, and 80) 
and relative concentrations. It was shown that Tween 80 was the most successful surfactant in 
terms of enzyme entrapment efficiency for this system, with an increase in concentration 
showing an increase in drug loading but a subsequent decrease in microsphere size. In 
comparison increasing the DCM concentration was shown to have a negative effect on both 
drug loading and size which was attributed to the drug leakage in the continuous aqueous 
phase as the droplets would stay in the liquid form for a longer period of time in comparison 
to lower DCM concentrations. Eudragit S100 microspheres have been successfully produced 
using a 10% polymer concentration by Lee et al. (2001) with the notable difference being that 
the external aqueous phase consisted of 1000 ml 0.4% PVA which would subsequently 
reduce the viscosity of the double emulsion and increase the likelihood of a homogenous 
dispersion.  
The effect of polymer concentration on particle size distribution is shown in Figure 4.3. The 
results fall very much in line with those presented for the SEM imaging, but a note of caution 
is required due to the nature of the sizing technique. The principle of measurement of the 
mastersizer assumes the particles to be spherical, polymer agglomerates that can be seen for 
both 10 and 15% Eudragit S100 may provide false readings of large microspheres being 
formed. With this in mind it can be observed that the curve with the narrowest size 
distribution is seen for the 6%, which is also indicated by the SEM imaging. In contrast to 
this the higher polymer concentrations provide a broader size distribution with a high 
percentage of large particle sizes which could be attributed to the agglomerations of polymer 
observed during processing.  
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Figure 4.3. Size distribution showing influence of Eudragit S100 concentration (% w/w) on size 
distribution of blank Eudragit S100 microspheres.   
 
4.4.2. Effect of homogenisation speed on Eudragit S100 microspheres 
As mentioned previously, a primary emulsion needs high enough shear forces to create a 
stable emulsion that can then be dispersed into the aqueous phase. It has previously been 
shown that the homogenisation speed can significantly alter the final microsphere product 
(Dunne et al., 2000). It can be seen from the current study that the case of Eudragit S100 
microspheres are no different (Figure 4.4.). The SEM images show a range of microsphere 
formulations produced using homogeniser speeds of 400, 3400, and 7400 rpm. The 
microsphere formulation produced homogenising at 400 rpm shows a number of fully formed 
microspheres with a diameter in the region of 100 µm. These microspheres are largely 
spherical in shape but do have a number of imperfections which can be attributed to the low 
shear forces produced at 400 rpm. Furthermore, a number of polymer agglomerates can be 
seen where a stable primary emulsion would not have been produced causing the droplets to 
agglomerate and subsequently harden when in the aqueous phase. At 3400 rpm the 
microsphere population appears to be more homogenous and in the majority, smaller than 
those observed at 400 rpm. A larger yield of microspheres can also be observed which can be 
attributed to the increased number of droplets formed in the primary emulsion, leading to 
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fewer polymer agglomerates being formed. Finally, the microspheres produced by 
homogenising at 7400 rpm display the most homogenous distribution with the majority of 
microspheres being approximately 60 µm or less. Furthermore, the image shows very few, if 
any unformed microspheres indicating the higher homogenisation speed offers the most 
polymer efficient production route for Eudragit S100 microspheres.  
The use of increasing homogenisation speed specifically in the production of Eudragit 
microspheres has been identified in a number of studies. Initially Mateovic et al. (2002) 
investigated the influence of stirring rate on the properties of Eudragit RS microspheres and 
found that increasing the stirring rate subsequently decreased the microsphere size due to a 
finer dispersion of droplets in the primary emulsion. Similarly, Sipos et al. (2005) reported a 
decrease in particle size with an increase in stirring rate with homogenisation speeds of 
14,400 and 20,800 rpm providing microsphere diameters of 250 and 116 µm respectively. 
Sipos et al. (2005) then went on to observe the drug release kinetics of the microspheres, 
showing the formulation produced using the highest homogenisation speed gave the fastest 
release rate due to the increased specific surface area.  
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(A) 
 
(B) 
 
(C) 
Figure 4.4. SEM images showing blank Eudragit S100 microspheres produced by homogenising for 2 
minutes at (A) 400 rpm, (B) 3,400 rpm, and (C) 7,400 rpm.  
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The results for the size distribution of Eudragit S100 microspheres produced using various 
homogenisation speeds are shown in Figure 4.5. The three peaks for the 400 rpm formulation 
indicate the heterogeneous nature of the sample which, coupled with the SEM images, 
indicate that the shear forces created by the low speed are too small to produce a disperse 
emulsion. The distribution for 3400 rpm displays a single peak, with a relatively broad span 
and a significant ‘shoulder’ at the lower end of the curve. This can be attributed to the 
majority of the formulation producing well formed spherical microspheres as seen by the 
SEM, but there is evidence of a number of smaller deformed microspheres which add a bias 
towards the smaller particle size distribution. In accordance with the SEM images the 
7400 rpm microsphere sample show a narrow particle size distribution in the region of 60 – 
70 µm.    
 
 
Figure 4.5. Size distribution showing the influence of primary emulsion homogenisation speed on size 
distribution of blank Eudragit S100 microspheres.   
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4.4.3. Effect of homogenisation time on Eudragit S100 microspheres 
The final parameter investigated is that of homogenisation time for the primary emulsion. A 
similar theory is applied to this parameter as that of homogenisation speed, where the ability 
to create a disperse primary emulsion through increased shear forces should lead to a more 
homogenous sample size. In the previous section the homogenisation speed of 3,400 rpm 
created a varied microsphere sample population and should therefore give a good indication 
into the effect of homogenisation time. SEM images for the three homogenisation time scales 
of 1, 2 and 4 minutes are shown in Figure 4.6. In each of the images the formation of 
microspheres is clearly evident. For 1 minute, there appears to be a range of microsphere size, 
with a number of polymer complexes which would indicate that a completely disperse 
primary emulsion has not been created during this time frame. As indicated previously this 
will subsequently increase the particle size distribution which may not give an accurate 
indication of the actual microsphere size formed. No real change in microsphere size was 
observed for the microsphere formulation produced using 2 minutes, the main difference 
being that of a reduced number of complexes being observed throughout the sample. The 
microsphere morphology and sphericity are maintained throughout, with each increase in 
homogenisation time showing little difference in microsphere characteristics. The final 
sample produced using 4 minutes homogenisation indicates a marginal decrease in 
microsphere size, with a number of small (<40 µm) microspheres being visible. Once again 
no polymer agglomerates can be observed in comparison to that of Figure 4.6 A, and it can 
therefore be assumed that a homogenous primary emulsion is being formed. Although the 
changes in microsphere sample are not as significant as those observed in Figure 4.4 the 
increase in homogenisation time appeared to improve the microsphere sample by producing 
smaller organic droplets and allowing for a more homogenous emulsion to be formed 
therefore producing smaller particles and fewer polymer agglomerates through the 
coalescence of droplets.  
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(A) 
 
(B) 
 
(C) 
Figure 4.6. SEM images showing blank Eudragit S100 microspheres produced by homogenising the 
primary emulsion for (A) 1 minute, (B) 2 minutes and (C) 4 minutes at 3,400 rpm.   
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The size distribution results (Figure 4.7) for homogenisation time reflect that of the SEM 
images, with a more narrow distribution being observed for microspheres being produced 
using longer homogenisation times. The 1 minute homogenisation time does not show a 
symmetrical size distribution which may be due to the effect of the polymer agglomerates 
seen in the SEM images and therefore skewing the sample. In comparison, the 2 and 4 minute 
samples show a symmetrical distribution which becomes narrower, showing a decrease in 
particle size as the homogenisation time increases. This once again is in accordance with the 
concept of increasing the shear forces present during homogenisation and therefore creating a 
more disperse primary emulsion. In comparison to other studies, Sipos et al. (2005) produced 
Eudragit RS microspheres by high shear mixing for 4 minutes and Jain et al. (2005) produced 
Eudragit S100 microspheres by using an ultrasonic disruptor for 1 minute. This indicates that 
although homogenisation time has an effect on the final microsphere product, the influence of 
homogenisation speed has a much greater significance.     
 
   
Figure 4.7. Size distribution showing the influence of primary emulsion homogenisation time on size 
distribution of blank Eudragit S100 microspheres.   
 
4.4.4. Microstructure of fractured Eudragit S100 microspheres using SEM 
Eudragit S100 microspheres produced using the standard protocol as outlined in section 4.3.2 
were fractured under cryogenic conditions. The resultant SEM images are shown in 
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Figure 4.8. From the images a wide microsphere outer (approximately 15 µm) can be 
identified in relation to the complete microsphere diameter. The wall is relatively dense with 
a few minor pores being visible towards the inner part of the shell. This is similar to that 
observed by Lee et al. (2001), where a smooth outer was observed, but the internal part of the 
microsphere wall had larger pores visible. This was attributed to the fact that firstly, the outer 
surface makes contact with the aqueous phase and therefore solidifies more rapidly in 
comparison to the internal part where solidification is a longer process. The formation of the 
skin layer then governs the subsequent solvent removal rate and therefore the shell structure 
(Crotts and Park, 1995). It is hypothesised that a porous skin formation would form with a 
high inner aqueous volume, therefore allowing for rapid solvent evaporation to occur. In 
comparison formulations with a low internal aqueous phase would create a nonporous skin 
layer and due to the low level of aqueous inclusion in the formulation, would lead to a slow 
rate of polymer solidification, providing a dense microsphere shell. The skin layer can 
therefore be governed by both the amount of internal aqueous phase and its relative 
homogeneity within the emulsion. The current methodology produces hollow microspheres 
that provide adequate aqueous space to encapsulate any form of liposomal formulation 
(MLVs, LUVs etc.). From these images it would be assumed that the microspheres would be 
able to protect its contents from bile salt attack that would be observed in the small intestine, 
in comparison to that observed for Eudragit S100 coated liposomes (Figure 3.7). For the 
Eudragit S100 microspheres a solid single structure of can be observed whilst for the coated 
liposomes an intermittent ‘crust’ could be observed. 
 
Figure 4.8. Cryo-SEM images showing the internal morphology of Eudragit S100 microspheres. Eudragit 
microspheres were produced using the standardised protocol as outlined in section 4.3.2. 
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4.4.5. Degradation of blank microspheres in simulated GI tract conditions 
It can be seen that Eudragit S100 microspheres maintain their structure and morphology 
whilst in pH 1.4 0.1M HCl for 2 hours, which is representative of the transit time found in the 
stomach (Figure 4.9.). No differences can be observed over the 2 hour period with some 
‘broken’ microspheres visible which are attributed to the processing conditions (3400 rpm) 
used, as discussed previously in this chapter. The important observation is that there is no 
visible surface erosion and therefore no obvious signs of microsphere degradation when in 
contact with the simulated stomach conditions.  
Similarly, the microspheres observed in Figure 4.10 can be seen to withstand the increased 
pH of 6.3 and the possibility of bile salt attack by maintaining a smooth surface morphology 
and spherical form. As no indication of polymer degradation can be observed this would 
indicate that the microspheres would be able to withstand any possible bile salt ingression, 
and therefore protect a liposomal formulation within the core.     
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(A) 
 
(B) 
Figure 4.9. SEM images showing Eudragit S100 microspheres in pH 1.4 HCl at (A) 1 hour and (B) 2 
hours.  
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(A) 
 
(B) 
 
(C) 
 
Figure 4.10. SEM images showing Eudragit S100 microspheres in pH 6.3 Hanks’ buffer containing the 
model bile salt sodium taurocholate at (A) 1 hour, (B) 2 hours and (C) 3 hours. 
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The SEM analysis of Eudragit S100 microspheres in pH 7.4 PBS are shown in Figure 4.11. 
The onset of dissolution could be observed within 30 minutes of exposure to pH 7.4, with 
certain areas of pitting being observed on the microsphere surface. The rapid onset of 
dissolution conforms to studies that have observed the dissolution rates of Eudragit S100 
films, which have shown that within a matter of minutes dissolution has been observed (Lee 
et al., 2001; Rawat et al., 2007). The dissolution of the microspheres continues at these 
inclusions exposing the microsphere wall and internal surfaces, subsequently increasing the 
surface area and therefore encouraging an increased rate of dissolution (Figure 4.11. B and 
C). The final images at 4 hours show mainly polymer remnants as opposed to any form of 
microsphere which would collect during the centrifugation stage. Samples were taken at 6 
and 8 hours, but nothing was observed under SEM and therefore it is assumed that complete 
dissolution of the microspheres had taken place within 6 hours of exposure to pH 7.4 PBS.  
As previously described in chapter 2, Eudragit S100 dissolves at a pH above 7 due to the 
ionization of the carboxylic acid groups within its structure. The specific type of degradation 
experienced has been evaluated in a number of studies (Sabot and Krause, 2002; Krause et 
al., 1997; McNeil et al., 1995). These studies use either impedance spectroscopy or quartz 
crystal microbalance impedance measurements to determine the specific dissolution 
associated with Eudragit S100. In each of the studies Eudragit S100 dissolution was 
attributed to a complex pore formation mechanism on the surface of the polymer. Further 
dissolution was then shown to be caused by the rigidity of the film and therefore lack of 
tendency to swell. Further dissolution was said to have taken place under the surface once the 
polymer had been penetrated through pore formation (Sabot and Krause, 2002). The images 
in Figure 4.11 give an indication that pore formation is occurring with Eudragit S100 
microspheres, with large pores being visible after only 30 minutes.   
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 (A)  
 (B)  
 (C)   
 (D)  
Figure 4.11. SEM images showing Eudragit S100 microspheres in pH 7.4 PBS at (A) 0.5 hours, (B) 1 hour, 
(C) 2 hours and (D) 4 hours. Microsphere degradation can be observed after just 30 minutes with only 
small polymer complexes remaining after 4 hours.  
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Looking at previous studies completed on the dissolution of Eudragit S100 microspheres, 
Lee et al. (2001) observed 90% drug release after 1 hour of exposure to pH 7.4 for ketoprofen 
loaded Eudragit S100 microspheres. Corresponding SEM micrographs of the formulations 
showed a microsphere wall thickness in the region of 30 µm, therefore supporting the current 
formulation and its possible release profile. Similarly, Jain et al. (2005) achieved up to 74% 
protein release (depending upon formulation parameters) in 6 hours for Eudragit S100 
microspheres in pH 7.4 PBS. It was also shown that altering the processing variables (internal 
and external aqueous volumes) could determine not only the cumulative release but also 
change the initial burst release observed. This is attributed to the altering the internal aqueous 
volume where a large quantity is considered to produce large droplets which have high 
amounts of surface associated protein in comparison to those produced using smaller 
volumes. Rawat et al. (2007) showed very little release of serratiopeptidase (STP) in HCl 
(6.56% in 2 hours) which was attributed to the adsorption of STP on the surface of Eudragit 
S100 microspheres. It was then shown that approximately 80% STP release was achieved in 
pH 7.4 PBS, which although still within the required times for colonic drug delivery is slower 
than that observed by Lee et al. (2001) despite having an average microsphere diameter of 
56 µm.     
4.5. Conclusions 
Hollow Eudragit S100 microspheres have been produced using a double emulsion – solvent 
evaporation technique.  Investigating a number of processing conditions showed that 
increasing the homogenisation speed and time led to a more homogenous population of 
microspheres.  
Subsequent analysis in simulated GI tract conditions have shown that the microspheres can 
withstand in vitro environments representative of the stomach and small intestine. The 
smooth surface and spherical morphology was maintained throughout the 2 hour exposure to 
1 M HCl and 3 hour exposure to Hanks’ buffer. The onset of microsphere dissolution was 
observed in pH 7.4 PBS after as little as 30 minutes, with continued polymer degradation 
taking place up to 4 hours. The microspheres were completely dissolved within 6 hours of 
exposure to pH 7.4 PBS which is well within the estimated transit time required for colonic 
drug delivery (Rawat et al., 2007).  
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The current chapter has addressed the problems that arose during chapter 3 where a single 
Eudragit S100 liposomes coating could not withstand the attack of bile salts. The solid 
Eudragit S100 microsphere has shown stability in the presence of bile salts and therefore the 
formulation can evolve by encapsulating drug loaded liposomes within the microspheres to 
produce an effective oral colonic drug delivery vehicle.  
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5.0 Chitosan-coated liposomes 
 
________________________________________________________________________ 
ABSTRACT  
A method for producing chitosan-coated liposomes to protect them during encapsulation 
within Eudragit microspheres was investigated. The technique was required to protect the 
liposomes from the organic solvents used when forming the primary emulsion of a proposed 
double emulsion solvent evaporation technique. Both neutral and anionic LUVs were 
produced and subsequently coated with chitosan. The chitosan coating layer was confirmed 
through a number of techniques including zeta potential analysis, cryo-SEM and fluorescence 
microscopy.  
The coated liposomes were then investigated for their suitability for colon targeted drug 
delivery by completing drug release profiles simulating the stomach, small intestine and 
colon. The small intestine conditions included the model bile salt sodium taurocholate which 
had previously been shown to cause drug release in insufficiently coated liposomes 
(chapter 3). The colonic conditions contained β-glucosidase to simulate the action of the 
colonic microflora and subsequently show its effect on the chitosan coating. It was shown 
that the chitosan coating slowed drug release through the stomach and small intestine 
compared to uncoated formulations with significant release being shown in the colonic 
conditions. A chitosan-coated liposomal formulation has been created suitable of 
withstanding the processing conditions of microsphere production and capable of significant 
release in the colon.          
________________________________________________________________________
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5.1. Introduction 
It has been previously shown that the direct coating of liposomes with Eudragit S100 did not 
prove successful at protecting the liposome bilayer from bile salt attack. It is therefore 
suggested that a liposome-in-microsphere (LIM) formulation could be produced 
encapsulating liposomes within solid Eudragit S100 microspheres. It was shown in the 
previous chapter that Eudragit S100 microspheres have the potential to remain intact through 
the stomach and small intestine, to subsequently begin degradation in the ileo-caecal junction. 
It is hypothesised the microspheres will begin to release the liposomes at the ileo-caecal 
junction, therefore allowing for sustained drug release at the site of the colon. The proposed 
method to produce LIMs is an adapted double emulsion solvent evaporation technique, 
therefore exposing the liposomes to a solvent mixture (DCM, ethanol, propanol) which would 
rapidly destroy the bilayer of the vesicles. With this in mind it is essential that the liposomes 
are protected through the microsphere production stages. Furthermore not only do the 
liposomes need to be protected during the production of LIMs but they must also show a 
suitable release profile that would enable colonic drug delivery. It is hypothesised that using a 
polysaccharide to coat the liposomes that will initially protect them from the organic solvent 
and then be solubilised by the colonic microflora when released by the Eudragit S100 
microspheres. The overall aim of this chapter was to devise a method of coating liposomal 
formulations with chitosan that would protect the vesicles during their exposure to the solvent 
mix when encapsulating them into the microspheres and provide a suitable release profile for 
colonic drug delivery.  
A number of researchers have shown that liposomes can be coated with the polysaccharide 
chitosan, which would not only protect the liposomes during transition through to the colon, 
but would also provide an enzyme controlled component to the system, which would 
therefore make the formulation with a two-trigger system. It has been demonstrated that a 
system with a two trigger formulation has a number of advantages over single trigger systems 
(Kaur and Kim, 2009), including site specificity and formulation stability. Kaur and Kim 
(2009) showed that producing a double coated formulation with a chitosan inner coat and 
Eudragit outer coat enables the chitosan to control drug release to the colon; the Eudragit 
coating would provide an enteric protective layer for the formulation, thus preventing 
solubilisation in the stomach. The use of an enzyme controlled release system is considered 
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to provide improved site specificity, as variability associated with transit time and pH through 
the GI tract does not influence the colonic microflora and the enzymes specifically found in 
the large intestine (section 1.4.3.4). This use of a double trigger system would allow for more 
flexibility in the Eudragit coating, as less emphasis is required on the site specificity due to 
the controlled release of the chitosan coating i.e. if the microspheres were to degrade in the 
proximal small intestine the chitosan coating would ensure that drug release is limited until 
arrival into the colon. This would enable a variety of Eudragits to be used, or even a 
combination of two different Eudragits (L100 and S100), in order to produce a solubility 
profile suitable for possible patient variability i.e. patients with a GI tract pH profile lower 
than ‘normal’ (Khan et al., 1999; 2000).       
5.1.1. Chitosan  
It has been proposed that liposomes can be coated with the polysaccharide chitosan (Laye et 
al., 2008; Guo et al., 2003; Mady et al., 2009; Henriksen et al., 1994; 1997), which is 
dissolved by bacteria present within the microflora of the colon (section 1.4.3.4). 
Investigations into chitosan and its suitability for resistance to solvents, and its ability to coat 
liposomal formulations has been well documented (section 2.3.2). As chitosan has a number 
of amine groups it also dissolves in weak acidic conditions and would therefore need an 
enteric coating to remain intact through the acidic conditions found within the stomach 
(Shimono et al., 2002).  
A number of studies have successfully looked at coating liposomes through electrostatic 
interactions, by producing anionic liposomes and subsequently coating with the cationic 
polymer (Laye et al., 2008; Wei and Lu, 2003; Henriksen et al., 1994; 1997). Laye et al., 
(2008) investigated the ideal chitosan concentrations for production of chitosan-coated 
liposomes through the electrostatic deposition of chitosan onto the surface of an anionic 
liposome formulation. It was concluded that below a minimum critical chitosan concentration 
(Cmin) large aggregates formed that phase separated in minutes which was attributed to the 
formation of coacervates. In comparison a maximum critical chitosan concentration (Cmax) 
was observed whereby concentrations above this value produced large flocs that sedimented 
within hours, which was attributed to depletion flocculation. It was shown that the Cmin and 
Cmax were dependent upon the liposome concentration and size. Wei and Lu (2003) showed 
that negatively charged, positively charged and neutral liposomes could all be coated with 
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chitosan. The resultant formulations, with an outer enteric coating, showed very little (< 7%) 
release in simulated gastric and enteric fluid (4 and 8 hours respectively) whilst simulated 
colonic fluid containing β-glucosidase showed considerable release with a t1/2 of 3.63 hours. 
Henriksen et al., (1994, 1997) closely investigated the interactions between chitosan and 
liposomes also taking into account the numerous factors involved including addition speed, 
stirring speed and the specific molecular weight of chitosan used.       
In contrast a number of studies have shown that neutral liposomes can be coated with the 
cationic polymer through hydrogen bonding between the polysaccharide and the phospholipid 
head groups (Mady et al., 2009; Guo et al., 2003; Perugini et al., 2000; Henriksen et al., 1994 
and 1997). It was suggested that coating neutral liposomes provided a more stable system that 
would be influenced less by any changes in pH and buffer upon dilution (Guo et al., 2003). It 
has been shown that the charge of the liposomes can significantly alter the chitosan coating 
process (Henriksen et al., 1994; 1997) and therefore this chapter will look at the coating of 
both neutral and negatively charged liposomes to compare the resultant formulations. As 
discussed in the introduction (section 1.7.5.1), there are advantages to colonic delivery of 
both neutral and negatively charged liposomes, and therefore if both can be coated with 
chitosan it would provide the opportunity to specifically attach to inflamed or healthy 
mucosa, depending upon the condition.     
5.1.2. The advantages of using LUVs over MLVs 
Previous experiments (chapter 3) attempted to utilise MLVs for drug delivery to the colon 
due to their multilayer structure and therefore slower release rates in comparison to LUVs 
and SUVs. With a view to the liposomes being coated and then subsequently encapsulated in 
Eudragit S100 microspheres a prolonged release rate is not required in comparison to MLVs 
directly coated with Eudragit S100 where the coating would be solubilised at the distal small 
intestine exposing the liposomes to drug release. It is therefore proposed that LUVs are 
encapsulated within the microspheres due to the size of MLVs being problematic for the 
microspheres produced in the previous chapter. The use of LUVs will also lead to an 
increased encapsulation efficiency in comparison to MLVs which should balance out with the 
losses associated with polymeric membrane extrusion. 
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The overall aims of the work described in the current chapter were to: 
• Investigate the extrusion of EPC MLVs with a view to producing LUVs with a narrow 
size distribution. 
• Develop a coating strategy to coat either neutral or negatively charged liposomes with 
chitosan. 
• Determine the size distribution and uniformity of coating through a variety of 
techniques. 
• Investigate the mechanism of the coating and assess its effects on the drug release 
profile of liposomes in buffers representative of the pH range observed within the GI 
tract. The buffers will include a model bile salt and enzyme for the small and large 
intestine respectively. This will provide a more detailed indication of the 
formulation’s properties in vivo and will ensure that the chitosan coat will withstand 
the distal region of the small intestine and subsequently release the active ingredient 
in the colon. 
5.2. Materials  
5.2.1. Lipids  
EPC was a gift from Lipoid GmbH, which had a purity of 99.2%. Cholesterol (≥99%) was 
purchased from Sigma Aldrich (Dorset, UK). Dicetylphosphate (DCP) (≥99% purity), a 
negatively charged lipid, was used to produce anionic liposomes and was also purchased 
from Sigma Aldrich. All lipids were stored at -20°C ± 5 °C in sealed containers. 
5.2.2. 5-Aminosalicylic acid (5-ASA) 
The model drug used throughout the investigations was 5-ASA which is an anti-inflammatory 
drug used in the treatment of ulcerative colitis and Crohn’s disease. The active dose of 5-
ASA is 400mg, the current formulation does not set out to deliver this but merely uses 5-ASA 
as a model drug that is delivered to the colon as a reference for the possibility of delivering 
specific peptides and proteins to the colon.   
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5.2.3. Chitosan 
Chitosan (Sigma Aldrich-medium molecular weight) had a molecular weight of 
approximately 237,000 as measured by GPC (section 2.4.2). A medium molecular weight 
chitosan was chosen as previous studies have shown that low and high molecular weight 
chitosan can promote extensive particle aggregation (Mun et al., 2006). Chitosan solutions 
(0.01, 0.25, 0.5, 1, 2 and 3%) for coating were created by dissolving the appropriate amount 
of chitosan in 1% acetic acid through vortex mixing and sonication.  
5.3. Apparatus and methodology 
5.3.1. Production of neutral and anionic LUVs 
MLVs were produced in the same way as outlined previously in section 3.3.1, using the 
original method published by Bangham et al. (1965). Neutral liposomes were produced using 
a EPC:CH ratio of 7:2 with it being hypothesised the lower CH concentration would lead to a 
faster drug release rate due to the increased bilayer mobility (Lemmich et al., 1996). Anionic 
liposomes were produced by including DCP in a ratio of 7:2:1 (EPC:CH:DCP). Blank MLVs 
were hydrated with PBS buffer whilst drug loaded MLVs were hydrated with a 1mg/ml 5-
ASA in PBS solution.    
LUVs were produced by polymeric membrane extrusion of MLVs through membranes with a 
reducing pore size (1 µm, 0.4 µm and 0.2 µm) using the Mini-Extruder (Avanti Polar Lipids, 
Inc., Alabaster). The mini extruder allows for small samples sizes (≤ 10ml) to be extruded 
using a variety of polycarbonate membranes (0.03 µm to 5 µm). The materials used in the 
production of the mini extruder are heat resistant, therefore allowing for a variety of lipids 
(with a phase transition temperature above room temperature) to be extruded up to a 
maximum of 80°C. Due to the low transition temperature of EPC (-5 to -15˚C), there was no 
requirement to heat the extrusion apparatus, therefore all extrusions were performed at room 
temperature.  MLV samples were extruded through the membrane a number of different 
times (5, 11, 15 and 19) to investigate how many extrusions were required to achieve a 
homogenous size distribution of LUVs. The manufacturers recommend that a minimum of 11 
passes are required, but sample requirements are governed by the lipids being used. The 
extrusion process relies on pressure being applied to the syringe to force the sample through 
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the membrane and therefore may be open to user variability (unless a peristaltic pump is 
used). With this in mind a full study on the number of passes required to obtain a 
homogenous sample size was necessary, with a minimum of three individual samples to be 
assessed.  
5.3.2. Characterisation of LUVs 
The size distribution using each membrane after the specific number of passes was measured 
by laser diffraction particle sizing as previously outlined in section 3.3.3.4. Three 
independent samples were produced with each sample being measured a total of five times.     
Liposomes were labelled with the lipophilic dye Nile red. The use of a lipophilic stain means 
the lipid will become fluorescent under a fluorescent light microscope therefore allowing the 
liposomes to be viewed non – invasively in their natural state with no need for freeze drying 
to view under SEM. The same thin film hydration method was adopted as before (section 
5.3.1) with 2mg of the Nile red being dissolved with the other lipids in the solvent. Samples 
were then imaged using a Leica microscope with attached fluorescence unit.   
 
5.3.3. Production of chitosan-coated liposomes 
The coating of liposomes was completed by adopting a technique used by Henriksen et al. 
(1994; 1996). Liposomes were added drop-wise to chitosan solution (0.01, 0.25, 0.5, 1, 2, 3% 
w/w) in equal volumes whilst under magnetic stirring (400 rpm). The sample was then left 
stirring for a further 2 minutes and allowed to stabilise at 4˚C for 24 hours. The chitosan-
coated liposomes were then washed three times by centrifugation (26,000 rpm, 63,000 g) and 
replacing the supernatant with fresh 1% acetic acid.    
5.3.4. Characterisation of chitosan-coated liposomes  
5.3.4.1. Zeta potential analysis for chitosan-coated liposomes 
A number of studies have used the change in zeta potential to indicate the evolution of a 
chitosan coating on both neutral and anionic liposomes (Mady et al., 2009; Laye et al., 2008; 
Guo et al., 2003; Takeuchi et al., 2005). 1 ml of washed chitosan-coated liposomes was 
added to 20 ml of distilled water. The sample was then measured using the method described 
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in section 3.3.3. The average of 10 measurements was calculated with three independent 
samples being measured overall.      
5.3.4.2. Influence of chitosan concentration on size distribution of liposomal 
formulations 
Chitosan-coated liposomes were measured using the laser diffraction method outlined in 
section 3.2.3. Both anionic and neutral liposomes were coated with 1% chitosan solution with 
the resultant formulations being dispersed in distilled water.    
5.3.4.3. Cryo-SEM analysis of chitosan-coated liposomes 
Chitosan-coated liposomes were imaged using the cryo-SEM method described in section 
3.2.4. Initial images of chitosan-coated LUVs proved inconclusive due to the small particle 
size (approximately 200nm) and the low accelerating voltage required to maintain cryo 
chamber temperature throughout. With this in mind images of chitosan-coated MLVs were 
also taken as it has been observed the initial liposome diameter has little effect on the coating 
properties (Laye et al., 2008).  
5.3.4.4. Fluorescence labelling of chitosan-coated liposomes 
To visualise the chitosan coating layer on the liposomes a method used by Amin et al. (2009) 
was adopted. FITC-labelled chitosan was synthesized by adding 100ml dehydrated methanol 
followed by 50 ml of FTIC in methanol (2.0 mg/ml) to 100 ml of chitosan (1% in 0.1 M 
acetic acid) in the dark and at ambient temperature. After 3 hours, the labelled polymer was 
precipitated in 0.2 M sodium hydroxide. The precipitate was pelleted at 40,000 x g (10 min) 
and washed with methanol-water (70:30, v/v) until no fluorescence was observed in the 
supernatant. The labelled chitosan was then re-dissolved in 20 ml of 0.1 M acetic acid and 
suitable for coating as in section 5.3.2. Further trials were completed using Nile red dyed 
liposomes (section 5.3.2.2.) in combination with labelled chitosan to so that the lipid and 
aqueous regions of the liposomes could be observed. All images were taken using the 
fluorescence method described in section 5.3.2.2.   
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5.3.5. Drug release properties of chitosan-coated liposomal formulations 
5.3.5.1. UV spectral analysis and calibration curves for 5-ASA quantification 
Initially, a UV spectrum was completed to determine the wavelength at which 5-ASA has a 
suitable absorbance to analyse drug release media for release (Figure 5.1). All UV spectra 
were completed on a Jasco V-530 UV/Vis spectrophotometer.  A small amount of 5-ASA 
was dissolved in water with the spectra being taken in the range 250-500 nm, at 5 nm/second.  
 
 
 
Figure 5.1. UV spectra of 5-ASA dissolved in distilled water. 
 
Calibration curves were then constructed for 5-ASA dissolved in each of the buffers to be 
used during the release trials (outlined in section 5.3.4.3). For each calibration curve a 
solution of 1 mg/ml of 5-ASA was made up in the required buffer, and then a serial dilution 
was completed to a point where the absorbance level became negligible. All measurements 
were completed in triplicate on independent samples at the λmax = 330 nm. The resultant 
calibration curves are shown in Figure 5.2. 
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(A)                                     (B) 
 
  (C)                                                                                                       (D) 
Figure 5.2. Calibration curves for 5-ASA dissolved in (A) 0.1M HCl, (B) Hanks’ solution, (C) PBS and (D) ethanol at 330nm. 
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5.3.5.2. Quantification of encapsulated 5-ASA 
The amount of drug present within the LUVs was quantified by lysing the liposomes after 
extrusion to give a total encapsulation for uncoated formulations. 0.1 ml of liposome sample 
was added to 0.9 ml ethanol and vortex mixed to ensure all the liposomes had been destroyed. 
The solution was then analysed spectrophotometrically with the concentration being 
calculated by referring to the calibration curve in ethanol (Figure 5.2 D). For all calibration 
curves and release experiments, initial trials were performed to ensure none of the individual 
components of the formulation would influence the UV absorbance when measuring for 
specific drug concentrations.  
5.3.5.3. Drug release studies in conditions representative of the GI tract 
As outlined previously the GI tract has a range of pHs and transit times. The release media 
used for the stomach and small intestine were the same as outlined in section 3.2.3. The use 
of 10 mM sodium taurocholate in the Hanks’ solution was continued as it not only provides 
similar conditions to those observed in the GI tract but was also shown to be a rigorous test 
when used for trials of Eudragit S100 coated liposomes (chapter 3).  
The method for the large intestine release media was adapted from previous experiments. The 
inclusion of a specific enzyme that is present in the colon is necessary to solubilise the 
chitosan as would be expected in vivo (described in section 2.3.3). A number of studies have 
evaluated the solubilisation of the chitosan coating layer of liposomes by assessing drug 
release within buffers containing either rat or human faecal slurries (McConnell et al., 2008; 
Zhang and Neau, 2002). Due to the number of safety considerations and complications 
associated with using faecal samples, a number of studies have investigated in vitro methods 
that utilise commercially available enzymes that will solubilise chitosan in a similar way to in 
vivo, whilst maintaining human relevance. Fang et al. (2009) showed that β-glucosidase (4% 
w/w) gave comparable results to rat cecal contents (4% w/w) for theophylline release of 
chitosan-coated tablets. Furthermore, Orienti et al. (2002) showed that in the presence of β-
glucosidase (1 mg/ml) an increased drug release was shown from a variety of chitosan salts in 
comparison to a standard pH 7.0 PBS to simulated colonic fluid. Wei and Lu (2003) observed 
that chitosan-coated liposomes released very little in simulated gastric and enteric fluids, but 
showed that there was a significant increase in percentage released and release rate when the 
liposomes were subjected to simulated colonic media containing β-glucosidase (concentration 
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unknown). It was decided to use a 4% (w/w) concentration of β-glucosidase in PBS with a 
pH of 7.4 which represents the average pH found at the ileo-caecal junction (outlined in 
section 1.4.3.4).   
5.3.5.4. Drug release profiles for uncoated and chitosan-coated LUVs 
Drug release trials with uncoated and 1% chitosan-coated neutral LUVs were conducted in 
the release media described in section 5.3.4.3. For each experiment 1 ml of liposome sample 
was injected into a 20,000 molecular weight cut off (MWCO) Slide-A-Lyzer dialysis cassette 
(Piercenet, Rockford). The cassette had been previously assessed that it maintained its 
integrity within the simulated media to be used. This assessment was completed by injecting 
a sample of 5-ASA in PBS and assessing the release media over a number of time points. It 
was shown that the dialysis cassette maintained its integrity over the required time periods 
with the indication of very little or no release being observed (<2%). The cassette had been 
previously hydrated in 0.1 M HCl (maintained at 37˚C) for 2 minutes. The dialysis cassettes 
were then attached to the rotating shaft of a USP Type II dissolution apparatus (Varian DS 
705, Agilent Technologies, England) dissolution apparatus and lowered into a 400 ml beaker 
containing 250 ml HCl. The beaker was held in a water bath within the 1 litre vessels of the 
apparatus which was maintained at 37˚C throughout. The stirring speed of the apparatus was 
maintained at 100 rpm in accordance with the British Pharmacopoeia’s guidance on 
dissolution testing (Appendix XII B). Aliquots of 1 ml were removed from the buffer at pre-
determined time intervals and replaced with 1 ml of pre-heated fresh buffer. The 
concentration of released 5-ASA was determined using UV spectrophotometry against a 
standard curve obtained at λ=330 nm. All measurements were taken against reference 
samples of the appropriate dissolution medium. After two hours the cassettes were moved 
from the HCl to beakers containing Hanks’ buffer with 10mM sodium taurocholate and the 
trial was continued with samples being taken at pre-determined time intervals for the next 
three hours. Finally the samples were moved from beakers containing Hanks’ buffer into 
beakers containing PBS and β-glucosidase. As the dialysis cassettes are cellulose based it was 
hypothesised that the inclusion of β-glucosidase in the release media would lead to the 
degradation of the membrane over time. A trial experiment was conducted whereby a blank 
cassette was placed into the release media. Samples were taken at pre-determined time points 
to observe if any alteration in the UV absorption occurred. It was shown that the absorption 
increased at approximately 7-8 hours and therefore it was decided every 5 hours the sample 
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was removed from the cassette and placed in a new cassette into the same buffer. The 5 hour 
time frame ensured membrane degradation would not influence the absorption readings 
obtained for the specific drug release of the liposomes.            
5.4. Results and Discussion 
5.4.1. Investigation into size distribution of extruded MLVs 
5.4.1.1. Investigation into the number of extrusions required for a homogenous sample 
Size distribution results for liposomes exposed to different numbers of passes through the 
extruder are shown in Figure 5.3. The results shown are for the three membrane sizes; 1, 0.4 
and 0.2 µm, for 5, 11, 15, and 19 passes. The size distributions are similar to those observed 
in previous studies (Macdonald et al., 1991; Subbarao et al., 1991) for this apparatus whereby 
a bimodal size distribution is observed initially, then as the number of passes increases and 
the membrane size decreases a unimodal, normal distribution is observed. The unimodal 
distribution is not observed until the 0.2 µm membrane is used which is also in accordance 
with the manufacturer’s literature whereby it is suggested a membrane pore size ≤ 0.2 µm is 
required for the production of LUVs. The membrane pore sizes above 0.2 µm are 
recommended to produce a polydisperse suspension of MLVs.     
The size distribution statistics (d10, d50, d90) also offer an insight into the change in size 
distribution with increasing passes through the membrane (Table 5.1.). The majority of 
difference can be seen between the samples produced using 5 passes and the samples 
produced using the recommended minimum number of passes of 11.  
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Figure 5.3. Size distributions for liposomes extruded using (A) 1 µm, (B) 0.4 µm and (C) 0.2 µm 
polycarbonate membrane. Samples were extruded through the membrane 5 (▲), 11 (■), 15 (●) and 19 (x) 
times. 
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Table 5.1. Table showing size distribution statistics (d10, d50, d90) of extruded liposomes using 
various membrane pore size filters and varying number of extrusions. 
 
d10 d50 d90 
Membrane size Membrane size Membrane size 
Number 
of 
Passes 
1 µm 0.4 µm 0.2 µm 1 µm 0.4 µm 0.2 µm 1 µm 0.4 µm 0.2 µm 
5 0.0903 0.0927 0.109 0.338 0.361 0.230 1.611 0.783 0.407 
11 0.0990 0.097 0.0937 0.376 0.360 0.197 1.450 0.706 0.367 
15 0.0927 0.101 0.0890 0.339 0.382 0.197 1.396 0.742 0.378 
19 0.0907 0.103 0.0873 0.286 0.347 0.187 1.338 0.699 0.365 
 
5.4.1.2. Results showing effect of reducing membrane size at 15 extrusions 
From the initial size distributions it was decided 15 passes through the polycarbonate 
membrane produced a suitably homogenous sample, and therefore it was decided to use this 
number of passes throughout the future studies. A size distribution comparing the change in 
liposomal size from MLVs to LUVs at 15 passes is shown in Figure 5.4. The transition from 
an MLV formulation into a low polydisperse LUV sample using the 0.2 µm can be observed. 
Further extrusions at lower membrane pore sizes could have been completed to produce a 
sample with a more narrow size distribution, but due to the drug losses associated with the 
extrusion process it was decided LUVs in the region of 0.2 µm would be suitable for coating 
and therefore maintain a high enough concentration of the original drug content (Berger et 
al., 2001; Bhardwaj and Burgess, 2010).  
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Figure 5.4. Size distribution for MLVs (▲) and liposomes extruded 15 times using 1 µm (■), 0.4 µm (○), 
and 0.2 µm (×) polycarbonate membranes. 
 
Fluorescence imaging was undertaken on Nile red stained liposomes and the subsequent 
stages of extrusion through the various membranes (Figure 5.5). This method highlighted the 
phospholipid bilayers due to the staining and therefore offers a clear indication of liposome 
size and homogeneity. The stained bilayers are very clear for the MLVs, with the use of ever 
decreasing pore sized membranes being used showing an alteration in the vesicle size, thus 
reinforcing Figure 5.4. The vesicle size decreases significantly with the 1 µm membrane 
appearing to show a homogenous sample, but still with individual vesicles being visible. The 
0.4 µm membrane shows less definition of vesicles which is a limitation of the current 
method using a light microscope. Finally, the 0.2 µm membrane shows no evidence of single 
vesicles, which is due to the resolution of the microscope and the subsequent small size of the 
LUVs. The lack of definition of vesicle observed for the 0.2 and 0.4 µm membrane is due to 
both the limitation of the microscope but also the nature of the fluorescent dye for small 
vesicles can cause excessive excitation which doesn’t allow for definition between the 
unstained internal core to be observed in comparison to the stained bilayer.  
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(A)                                              
(C)                                
Figure 5.5.  Fluorescence microscope images of Nile red stained (A) MLVs, and extruded liposomes using 
the (B) 1 µm, (C) 0.4 µm and (D) 0.2 µm polycarbonate membrane.
 
5.4.2. Investigation into chitosan
5.4.2.1. Change in zeta potential for 
It has been widely documented that the evolution of a chitosan coating on liposomal surfaces 
can be monitored through analysis of zeta potential (Mady 
Guo et al., 2003; Takeuchi et al
studies as the final coated liposomes should have a similar zeta potential regardless of the 
lipid used in the production of the liposomes. It
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liposomes, coupled with the variation in specific lipid and its concentration. The change in 
zeta potential observed for neutral and negatively charged LUVs is shown in Figure 5.6. For 
anionic liposomes an initial zeta potential in the region of -40 mV can be seen with neutral 
liposomes having a marginally negative charge of -1.2 mV, which is in accordance with 
previous studies (Mady et al., 2009; Makino et al., 1991). An increase in zeta potential can be 
observed for both liposomal formulations as the chitosan concentration increases. This would 
be expected as the cationic chitosan is absorbed onto the liposomal surface causing a change 
in overall surface charge. At 1% chitosan coating the zeta potential appears to plateau with no 
further increase observed for 2 and 3% coating in both liposome formulations. This is similar 
to that observed by Henriksen et al. (1997) where it was shown for washed liposomes the 
plateau occurred at similar zeta potentials for both neutral and negatively charged liposomes. 
A much higher zeta potential (~ +85 mV) was observed for unwashed due to excess chitosan 
polymer chains being loosely associated with the coated liposomes and therefore increasing 
the electrophoretic mobility. Henriksen et al. (1997) observed changes in zeta potential of -25 
to +32 mV and -1.8 to +29 mV for negatively charged and neutral liposomes respectively 
when coating with chitosan, which are similar to those seen in Figure 5.6. Similarly, Guo et 
al. (2003) and Mady et al. (2009) observed a plateau in zeta potential at approximately 40 
mV for liposomes produced using EPC and DPPC respectively when coated with chitosan.  
 
Figure 5.6. Influence of chitosan concentration on zeta potential of neutral (○) and negatively charged (■) 
chitosan-coated LUVs. Each point represents the mean of three independent trials, with the mean of 10 
measurements completed for each trial.  
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Due to the plateau observed during the zeta potential trials it was decided that a sufficient 
chitosan coating would be achieved through the addition of 1% chitosan. This was not only to 
reduce the excess quantities of chitosan being removed during the washing process but also to 
attempt to reduce the possibility of aggregation and subsequent phase separation observed by 
Laye et al. (2008) when going below or above the saturation concentration. The saturation 
concentration was shown to have a linear relationship with liposomal concentration as an 
increase in liposomes leads to an increase in exposed surface area and therefore an increased 
amount of chitosan is required for coating.  
5.4.2.2. Influence of chitosan concentration on size distribution of LUVs 
Size distribution analysis was completed on uncoated and 1% chitosan-coated samples to 
observe the influence the chitosan coating had upon the particle diameter (Figure 5.7). It can 
be seen that for both coated formulations the size increases marginally compared to that of 
the uncoated formulations. This size increase, above the saturation concentration as defined 
by Laye et al. (2008), is expected for chitosan-coated formulations. Interestingly, there is a 
small volume of the anionic coated formulation with a much larger particle diameter above 
10 µm which is indicative of possible aggregation through interactions between uncoated and 
coated sections of liposomes.  
  
Figure 5.7. Size distribution of uncoated anionic (□) and neutral (○) LUVs, with 1% chitosan-coated 
anionic (■) and neutral (●) LUVs. 
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The coating mechanism for anionic liposomes combined with chitosan is predominantly 
attributed to electrostatic interactions which has been extensively investigated (Henriksen et 
al., 1994; 1997; Laye et al., 2008; Guo et al., 2003). The coating of liposomes through 
electrostatic interactions is often interpreted through the charge mosaic theory or adsorption 
coagulation (Gregory, 1973; Mabire et al., 1983). A diagram published by Mabire et al., 
(1983) suggesting the possible interactions during the coating of anionic particles with 
cationic macromolecules is shown in Figure 5.8. The diagram indicates that the uncoated 
formulation (interactions b) would not flocculate due to the repulsive forces between the two 
anionic particles. Similarly for two coated particles (interactions a) it can be seen that the two 
positive charges would also repel each other, therefore maintaining a homogenous dispersion 
of coated particles. The situation whereby flocculation could be observed is when a partially 
coated formulation is attracted to an uncoated particle (interactions c), therefore resulting in 
the aggregation of particles, which further supports the size distributions observed in Figure 
5.7. This further supports Henriksen et al.’s (1994) strategy of adding liposomes to excess 
chitosan as this allows for particles to become completely coated and thus reducing the 
possibility of flocculation compared to if the chitosan solution was added to the liposomes.  
Henriksen et al. (1997) indicated that a number of mechanisms of flocculation would be 
present (polymer bridging, double layer coagulation etc.), but identified that there were two 
main reactions taking place between chitosan and liposomes during the coating process. The 
two reactions, where C indicates chitosan and L liposomes, are; 
C + L → CL           (3) 
CL + L ↔ LCL           (4) 
Where (3) represents the irreversible coating of the liposome with chitosan and (4) represents 
a partly coated liposome interacting with a part of an uncoated liposome causing an increase 
in the measured particle size. If chitosan is present in excess then (3) should be able to 
proceed until a stable positive charge is formed therefore preventing (4) from occurring. This 
supports the need to maintain consistency in the production of chitosan-coated liposomes 
through both the stirring rate used and the rate of liposome addition as indicated by 
Henriksen et al. (1997).    
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Figure 5.8. Diagram representing the possible interactions through the addition of chitosan to anionic 
liposomes. Interactions a and b are repulsive whilst c is attractive. (Mabire et al., 1983). 
 
In comparison to the electrostatic interactions observed for the coating of anionic liposomes, 
the mechanism of coating neutral liposomes has not been as well documented. It has been 
hypothesised that hydrophobic interactions dominate the coating process (Perugini et al., 
2000; Guo et al., 2003), through hydrogen bonding taking place between the chitosan and the 
phospholipid head groups. Guo et al. (2003) compared the same lipid of two different purities 
to compare the possible interactions involved; Epikuron 170 and 200. A lipid of low purity 
was used, which produced anionic liposomes, to investigate the electrostatic interactions 
whilst a high purity lipid was used, which produced marginally positive liposomes, to 
investigate the possibility of hydrophobic interactions. An increase in zeta potential, size and 
stability upon dilution was observed for both batches of liposomes, but a number of 
differences were observed. The lipid of low purity (electrostatic interactions dominate) 
produced a coated liposomal formulation four times the size compared to that of the high 
purity lipid. Furthermore, Guo et al. (2003) observed a significant difference for the zeta 
potential measurements where the low purity lipid reached a plateau at approximately 40 mV 
whilst the high purity lipid at approximately 20 mV. This does however contradict the work 
of Henriksen et al. (1994) where similar zeta potentials were observed for both neutral and 
negatively charged liposomes. Guo et al. (2003) hypothesised that the addition of 
electrostatic interactions provided the increased affinity for the liposomes to the chitosan and 
therefore produced a thicker coating. It was concluded that chitosan coating through 
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hydrophobic interactions would be more favourable as it is considered more stable and was 
affected negligibly by the changes in pH and buffer upon dilution. It was also hypothesised 
that the thickness of coating could be problematic as it may restrict the release of the active 
ingredient at the target site.      
5.4.2.3. Imaging techniques used to investigate the chitosan coating of neutral and 
negatively charged liposomes dispersed in water. 
Cryo-SEM 
Initially uncoated and chitosan-coated anionic LUVs were investigated using cryo-SEM 
(Figure 5.9). The images of uncoated LUVs show a large population of small vesicles with a 
wide size range, which could not be seen during light microscopy (Figure 5.5). This variation 
is more representative of the size distribution observed during the extrusion process, which is 
indicative of using the largest membrane pore size suitable for the production of LUVs 
(0.2 µm). The subsequently coated LUVs showed a significant increase in size, with a much 
lower population of liposomes being observed (Figure 5.9 B). It can be assumed that due to 
the size change and significant reduction in liposome quantity that a number of chitosan-
liposome complexes were produced, therefore not producing a single liposome with a defined 
coating layer. If this is the case it can be assumed that some sort of flocculation may be 
occurring during the production of chitosan-coated liposomes, as outlined by the mosaic 
charge theory.  
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(A) 
 
(B) 
Figure 5.9. Cryo SEM images showing (A) uncoated and (B) chitosan-coated anionic LUVs. 
 
Due to having to work at a lower accelerated voltage during cryo-SEM to maintain the 
temperature, the resolution possible did not give a clear indication of the coating layer and 
therefore chitosan-coated MLVs were observed. As it has been shown that there is little 
difference between the chitosan coating of varying size vesicles it was assumed that the same 
coating would take place for MLVs as LUVs (Laye et al., 2008). As mentioned previously, 
Laye et al. (2008) observed a linear relationship between the lipid concentration and required 
amount of chitosan to reach saturation, but as the same lipid concentrations were maintained 
throughout it was decided no change in chitosan concentration would be required to coat 
MLVs. Figure 5.10 shows the resultant cryo-SEM images of uncoated and chitosan-coated 
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anionic MLVs. The uncoated MLVs display an uneven surface representing the phospholipid 
outer layer of the vesicle. The individual bilayers can also be observed in one of the images 
where the actual liposome has been fractured. In comparison the coated formulation show a 
smooth outer shell which would indicate the presence of an outer chitosan shell having been 
formed. The first image shows the presence of two liposomes in what appears to be a single 
chitosan complex, which further indicates that flocculation occurs during the processing. The 
second image of chitosan-coated MLVs shows what appear to be individually coated 
liposomes that have agglomerated into a single complex. This may be partially due to some 
electrostatic interactions still being prominent between uncoated sections of a liposome with 
coated sections of liposomes, similar to that observed by Laye et al. (2008). Laye et al. 
(2008) observed small aggregates forming when coating liposomes, which were visible as 
flocculations to the naked eye, but did not sediment to form a separate layer. It can be 
assumed that when measuring the size distribution of chitosan-coated anionic liposomes that 
the stirring speed (1750 rpm) was sufficient to disrupt these agglomerations and produce a 
homogenous formulation throughout.         
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(A) 
 
(B) 
Figure 5.10. Cryo-SEM images showing (A) uncoated and (B) 1% chitosan-coated anionic MLVs. 
Samples are dispersed in distilled water. 
 
Cryo-SEM images for uncoated and chitosan-coated neutral MLVs are shown in Figure 5.11. 
Uncoated neutral MLVs show a similar uneven, ‘globular’ surface morphology as seen for 
uncoated anionic MLVs. Chitosan-coated neutral MLVs show the same smooth outer shell as 
seen for anionic coated MLVs with the main difference being the neutral MLVs appear to 
remain as individual vesicles. The first image shows a complete liposome with a smooth 
outer shell whilst the second image shows a number of fractured vesicles. The fractured 
liposomes show a solid outer shell (circled on diagram) which indicates the presence of a 
solid chitosan coating. The appearance of this coating differs significantly to that observed 
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for Eudragit S100 coated liposomes where the polymer appeared to agglomerate on the 
liposome surface. This solid layer observed is indicative of a permanent coating that has a 
number of interactions including electrostatic and hydrogen bonding.       
 
(A) 
  
 (B) 
Figure 5.11. Cryo-SEM images showing (A) uncoated and (B) 1% chitosan-coated neutral MLVs. 
Samples are dispersed in distilled water.  
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Fluorescence Imaging 
Cryo-SEM indicated the presence of a chitosan coat as the surface morphology changes from 
an uneven to smooth surface, with an outer shell being visible. As the Eudragit S100 coated 
liposomes also showed a form of coating but could not withstand bile salt attack, it was 
necessary to further investigate the nature of the coat and therefore its suitability to prevent 
liposome lysis when exposed to the solvent mixture during microsphere production. By 
labelling the chitosan with FITC it was assumed that the nature of the coat could be 
investigated by observing whether a single layer had been produced or if an agglomeration on 
the surface of the liposomes had occurred as observed for the Eudragit S100 coating. 
Figure 5.12 shows the effect of FITC labelling of chitosan prior to the coating of both anionic 
and neutral liposomes. The anionic liposomes (Figure 5.12 A) can be clearly seen with a 
black inner core indicating the internal structure of the liposomes and therefore where the 
FITC does not penetrate. The coating layer itself appears to be a uniform single layer around 
each liposome. There is also a clear indication of agglomeration in the sample with an excess 
of chitosan surrounding the liposomes. The images in Figure 5.12 provide a more conclusive 
indication of the chitosan coating thickness in comparison to the previous FITC labelled 
chitosan coating study by Amin et al. (2009). The images obtained are very similar to the 
cryo-electron micrographs presented by Henriksen et al. (1994) which show what he 
describes as a liposome double membrane having formed with the coating of LUVs. The 
neutral liposomes (Figure 5.12 B) show examples of single chitosan-coated liposomes with 
no chitosan agglomerations around the liposomal structure, which is in accordance with the 
cryo-SEM images. This further reinforces the use of the charge mosaic theory whereby 
chitosan agglomerations can be observed for anionic liposomes but not for neutral, which 
also supports the hypothesis that different coating mechanisms are involved.      
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(B) 
Figure 5.12. Fluorescence microscope images showing FITC labelled 1% chitosan-coated (A) anionic 
MLVs and (B) neutral MLVs dispersed in water. Each scale bar represents 10.0 µm.   
 
5.4.2.4. Cryo-SEM investigation into chitosan-coated liposomes stability when exposed 
to microsphere processing conditions.  
Previous images of chitosan-coated liposomes (section 5.4.2.2.) have shown what appears to 
be a solid layer around the liposomes. The presence of the coating layer has been confirmed 
through a number of techniques (zeta, size and imaging), but the initial reason for coating the 
liposomes was to protect them during microsphere production and therefore it still remains to 
be seen whether the liposomes remain intact when exposed to the solvent mixture. 
Figure 5.13 shows cryo-SEM images of both anionic and neutral chitosan-coated MLVs 
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homogenised for 4 minutes at 7,400 rpm in the solvent mixture used for microsphere 
production. From both sets of images it can be seen that the chitosan coating and the internal 
liposomal bilayers have remained intact throughout the processing. No major differences in 
chitosan-coated structure or morphology can be observed between those dispersed in water 
and those dispersed in the solvent mix. This indicates that the liposomes would therefore be 
able to be successfully encapsulated within the Eudragit S100 microsphere.    
 
(A) 
 
(B) 
 
Figure 5.13. Cryo-SEM images showing chitosan-coated (A) anionic MLVs and (B) neutral MLVs 
dispersed in solvent mixture of DCM:ethanol:propanol (5:6:4).  
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To provide further evidence of the protection provided by the chitosan coat in the solvent 
mix, Nile red stained liposomes were coated with FITC labelled chitosan. The resultant 
images of the sample homogenised in the solvent mix are shown in Figure 5.14. A number of 
liposomes can be observed with a definite chitosan coating surrounding them. If the coating 
had not protected the liposomes then the Nile red dye would not be visible as it would have 
leaked into the background. These images further support the conclusion that chitosan 
coating offers significant protection for both anionic and neutral liposomes to enable their 
encapsulation into Eudragit S100 microspheres using a double emulsion – solvent 
evaporation method.    
 
Figure 5.14. Fluorescence microscope images of neutral Nile red stained MLVs, coated with 1 % FITC 
labelled chitosan and subsequently homogenised in solvent mix (DCM:ethanol:propanol).  
 
5.4.3. Drug release profiles for uncoated and chitosan-coated LUVs 
A number of studies have investigated the drug release profiles of chitosan-coated liposomes 
and shown it is necessary for an enteric coating to be used as the coat is soluble within the 
acidic conditions of the stomach. Therefore, the current drug release profiles are to assess the 
release rates of the liposomes and their suitability for the application of colonic drug delivery 
whilst encapsulated within Eudragit S100 microspheres. The drug release profiles produced 
are shown in Figure 5.15. It was shown that the drug release curves were not statistically 
different (Mann Whitney U test), and therefore indicates that the presence of a chitosan 
coating layer would not sufficiently protect liposomes through the upper GI tract. The release 
data has been split into the three sections which correspond to the average transit time in the 
Chapter 5  Chitosan-coated liposomes 
153 
 
GI tract and therefore the point where the dialysis cassettes were moved to the next release 
media. The uncoated liposomes show a continual steady release which leads to over 50% of 
drug release occurring in the first 10 hours. The release appears to slow considerably in the 
PBS with a plateau occurring at approximately 40 hours. Although continued release is 
observed for the uncoated formulation the actual timings of release may be subject to a short 
lag time whereby the drug has to diffuse through the dialysis membrane of the cassette. With 
this in mind though, both formulations will be subject to the same lag time and therefore 
allows for a comparison to be made.  
The chitosan-coated liposomes follow a similar shaped curve to that of the uncoated 
formulation, the main difference being, the initial drug release in HCl and Hanks’ buffer 
appearing to be considerably slower. After exposure to both HCl and Hanks’ buffer only 15% 
of 5-ASA had been released, whereas 5 hours in the large intestine condition increased the 
cumulative release to 50%. The delayed drug release could be due to the slow solubilisation 
of the chitosan coating in the HCl and therefore preventing the diffusion of 5-ASA across the 
liposomal membrane. The results for chitosan-coated liposomes are comparable to that of 
Wei and Bin (2003) who observed that chitosan-coated liposomes released 13.1% of the drug 
when exposed to 4 hours in pH 1.2 and 8 hours in pH 6.8, with the majority of release 
(approximately 80%) taking place when exposed to pH 7.8 containing β-glucosidase for 12 
hours. This further indicates the suitability of using β-glucosidase in vitro due to its specific 
ability to solubilise the 1-4 glycosidic bonds within chitosan (as described in section 2.3.2). 
The release of drug from chitosan-coated liposomes in HCl has been observed by Guo et al. 
(2003), where it was shown that over a two hour period chitosan-coated liposomes showed 
significant leakage of leuprolide when diluted in both HCl (pH 1.2) and PBS (pH 6.9). 
The release profiles comparing uncoated and chitosan-coated liposomes indicate that the 
presence of the chitosan does slow the drug release considerably through the simulated GI 
tract conditions. Despite these findings the leakage that has been observed during these in 
vitro conditions further indicate the need for an enteric coating to protect the chitosan layer 
and therefore prevent premature drug release in the upper GI tract (Kaur and Kim, 2009).   
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Figure 5.15. Drug release profiles for uncoated (○) and 1% chitosan-coated (●) neutral liposomes in 0.1 M HCl, Hanks’ buffer containing sodium taurocholate and 
pH 7.4 PBS containing β-glucosidase. 
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5.5. Conclusions 
Both anionic and neutral liposomal LUVs were produced through membrane extrusion. It 
was shown that 15 extrusions produced a homogenous sample size, which would then be 
suitable for coating. The effect of chitosan concentration on zeta potential was investigated 
when coating LUVs, with a 1% concentration proving adequate to coat the LUVs and reach a 
plateau therefore being at the saturation point of the liposomes. The presence of a chitosan 
coating layer in both liposomal formulations was confirmed through size distribution, cryo-
SEM and fluorescence microscopy. The coating appeared as solid single coating which 
contrasts that of Eudragit S100 coated liposomes observed in chapter 3. The stability of the 
coat was subsequently investigated by exposing the liposomes to the solvent mixture and 
processing conditions involved in the production of Eudragit S100 microspheres. Both cryo-
SEM and fluorescence microscopy confirmed that the liposomes still remained in the 
dispersion, therefore indicating that the chitosan coating had protected them during solvent 
exposure. 5-ASA release from uncoated and chitosan-coated neutral LUVs was investigated 
in simulated GI tract conditions. The coated formulation showed an improved drug retention 
in comparison to that of the uncoated formulation for the stomach and small intestine 
conditions, with both showing significant release in PBS containing the model enzyme β-
glucosidase. Despite the improved drug retention it is evident that an enteric coating is 
required to protect the chitosan coating in the strong acidic conditions found within the 
stomach and therefore their incorporation into Eudragit S100 microspheres is essential for 
colonic drug delivery. 
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 6.0 Development of a liposome in microsphere (LIM) 
formulation 
 
________________________________________________________________________ 
ABSTRACT  
A liposome in microsphere (LIM) formulation has been created. Eudragit S100 microspheres 
were successfully used to encapsulate liposomes containing the model drug 5-ASA. The 
liposomes were coated with the natural polysaccharide chitosan, to protect the vesicles during 
the production stages of the LIM formulation. Characterisation of the LIMs was completed 
by laser diffraction particle sizing, cryo-SEM and drug release studies. Drug release studies 
were carried out in three media simulating the stomach, small intestine and large intestine. 
The simulated small intestinal fluid contained a model bile salt and the simulated large 
intestinal fluid contained a model enzyme produced within the human colon. The drug release 
trials showed that LIMs prevented drug release within the simulated stomach and small 
intestine conditions with subsequent drug release occurring in the large intestine conditions. 
The microspheres were solubilised by the pH 7.4 PBS which then exposed the chitosan-
coated liposomes. The chitosan coating was then solubilised by the presence of the colonic 
enzyme β-glucosidase therefore releasing the LUVs and allowing drug release. It was 
concluded that Eudragit S100 microspheres encapsulating chitosan-coated LUVs was a 
successful formulation and has the potential for targeted colonic drug delivery.  
________________________________________________________________________ 
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6.1. Introduction 
It has been previously shown that Eudragit S100 coated liposomes did not provide suitable 
protection to prevent bile salt ingress and subsequent exposure to in vitro small intestine 
conditions (chapter 3). It was then shown that solid Eudragit S100 microspheres produced 
using a double emulsion-solvent evaporation technique were stable through both the stomach 
and small intestine simulated conditions, with solubilisation taking place in conditions 
representative of the ileo-caecal region (chapter 4). It was then shown that liposomes could 
be coated with the natural polysaccharide chitosan, to protect the lipid vesicles during 
microsphere production (chapter 5). The next stage was to encapsulate chitosan-coated LUVs 
into the Eudragit S100 microspheres and therefore produce a formulation controlled by two 
separate factors within the GI tract. The dosage form would consist of the pH controlled 
Eudragit S100 microspheres followed by the enzyme dependant chitosan coating. The use of 
a microflora-activated system is seen as the most promising current trigger as the increase in 
bacteria population and enzyme activity represent a non-continuous event which is 
independent of GI transit time and therefore eradicates any problems associated with patient 
transit time variability (Yang et al., 2002).    
A number of LIM systems have been reported (Stenekes et al., 2001; Feng et al., 2004; Park 
et al., 2006), all of which comprise encapsulated liposomes within microspheres produced 
from biodegradable polymers. With this in mind each of these formulations are susceptible to 
variations in patient transit times and therefore specific targeted release of the active 
ingredient could not be guaranteed. The use of a pH responsive polymer (i.e. Eudragit S100) 
as the microsphere material not only provides a suitable enteric coating that will protect the 
liposomal formulation through the acidic conditions in the stomach but will also provide a pH 
trigger that will begin to solubilise within the ileo-caecal junction. This will then enable the 
chitosan-coated liposomes to continue to the colon where enzyme triggered drug release will 
occur.   
Feng et al. (2004) encapsulated both chitosan-coated LUVs and MLVs into PLA/PLA-PEG-
PLA microspheres. The initial release of liposomes from PLA microspheres was shown to be 
significantly slower than GI transit times (50% release in 30 days) but the inclusion of PEG 
into the polymer matrix increased the liposome release rate showing approximately a 20% 
increase in the same time-frame. This release rate would not be suitable for the targeting 
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within the GI tract due to the mis-match with transit times but changes in polymer molecular 
weight and PEG concentration could further increase the rate at which the liposomes are 
released. The size of encapsulated liposome was also shown to significantly influence the 
release rate from the microspheres with the use of LUVs (<200 nm) showing the highest 
percentage release in comparison to larger liposomes. It is hypothesised the use of chitosan-
coated LUVs in a pH responsive microsphere should produce a more specifically targeted 
system for the use in colonic drug delivery.     
The main aims of the work described in this chapter were to: 
• Successfully encapsulate chitosan-coated LUVs into Eudragit S100 microspheres and 
confirm their presence through a number of characterisation techniques.  
• Perform a degradation study observing the LIMs and their response in different simulated 
GI tract conditions. 
• Perform a drug release investigation into the ability of the LIM system to remain intact 
through simulated stomach and small intestine buffer solutions, and subsequently release 
the active ingredient (5-ASA) in simulated colonic conditions.  
6.2. Materials 
6.2.1. Lipids  
Neutral liposomes were produced using a 7:2 molar ratio of EPC:CH. EPC was a gift from 
Lipoid (Ludwigshafen, Germany) and CH was purchased from Sigma Aldrich (Dorset, UK).  
6.2.2. Polymers 
Chitosan-coated liposomes were produced using medium molecular weight chitosan (Sigma 
Aldrich) as investigated in chapter 2 (approximate molecular weight 236,000). Microspheres 
used to encapsulate liposomes were created using Eudragit S100 (Evonik Industries, Essen) 
as investigated in chapter 2 and used for the production of blank microspheres in chapter 4.  
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6.3. Methods 
6.3.1. Production of chitosan-coated LUVs 
MLVs were initially produced using the Bangham et al. (1965) thin film hydration method. A 
detailed method for liposomal production can be found in chapter 3. Briefly, the lipid 
components were dissolved in 5ml chloroform and then evaporated to leave a thin film on the 
bottom of a round bottomed flask. The film was then hydrated with a 1mg/ml 5-ASA in PBS 
solution and vortex mixed to create MLVs. The subsequent MLVs were then membrane 
extruded through to a pore size of 0.2 µm as investigated in section 5.4.1. The subsequent 
LUVs were then washed three times through centrifugation at 26,000 rpm (63,000 g) for 10 
minutes with the supernatant being replaced with fresh buffer. The LUVs were then coated 
with chitosan by adding LUVs dropwise to a 1% chitosan solution whilst under magnetic 
stirring as outlined in section 5.3.3.  
6.3.2. Production of LIMs 
LIMs were produced by using 5-ASA loaded chitosan-coated LUVs in the internal aqueous 
phase (IAP) during microsphere production. 0.8 ml of chitosan-coated LUVs were vortex 
mixed with 0.2 ml 3% (w/w) polysorbate 20 solution to form the internal aqueous phase 
(IAP). The primary emulsion (W1/O) was then formed by homogenising (7,400 rpm, 2 
minutes) the IAP with 5 ml 6% w/w Eudragit S100 dissolved in a solvent mixture of 
DCM:ethanol:propanol (5:6:4). The primary emulsion was then poured into 100 ml 1% PVA 
whilst under magnetic stirring at 125 rpm. Stirring was continued for three hours to ensure 
complete microsphere hardening and solvent evaporation. The microspheres were then 
washed using vacuum filtration with a filter membrane with a pore size of 1.6 µm. The 
microspheres were then subsequently harvested and primarily used in their ‘wet’ state for 
release trials.     
6.3.3. Characterisation of LIMs 
6.3.3.1. Size distribution analysis  
Particle size distribution was measured using the method outlined in section 3.3.3.4. Samples 
were measured in their ‘wet’ state immediately after filtration as this was the state in which 
the LIMs would be used for drug release trials. The samples were added to the dispersion unit 
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until the obscuration level was in the range of 14-18% (Mastersizer 2000 handbook, Malvern 
Instruments). The sample was dispersed in pH 7.0 distilled water.  
6.3.3.2. SEM imaging of microsphere morphology 
The surface morphology of dried LIMs could be analysed using SEM. It not only gave an 
indication of the size of the LIMs but also supplies information regarding the homogeneity of 
the sample and if there is any excess polymer or unformed microspheres. LIMs were allowed 
to dry out in an oven at 37°C for 48 hours and then subsequently mounted, coated and 
imaged according to the method used for blank microspheres outlined in section 4.3.2.   
6.3.3.3. Cryo-SEM 
Cryo-SEM imaging was undertaken to establish the internal structure of the microspheres and 
confirm the presence of encapsulated chitosan-coated liposomes. The microspheres were 
suspended in a highly viscous 5M sucrose solution to reduce mobility within the sample well 
and therefore ensure the sample remained suspended for the duration of the sectioning. 
Sectioning and imaging was then completed as previously described in section 4.3.5.     
6.3.3.4. Degradation study of LIMs in GI tract simulated conditions 
An SEM study was designed to observe the effect of varying conditions on the morphology 
and structure of LIMs. 10 mg of LIMs were placed in 20 ml (concentrations representative of 
drug release trials) of each of the release media representing the three sections of the GI tract 
(outlined in section 6.3.4.2) including both the model bile salt state and colonic enzyme state. 
The vessels were then maintained at 37˚C and agitated at 100 rpm in a New Brunswick G25 
incubator-shaker. 1 ml samples were removed at pre determined time intervals: stomach (0.5, 
1, and 2 hours), small intestine (1, 2, and 3 hours) and large intestine (1, 2, 4, 6, and 40 
hours). In each case, the maximum time in each buffer system was representative of average 
normal transit time. 1 ml of fresh pre-heated buffer was added after each sample was taken to 
maintain sink conditions throughout. The samples were centrifuged at 26,000 (63,000 g) for 
10 minutes, with the supernatant being removed. The remaining microspheres could then be 
completely dried in an oven at 37°C for 48 hours, ready for subsequent analysis as described 
in section 4.3.2.    
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6.3.4. Investigation into drug loading and release profiles for LIMs 
6.3.4.1. Establishing drug loading of LIMs  
The specific drug loading of the LIMs was investigated by ‘stripping’ off each layer (as 
would be experienced during drug release trials) protecting the liposomes, followed by lysing 
the liposomes in solvent. Initially 10 mg of LIMs were placed in 2 ml of the solvent mixture 
(DCM: ethanol: propanol) used in microsphere production. The solution was vortexed for 5 
minutes to ensure that the Eudragit S100 microspheres had been completely dissolved. The 
solution was then centrifuged at 26,000 rpm (63,000g) for 10 minutes to form a pellet of 
chitosan-coated LUVs at the bottom of the Eppendorf tube. The supernatant was then 
removed, with 2 ml of 1% acetic acid being added to the liposomes to solubilise the chitosan 
coating. 5 minutes of further vortex mixing ensured the chitosan coating was solubilised and 
therefore exposing the LUVs. The LUVs were then pelleted through centrifugation (26,000 
rpm, 10 minutes). The liposomes were then lysed through the addition of 2 ml of ethanol, 
releasing the encapsulated 5-ASA. The resultant solution was then measured 
spectrophotometrically at a wavelength of 330 nm and related to the calibration curve in 
Figure 5.2D to calculate the total 5-ASA encapsulated in the LIMs. This technique would 
also indicate whether the liposomes were intact in the microspheres as each supernatant was 
analysed when ‘stripping off’ the layers. The levels of drug within the supernatant would 
indicate whether the liposomes were intact within the microspheres or whether considerable 
leaking had taken place during production.  
6.3.4.2. In vitro conditions to simulate GI tract pH, bile salt and enzyme activity 
The in vitro conditions were the same as those described in section 5.3.4.3. 0.1 M HCl was 
used to simulate the stomach condition. pH 6.3 Hanks’ buffer containing 10 mM sodium 
taurocholate was used to simulate the small intestine and finally pH 7.4 PBS containing 4% 
w/w β-glucosidase was used for large intestine simulation.  
6.3.4.2. Drug release profiles for LIMs in simulated GI tract conditions 
In order to accommodate the large particle size of the LIMs, it was not possible to use the 
20,000 MWCO dialysis cassettes used in chapter 5 as they were too large to be injected into 
the syringe ports at each corner of the cassette. A similar drug release method was adopted by 
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using 14,000 MWCO dialysis membrane (BioDesign, New York) that would allow suitable 
LIM insertion due to the wider end opening. 50 mg of LIMs were placed inside the hydrated 
dialysis membrane and sealed. The membranes were then placed in 100 ml of release media 
in a 250 ml conical flask. The flasks were then placed in a New Brunswick G25 incubator 
maintained at 37˚C. The flasks were agitated at 100 rpm with 1 ml samples being removed at 
pre-determined time intervals. 1 ml of fresh pre-heated buffer was then added to the flask to 
maintain sink conditions throughout. The removed sample was analysed 
spectrophotometrically at a wavelength of 330 nm and related back to the calibration curves 
in Figure 5.2 to determine the amount of 5-ASA that has been released. The release curve 
was calculated by taking into account the drug that had been released at each time point and 
the effect of the dilution through the addition of the fresh buffer.    
6.4. Results and Discussion 
6.4.1. LIM characterisation  
6.4.1.1. Size distribution analysis 
The average volumetric mean size of the LIMs was found to be 86 µm (± 6.36 µm) which is 
approximately 30 µm larger than the blank Eudragit S100 microspheres (Figure 6.1). Despite 
the apparent large size difference there are a number of similarities between the two size 
distributions. Both distributions have a similar shape, with the LIMs showing a broader 
distribution in comparison to the narrow peak observed for the blank microspheres. A small 
‘shoulder’ can be seen for both formulations towards the larger particle size, which may be an 
indication of agglomeration or coalescence of the IAP. The ‘shoulder’ is more pronounced 
for the LIMs which may be an indication of the increased electrostatic and hydrophobic 
forces present when the liposome/chitosan complexes come into contact with the solvent 
mixture. In comparison Feng et al. (2004) showed very little change between blank PLA 
microspheres and LIMs with the general particle size being 60-70 µm for both formulations. 
The difference observed between the current findings and those of Feng et al. (2004) can be 
attributed to a number of factors most importantly the materials used. Feng et al. (2004) used 
ethyl acetate for the organic solvent and therefore could produce a more stable W1/O and 
subsequently maintain that stability when the chitosan-coated liposomes were introduced. 
The use of a three solvent system may also have a considerable impact when chitosan-coated 
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liposomes are introduced due to the specific miscibility of the solvent mix in comparison to 
the single solvent used by Feng et al. (2004).    
 
 
Figure 6.1. Size distribution comparison between blank Eudragit S100 microspheres (○) and drug loaded 
LIMs (■). Each point is the mean of three independent measurements ± the standard deviation. Particle 
size statistics (d10, d50 and d90) are displayed with their standard deviations.  
 
6.4.1.2. SEM imaging of LIMs 
SEM imaging 
SEM images of air dried LIMs are shown in Figure 6.2. In comparison to the blank Eudragit 
S100 microspheres (Figure 4.2 B) the LIMs are similar in sphericity and surface morphology 
having a smooth appearance with very few of the polymer strands visible that were seen for 
less successful formulations (higher polymer concentrations and lower homogenisation 
speeds). This indicates that although the size may have altered with the incorporation of 
chitosan-coated liposomes that the general emulsion formation and subsequent polymer 
hardening takes a similar form to that of the blank microspheres.    
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Figure 6.2. SEM images of air dried LIMs. 5-ASA loaded chitosan-coated LUVs were encapsulated within 
Eudragit S100 microspheres using a double emulsion-solvent evaporation technique.  
Cryo-SEM 
A comparison of the microsphere internal structures for blank microspheres and LIMs show a 
stark difference (Figure 6.3). From the blank microspheres an empty shell can be seen, which 
would be expected due to the use of distilled water alone for the IAP. The blank Eudragit 
S100 microspheres shown in Figure 6.3A differ internally to the PLA microspheres produced 
by Feng et al. (2004) in that the internal structure of the PLA microspheres comprised a 
porous polymer matrix throughout, whereas the Eudragit S100 microspheres show a definite 
shell with an empty core. The observed shell thickness appears to be variable between 
microspheres, with only a thin shell seen in the first image whilst the second shows a shell 
wall with a thickness of over 2 microns in places.  
In contrast, the LIMs show a solid internal structure with the presence of chitosan-coated 
liposomes throughout. Some larger particles are also visible within the microspheres which 
are thought to be liposome/chitosan complexes which form when the chitosan-coated 
liposomes are exposed to the solvent mixture, therefore causing agglomeration. The images 
of LIMs are very similar to those observed by Feng et al. (2004) where individual liposomes 
could also be seen within the porous polymer matrix of PLA microspheres.    
Chapter 6  Liposomes in microspheres 
165 
 
 
(A) 
 
 
(B) 
Figure 6.3. Cryo-SEM images comparing (A) blank Eudragit S100 microspheres and (B) chitosan-coated 
LIMs. The liposomes are visible in the internal structure of the LIMs compared to the blank interior of 
the microspheres.  
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6.4.1.3. Degradation of LIMs in simulated GI tract conditions 
It has been previously shown that blank Eudragit S100 microspheres can maintain their 
stability when subjected to the in vitro conditions of the stomach and small intestine (section 
4.4.5.). It is therefore essential that the incorporation of chitosan-coated liposomes does not 
influence the stability of the microspheres and subsequently protect the liposomal contents 
through to the proposed site of microsphere solubilisation at the ileo-caecal junction. SEM 
images of LIMs subjected to in vitro conditions representative of the stomach are shown in 
Figure 6.4. The images show exposure up to 2 hours which is the widely regarded average 
transit time within the stomach (Wilding, 2001). From the three time points it can be seen that 
the LIMs maintain their stability and have a consistent surface morphology throughout. The 
stability of the LIMs during exposure to the acidic environment of the stomach is essential as 
the chitosan coating is soluble in acidic conditions and therefore any exposure to the HCl 
would lead to drug release as seen in section 5.4.3.   
        
(A)                                                                        (B) 
 
(C) 
Figure 6.4. SEM images showing LIMs suspended in 0.1 M HCl for (A) 0.5, (B) 1 and (C) 2 hours. 
Samples show very little change in surface morphology through the time periods.  
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SEM images for LIMs exposed to pH 6.3 Hanks’ buffer containing sodium taurocholate are 
shown in Figure 6.5. The exposure is up to 3 hours which is widely accepted as the average 
transit time observed in the small intestine (Wilding, 2001). Once again the LIMs appear to 
maintain their stability as observed for blank Eudragit S100 microspheres which would 
indicate the protection of the chitosan-coated liposomes and therefore drug retention through 
both the stomach and small intestine.  
 
 
                             (A)                      (B) 
 
(C) 
Figure 6.5. SEM images showing LIMs suspended in pH 6.3 Hanks’ buffer containing sodium 
taurocholate (10 mM) for (A) 1, (B) 2 and (C) 3 hours. 
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Figure 6.6 shows SEM images from the LIM formulation suspended in large intestine 
conditions of pH 7.4 PBS containing β-glucosidase. Due to the solubility profile of Eudragit 
S100 it would be expected that the microspheres would solubilise within this media similar to 
that of the blank microspheres. The images show times up to 6 hours, a sample was taken 
after 8 hours but after centrifugation only a small amount of ‘sticky’ residue could be seen at 
the bottom of the eppendorf which was thought to be lipid from the released liposomes. The 
solubilisation of the microspheres can be seen within one hour of exposure to the PBS, with 
pore formation being observed due to the mechanism described in chapter 4. The continued 
solubilisation of the microspheres can be seen after 2 hours with the microsphere shape still 
being identifiable but the internal area is becoming greater and therefore providing a larger 
contact area for further solubilisation. The images after 1 and 2 hours show a number of small 
particles exposed at the surface where solubilisation is occurring. These vesicles are assumed 
to be chitosan-coated liposomes that are being released from the internal aqueous core of the 
microsphere upon solubilisation of the solid Eudragit S100 shell. Each stage of solubilisation 
can be seen through the different time points with very little spherical form being observed 
after 4 hours. At 6 hours only remnants of microspheres can be seen with no distinctive 
spherical shape remaining or smooth surface morphology that was observed initially in 
Figure 6.2.  
In comparison to the blank Eudragit S100 microspheres the LIMs remain intact for a longer 
period of time, with blank microspheres completely degrading after 6 hours while LIMs 
degraded after 8. It is thought that the stability of the internal aqueous phase of 
chitosan-coated liposomes offers increased stability to the microspheres upon solubilisation 
in comparison to the aqueous core of distilled water in the blank microspheres.   
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 (A)  
 (B)  
 (C)  
 (D)  
Figure 6.6. SEM images showing LIMs suspended in pH 7.4 PBS containing β-glucosidase (4% w/w) for 
(A) 1, (B) 2, (C) 4, and (D) 6 hours. Significant microsphere solubilisation can be observed from the first 
time point with further solubilisation taking place throughout the experiment. 
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6.4.2. Drug release profiles for LIMs in simulated GI tract conditions 
When establishing the drug loading of the LIMs it is to be noted that when each individual 
layer was sequentially ‘stripped off’ by exposing each to an appropriate solvent, the 
supernatant was analysed for drug. Very little drug was found in the microsphere layer (<2%) 
and the vast majority was observed in the internalised liposomes. The drug release profiles 
for both chitosan-coated LUVs and LIMs are shown in Figure 6.7. The drug release profile 
for chitosan-coated LUVs differs considerably compared to that investigated using the 
dialysis cassettes in chapter 5. For overall drug release across all three media it was shown 
that there is a statistical difference between chitosan coated LUVs and LIMs (Mann-Whitney 
U test (chosen level of significance α=0.02). Drug release within the dialysis membrane is 
thought to be much quicker due to a number of factors including the increased surface area in 
comparison to the dialysis cassettes and the presence of the release media within the 
membrane therefore facilitating drug release without the need to pass through the membrane 
pores. Drug release from chitosan-coated LUVs can be observed in all three release media 
similar to that in chapter 5 with the 2 hours in HCl attributing to the solubilisation of the 
chitosan coating and therefore allowing the sustained drug release associated with liposomal 
formulations to continue throughout. The mechanisms involved in chitosan solubilisation 
have been discussed in chapter 2, therefore indicating the necessity of the Eudragit S100 
micropshere to protect the chitosan coating and therefore prevent any drug release until the 
target site of the colon.  
The drug release profile for the LIMs shows high levels of drug retention in both the stomach 
and small intestine (0-5 hours). This is due to the Eudragit S100 microsphere staying intact 
which has been previously shown in Figures 6.4 and 6.5. The stability of Eudragit S100 in 
release media less than pH 7 reflects that the microspheres maintain their stability until they 
reach the distal small intestine where the pH rises above pH 7. The nature of the release 
observed for LIMs in the PBS reflects that observed through SEM where after only 2 hours 
large channels had formed which would lead to extensive liposome release and therefore 
subsequent drug release. Furthermore, after 6 hours it was shown that very little of the 
microsphere structure remained, therefore indicating that the liposomes would be completely 
released and susceptible to solubilisation through the colonic enzyme. The release mechanism 
for LIMs is defined through both the diffusion of liposomes and the dissolution of the 
polymer matrix (Feng et al., 2004), therefore in the case of Eudragit S100 microspheres the 
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speed at which the polymer dissolves
liposomes into the bulk media. When producing LIMs using biodegradable polymers the 
formation of water channels to allow the liposomes to diffuse out has been seen as the rate 
limiting step, but once again due to the nature of Eudragit S100 the polymer d
indicates that liposomes can diffuse out much more rapidly.  
Figure 6.7. Drug release profiles comparing chitosan
represents the mean of three independent measurements 
conducted in HCl for 2 hours, Hanks’ buffer
Due to the novel nature of LIM formulations there are very few similar studies to compare 
the drug release profiles to, especially studies that use pH responsive polymers for the 
microsphere production. Feng 
and therefore the biodegradation rate is much slower than that observed for the pH responsive 
Eudragit S100. To further support the ‘water channel’ the
Feng et al. (2004) showed that LUV
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channels of the microspheres. Furthermore, it took 25 days to see any notable liposome 
release when MLVs were encapsulated within the microspheres, which is due to the time 
taken for suitably sized water channels to form. Increasing the percentage of PEG also led to 
an increased rate of liposomal release which provides a similar effect to the pores developing 
as the Eudragit was solubilised in the PBS as shown in Figure 6.6. The specific drug release 
of PLA-PEG-PLA is not described in Feng et al.’s (2004) study but it can be presumed that 
as the liposomes are said to be released intact that they would undergo the normal sustained 
drug release profile associated with chitosan-coated liposomes.  
A similar system to the PLA-PEG-PLA microspheres produced by Feng et al. (2004) is that 
of the liposome loaded dextran microspheres produced by Stenekes et al. (2000). These 
microspheres had a similar liposome release profile with it taking approximately 20 days to 
see any notable liposome release. In contrast to the two delayed liposomal release 
formulations Park et al. (2006) produced LIMs using alginate microspheres to protect the 
liposomes through the stomach conditions and therefore begin drug release at the small 
intestine. The drug release showed an initial burst release within the first 15 hours then a 
sustained release for the following 35 hours to a relative plateau.    
6.5. Conclusions 
Chitosan-coated LUVs were successfully incorporated into Eudragit S100 microspheres. 
Characterisation techniques including laser drug loading experiments, SEM and cryo-SEM 
all indicated the presence of liposomes within the microspheres. Through simulated 
solubilisation experiments it was shown that the LIMs remained intact through both 
simulated stomach and small intestine conditions with subsequent microsphere solubilisation 
taking place in ileo-caecal junction conditions, with chitosan solubilisation taking place in the 
simulated colonic conditions containing β-glucosidase. Drug release studies were undertaken 
to investigate the LIMs for the application of colonic drug delivery. Drug retention levels in 
the simulated stomach and small intestine were very high (approximately 95%), with 
liposome and subsequent drug release occurring in pH 7.4 PBS containing the colonic 
enzyme β-glucosidase. Drug release was completed within 10 hours of exposure to the PBS 
and enzyme which would therefore indicate that the current formulation of LIMs has the 
potential as a colonic targeted drug delivery system.  
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7.0 Concluding remarks and suggestions for further work 
Liposomal formulations for targeted drug delivery to the colon have been investigated. The 
techniques used in targeted delivery were researched with a view to producing a novel 
liposomal formulation capable of delivery to the colon. Various polymer systems were 
analysed in relation to the complexities of the GI tract. It was decided that the current studies 
would utilise the pH responsive polymer Eudragit S100 and the enzyme triggered chitosan 
throughout. Both polymers were introduced through their specific chemical structure, 
molecular weight, FTIR trace and SEM images. The solubilisation mechanism for each 
polymer was described with Eudragit S100 solubilising due to the ionisation of carboxylic 
acid side groups as the pH is increased and chitosan by the breaking of the 1-4 glycosidic 
bonds by the enzymes present in colonic microflora.     
Initial trials producing Eudragit S100-coated liposomes proved promising with improved 
drug retention being observed in simulated stomach and small intestine conditions. The use of 
more complex simulated conditions proved unsuccessful at preventing bile salt ingress and 
subsequent bilayer solubilisation despite the obvious precipitation of the anionic polymer on 
the surface of the cationic liposomes. Investigations into the production of solid Eudragit 
S100 microspheres produced formulations capable of withstanding bile salts and showed 
suitable rates of solubilisation in the simulated ileo-caecal region of the GI tract to allow for 
colonic drug delivery.  
Chitosan-coated liposomes were investigated to enable their encapsulation into the Eudragit 
S100 microspheres and protect the liposomes during exposure to the solvent mixture required 
during microsphere production. It was shown that both neutral and negatively charged 
liposomes could be coated with chitosan which would offer an enzyme controlled component 
to the system only found in the microflora of the colon.     
The use of chitosan-coated liposomes within a Eudragit S100 microsphere offers the stability 
to navigate the stomach and small intestine for drug release to occur within the large 
intestine. Characterisation techniques have confirmed the presence of chitosan-coated 
liposomes within the microsphere core. Drug release trials have shown the relative stability of 
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the LIMs through the simulated stomach and small intestine with release being observed in 
the large intestine where the greater enzyme population is present.  
Based on the results from the current investigation, the following areas of research are 
considered to have the most promise; 
(1) To ensure a clinically relevant drug loading is possible and to ensure the optimum 
release is achieved. This may involve optimising both the liposomes and microspheres 
to ensure maximum drug encapsulation into the liposomes and subsequent maximum 
liposome encapsulation within the microspheres. 
(2)  Investigate a range of drugs that may be encapsulated into the liposomes whether it 
be in the aqueous core or the lipid bilayers. 
(3) A long term stability study would be required to take the formulation further to ensure 
leakage does not occur over time. Further scope in this area would involve 
understanding the possibility of drying the formulation and subsequent rehydration 
and the effects this may have. This is an important factor as the effect of having the 
‘wet’ liposome dispersion interacting with the hardened microsphere is not fully 
understood. 
(4) As in vitro testing on the LIM formulation has been completed, continued 
development of the product would be completed through testing in cell cultures and 
then in vivo studies within animals.  
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1.0 Introduction 
Liposomes have been widely explored as drug delivery vehicles for several decades, offering 
temporal control of drug release and/or site specific drug delivery for a wide range of drugs 
with different physiochemical properties. To date they have found clinical utility primarily 
for the treatment of severe systemic infections and cancer (Cattel et al., 2004), for which their 
parenteral delivery is necessary and appropriate. To further exploit the advantages associated 
with liposomes (e.g. their ability to interact with cells (Voskuhl and Ravoo, 2008), the 
relative ease in which they can be produced in a wide range of structural and compositional 
configurations (Lasic, 1998), their potential in gene transfection (Montier et al., 2008) and 
capacity to carry a vast array of chemical and biopharmaceutical drugs (Lasic, 1998) it is 
beneficial to explore formulations with potential for non-parenteral delivery.  Indeed, a 
formulation suitable for oral drug delivery (widely accepted as the most practical, efficient 
and cost effective route for drug administration) could broaden the portfolio of applications 
for liposomes and open up several new avenues for treatment. 
  
Of growing interest generally in the world of oral drug delivery is colon-targeted delivery for 
treatment of both local and systemic conditions. It is recognised that this region of the 
gastrointestinal (GI) tract offers advantages over the stomach and small intestine, e.g. milder 
pH, lower enzymatic activity, lower bile salt concentrations, longer residence time and slower 
turnover of the mucus layer. For biopharmaceutical delivery, it also appears to offer the 
benefit of allowing greater functioning of absorption enhancers, thus allowing reasonable 
bioavailability of drugs such as peptides which would normally be poorly absorbed from the 
GI tract (Haupt and Rubinstein, 2002; Sinha et al., 2007).  
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Several researchers have already recognised the potential of combining the advantages of 
liposomes and colonic drug delivery. Rubenstein’s group (Tirosh et al., 2009 and Jubeh et al., 
2004) have investigated liposomal adhesion to healthy and inflamed colonic mucosa in vitro. 
Their work lays important foundations for understanding how liposomes may interact with 
colonic tissue. D’Argenio et al. (2006) have considered liposomes as vehicles for delivery of 
carnitine for the reversal of colitis. Kesisoglou et al. (2005) used liposomes for encapsulating 
5-aminosalicylate and 6-mercaptupurine against inflammatory bowel disease. Although for 
colonic action, administration of the liposomes in all of these studies was either intraluminal 
or in vitro to excised tissue; delivery via oral administration was not considered.  
 
One study that has considered liposomes in the context of oral administration to the colon is 
that of Xing et al. (2003) who describe a multicomponent drug delivery vehicle comprising 
drug loaded liposomes within Eudragit-coated alginate beads. Although both in vitro and in 
vivo results were promising, drug release was controlled by the alginate and not the 
liposomes and it was not clear whether the liposomes were released to allow them to undergo 
the advantageous interactions with colonic mucosa that are described above. A further 
potential drawback of the formulation was the complexity of its preparation (particularly the 
multiple process steps), potentially limiting economically viable commercial manufacture.  
 
In the present study the emphasis is therefore on simplicity of preparation, with the liposomes 
retaining dominance as the drug delivery vehicle. Taking the lead from the successful 
development of commercially available tablet formulations for colonic drug delivery 
(Baumgart and Sandborn, 2007), the methacrylic acid copolymer Eudragit S100 ® has been 
used as the coating material. This polymer, with its anionic carboxylic acid side groups, has a 
solubility threshold of pH 7, remaining insoluble at lower pH values. On the journey through 
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the gastrointestinal tract, it is generally accepted that pH 7 is not normally reached until at 
least the distal small bowel/ileocaecal region; thus drug release from formulations coated 
with Eudragit S100 is likely to commence at the junction between the small intestine and 
colon, continuing into the colon.  
 
2.0 Materials and methods 
2.1 Materials 
Liposomal membrane components included egg phosphatidylcholine (EPC) (a gift from 
Lipoid, Ludwigshafen, Germany, minimum 98 % purity), cholesterol (CH) (Sigma Aldrich, 
Dorset, UK, and stearylamine (SA) (Sigma Aldrich). SA was incorporated to give the 
liposomes a positive charge, facilitating electrostatic interaction with the anionic polymer. 
Vitamin B12 (Sigma Aldrich) was chosen as a model drug due to its high solubility in all of 
the release media used (thus ensuring drug release would not be limited by solubility). 
Eudragit S100, the pH responsive polymer used for the coating of the liposomes, was a gift 
from Evonik (Essen, Germany). For the drug release studies 0.1 M hydrochloric acid (HCl), 
Hanks’ balanced salt solution (99.015 mol % water, 0.95 % Hanks’ balanced salt and 
0.035 % sodium bicarbonate adjusted to pH 6.3 using 0.1 M HCl) and phosphate buffered 
saline (PBS, increased to pH 7.8 using tribasic sodium phosphate) were used to simulate the 
pH conditions of the stomach (Sinha and Kumaria, 2003 and Ibekwe et al., 2006), small 
intestine (Ibekwe et al., 2006) and ileocaecal junction (Khan et al., 1999), respectively. All 
components for the release media were purchased from Sigma Aldrich (Dorset, UK). All 
other chemicals and solvents used were of an analytical grade and used as received.  
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2.2 Preparation of liposomes and their formulation with Eudragit S100 
Liposomes were prepared using EPC and CH in the molar ratio 1:1, with SA comprising 5% 
of the total lipid. This level of SA (5 mol%) was chosen after an initial screening study 
showed that it increased the zeta potential of liposomes at pH 7.4 from -12 mV (without SA) 
to +63 mV. Higher levels of SA were not found to significantly increase zeta potential. The 
conventional thin film hydration method (Bangham et al., 1965) was used to produce 
multilamellar vesicles (MLVs) for the study. Briefly, the lipids were dissolved in 5 ml 
chloroform in a 50 ml round bottom flask. The chloroform was then removed using a rotary 
evaporator, leaving a thin lipid film on the side of the flask which was then dried under 
nitrogen for 2 hours to remove trace chloroform. The film was then hydrated with an aqueous 
solution containing 10 mg/ml of vitamin B12 in PBS (pH 7.4). During hydration the flask was 
agitated using a vortex mixer. Excess drug was removed through three cycles of 
centrifugation and replacement of supernatant with PBS. The final pellet was then re-
suspended in 10 ml of PBS.  
 
To prepare the coated liposomes equal volumes of liposomal suspension and aqueous 
solution of Eudragit S100 of various concentrations (0.0125, 0.025, 0.05 and 0.1 % w/v in 
PBS) were combined and hand-shaken for 2 minutes. 
 
2.3 Characterisation of liposomes 
2.3.1 Zeta potential 
Changes in dispersion zeta potential as a function of Eudragit S100 concentration were 
determined through electrophoretic mobility measurements (Zetamaster, Malvern 
Instruments, UK) at pH conditions in which the polymer was insoluble. Briefly, 500 µl of the 
liposome/polymer suspensions (from section 2.2.) were diluted with 20 ml of distilled water 
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(pH<7) before introducing to the electrophoresis cell. Ten measurements were taken at 25˚C 
on three independent samples of each preparation. 
  
2.3.2 Light Microscopy 
Light microscopy was conducted using an Olympus BX50 light microscope interfaced with a 
Leica Q500IW computer, with images taken using Ph 3 (phase plate) under the phase contrast 
setting. A small drop of liposome sample was placed on a pre-cleaned microscope slide 
before covering with a cover slip. Images were taken at 1000× magnification. 
 
2.3.3. Cryo-electron microscopy (cryo-EM)  
Drops of liposomal samples were dispersed into sample wells. The sample holder was then 
quenched in liquid nitrogen under vacuum conditions. Fracturing of the samples was 
conducted within the preparation chamber through the use of a fine blade. Samples were 
fractured using a Polaron Polar Preparation 2000 attached to a Phillips XL 30 Environmental 
Scanning Electron Microscope (ESEM). The samples were then coated with gold to increase 
conductivity and transferred into the SEM chamber. Images were taken at a maximum 
voltage of 3.0 kV to reduce temperature fluctuations associated with higher voltages, with the 
instrument maintained at -180°C by the periodic addition of liquid nitrogen to the cooling 
chamber.  
 
2.3.3 Size distribution 
Vesicle size and size distribution, as a function of Eudragit S100 concentration, were 
measured using wet laser diffraction particle sizing (Mastersizer 2000 connected to a Hydro 
SM small volume sample dispersion unit, Malvern Instruments, UK). Measurements were 
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carried out in distilled water in which the polymer was not soluble. Three independent 
formulations of each preparation were each measured 5 times.  
 
2.4 Drug release studies 
Drug release studies with uncoated liposomes and liposomes + polymer were conducted in 
each of the different pH media described in section 2.1. For each release experiment, 1 ml of 
liposomal suspension was added to 40 ml of preheated (37˚C) release medium and well-
agitated in an incubator maintained at 37°C. Sink conditions were maintained throughout 
each experiment. Aliquots of 1ml were removed at 0, 0.5, 1, 2, 4, 6, 10, 20, 30, 45, 70 and 
120 hours and centrifuged to precipitate the liposomes. The concentration of released vitamin 
B12 in the supernatant was determined using UV spectrophotometry against a standard curve 
obtained at λ=361 nm. All measurements were taken against reference samples of the 
appropriate dissolution medium. For each formulation, the initial amount of drug (mg drug/ 
mg phospholipid) prior to release was determined by lysing the liposomes with ethanol and 
measuring the resulting drug concentration using UV spectroscopy, allowing drug release to 
be reported as a percentage of the total encapsulated.  
 
Further drug release trials with uncoated and coated liposomes were completed in the 
presence of bile salts at a concentration representative of that found in the small intestine 
(10 mM sodium taurocholate in pH 6.3 Hanks’ solution). These trials aimed to test the 
liposomal formulations beyond response to pH alone. Over a period of 4 hours 
(representative of small intestine transit time) samples were removed and analysed 
spectrophotometrically at λ=361nm against a reference sample of the release medium.      
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3.0 Results 
 
The results presented in this section are discussed in section 4.  
 
Table 1 shows the vesicle zeta potential as a function of polymer concentration, where the 
polymer concentration shown is that of original solution that was mixed with the liposomes.  
As no further decrease in zeta potential was seen by increasing the polymer concentration 
beyond 0.05 % this was assumed to be the concentration necessary to cover the surface of the 
liposomes and was that used in all further studies. Vesicle size (Table 1) was seen to increase 
with increasing polymer concentration until 0.05 % at which point there was a plateau similar 
to that seen for the zeta potential results. 
 
Evidence of an association between the polymer and liposomes was also seen using light 
microscopy. Figure 1A shows the uncoated liposomes at pH 6.3. Typically for MLVs, the 
size of the vesicles was originally around 5 - 10 µm. On addition of polymer to a system at 
pH 7.8 no increase in size was observed (Figure 1B), consistent with the fact that the polymer 
was in solution at these conditions. At pH 6.3 the polymer was seen to precipitate around the 
vesicles forming larger agglomerates (Figure 1C). A control experiment (results not shown) 
in which liposomes were excluded showed that polymer ‘particles’ resulting from 
precipitation at pH 6.3 were considerably smaller (approximately 200 nm) than the liposomes 
used in this study. In this way, the agglomerates seen in Figure 1C were assumed to be 
liposomes + polymer and not precipitated polymer alone.  
 
In Figure 2 typical images from cryo-EM are shown. In Figure 2A the lamellae and central 
aqueous core of liposomes are clearly visible. In the presence of polymer a crust was 
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observed around and across the liposomes and the lamellae were no longer visible 
(Figure 2B).  
In Figure 3 drug release profiles for liposomes with and without polymer are shown in the 
different release media. At pH 1.4 and 6.3 (Figures 4A and B) the amount of drug released 
was significantly lower at all time points on addition of polymer (Mann Whitney U Test 
(chosen level of significance α=0.05). For example at pH 1.4, over a 20 hour period, only 
10 % of the drug was released, which is in contrast to the 40 % release over the same time 
period for the uncoated formulation. Over a time period more representative of gastric 
residence time (boxed graph in Figure 4A) only 2.5 % was released from the coated 
formulation compared to 10 % for the uncoated. However it can clearly be seen that although 
drug release was significantly reduced it was not abolished.  
 
Addition of bile salts to the release media significantly increased the drug release rate for 
both uncoated and coated liposomes. Interestingly there was no statistically significant 
difference between coated and uncoated formulations in the presence of bile salts indicating 
that both the structural integrity of the vesicles and the polymer barrier were affected by the 
bile salts.  
 
4.0 Discussion 
The formulation of liposomes into a preparation suitable for colon-targeted oral drug delivery 
could open up a range of new applications and indications extending the utility of liposomes. 
However, production and quality control of liposomal preparations can be difficult, hence the 
need to keep additional process steps and production methods as simple possible. Here we 
have therefore evaluated a conceptually simple idea of bringing together cationic liposomes 
and anionic polymer with the intention of creating a pH responsive coat around the liposomes 
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which would protect the vesicles en route through the stomach and the small intestine. This 
general route to coating has been previously explored when anionic liposomes were coated 
with the cationic polymer chitosan (Guo et al., 2003; Takeuchi et al., 1996, 2005), but no 
similar work has been completed using a pH responsive polymer for coating. The polymer 
Eudragit S100 was chosen as the coating material as it is widely used in both commercially 
available and experimental formulations for colonic targeting e.g. tablets (Khan et al., 1999 
and 2000), microspheres (Paharia et al., 2007) and capsules (Kraeling and Ritschel, 1992).    
 
The use of pH responsive materials for targeted oral delivery is not a perfect science and is 
not without its drawbacks. For example, substantial inter-patient differences in pH can lead to 
unpredictable targeting and release (Ibekwe et al., 2008). In the case of Eudragit S100, the 
likelihood of inappropriately early release upstream of the colon can also be increased when 
partial neutralisation of the polymer’s acidic function groups is carried out to facilitate 
creation of an ‘aqueous dispersion’ for coating purposes (Ibekwe et al., 2006b). Hence 
although the coating method explored here was one involving only aqueous solutions, 
unmodified Eudragit S100, albeit at low concentration, has been used to reduce the risk of 
drug release in the small intestine.  
 
Zeta potential measurements were used to monitor the evolution of the coat. This strategy has 
previously been used in the development of polymer-coated cationic and anionic liposomal 
formulations, where the point at which the zeta potential plateaus is taken to indicate 
saturation of the vesicle surface with polymer (Guo et al., 2003; Davidsen et al., 2001; 
Takeuchi et al., 2005). Results from our other studies (sizing, cryo-EM and drug release) 
indicate that such an assumption should be made with caution or that certainly further 
experimentation should always be carried out to provide information on the physical 
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characteristics and functionality of the coat. In Table 1, the plateau of the size increase 
beyond 0.05% indicates that the coat was not building up evenly – instead perhaps 
developing preferentially on some vesicles before others.  Light microscopy images in 
Figure 1 point to a heterogeneous distribution of polymer and in Figure 2 a discontinuous 
‘crust’ around the liposomes rather than a homogenous coat is observed. 
  
Despite these observations, the polymer was able to substantially slow down drug release at 
pH 1.4 and 6.3, presumably acting as a diffusional barrier.  However, it was unable to protect 
against bile salts which indicates that premature drug release and liposomal degradation could 
be expected in vivo. This is an interesting finding as it reinforces the importance of going 
beyond evaluation of liposomal formulations for site specific delivery in the GI tract on the 
basis of pH shifts alone. The addition of bile salts, while adopted by some researchers in 
examining in vitro liposomal release for oral delivery (e.g. Lee et al., 2005) has not been 
pursued by others (e.g. Guo et al., 2003; Filipović-Grčić et al., 2001). 
 
Drug release results in Figure 4 indicated that both the liposomes and the coat were disrupted 
by the bile salts.  It was hypothesised that damage to the coat could be due to either the bile 
salts interacting directly with the polymer, facilitating its dispersion, or a secondary effect of 
liposomal degradation i.e. once the liposomes were ‘digested’ the coat dispersed due to the 
lack of a vesicle core holding it in place. To explore which of these was more likely, we 
carried out an additional experiment in which Eudragit S100 powder (as received from the 
manufacturer) was dispersed in either Hanks’ solution or Hanks’ solution + sodium 
taurocholate and analysed using wet laser diffraction particle sizing over 2 hours. All material 
concentrations were equivalent to those of the drug release studies. The resulting polymer 
particle size distributions were identical in both dispersion media, indicating that the bile salts 
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did not facilitate polymer dispersion or dissolution. Additionally, infra red spectra of aqueous 
pastes containing polymer, bile salt and their mixture were recorded using a Fourier 
transform infra red (FT-IR) spectrometer (FT-IR-6300, Jasco, Great Dunmow, UK) with an 
attenuated total reflection (ATR) infrared optical unit (golden gate
TM
, part number 10586, 
Specac Ltd., Orpington, UK). The purpose of this analysis was to test for the presence of any 
chemical interaction between the paste components. Any interactions between the Eudragit 
and the bile salt would result in a shift in the peak positions (e.g. ester vibrations at 1150 cm
-1
 
and 1250 cm
-1
, and C=O vibrations of the carboxylic acid groups at 1705 cm
-1
)  associated 
with the functional groups involved in the interaction.  Examination of the spectra revealed 
no variation in peak position; in fact, the spectra could be superimposed. It therefore seems 
likely that disruption to the coat was due to the loss of liposome structure. While liposomes 
can be designed to increase their resistance to bile salts (Andrieux et al., 2009), it would also 
be necessary to improve the integrity of the coat to prevent bile salt ingress and strategies for 
encapsulating liposomes within microparticles are therefore being explored.  
5.0 Conclusion 
Eudragit S100 can be associated with cationic liposomes through a simple mixing strategy 
creating a barrier that significantly reduces liposomal drug release at pH conditions 
representative of the stomach and small intestine. The importance of evaluating coated 
liposomes for oral drug delivery beyond pH shift studies has been demonstrated with the 
addition of bile salts.  
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Table 1. The effect of Eudragit S100 addition upon the particle size (d50), size distribution 
(span*) and zeta potential of liposomes. Each value represents the overall mean of three 
independent experiments ± the standard error of the mean. *Span =    
 
 
Concentration of 
polymer coating 
solution (%w/v) d(50) (µm) Span Zeta potential (mV) 
0 7.7 ± 0.1 1.2 ± 0.1 63 ± 2.4 
0.01 13.1 ± 2.1 2.3 ± 0.2 45 ± 2.4 
0.025 22.0 ± 2.8 1.9 ± 0.4 28 ± 1.9 
0.05 22.0 ± 3.4 2.4 ± 0.3 -28 ± 1.3 
0.1 20.0 ± 1.7 2.0 ± 0.2 -30 ± 0.5 
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Figure captions 
 
Figure 1.  Light microscopy images showing liposomes: (A) without polymer, and in the 
presence of Eudragit S100 at (B) pH 7.8 and (C) pH 6.3. 
 
Figure 2. Cryo-SEM images of (A) uncoated liposomes in pH 6.3 and (B) liposomes in the 
presence of Eudragit S100.  
 
Figure 3. Drug release profiles for liposome formulations with (■) and without (◊) Eudragit 
S100 at (A) pH 1.4, (B) pH 6.3 and (C) pH 7.8. In Figure 4 (A) drug release over 2 hours is 
additionally highlighted, corresponding to the typical residence time in the stomach. Each 
data point represents the overall mean of three independent experiments ± the standard error 
of the mean. 
 
Figure 4. Drug release profiles for liposome formulations with (●) and without (▲) Eudragit 
S100 at pH 6.3 in the presence of 10mM sodium taurocholate. Release data from Figure 4 (B) 
(no bile salts) are shown for comparison with (■) and without (◊) Eudragit S100. Each value 
represents the overall mean of three independent experiments ± the standard error of the 
mean. 
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